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The causes of sporadic neurodegenerative disease in aging adults likely 
involve a complex interplay of genetics, epigenetics, and a lifetime of 
environmental exposures.  The current dissertation uses two molecular 
epidemiology studies to investigate biomarkers of environmental exposures and 
neurodegenerative outcomes.  
A major challenge of chronic disease environmental etiology research is 
the long latency between environmental exposures and the onset of disease. The 
Veteran’s Affairs Normative Aging Study is an epidemiologic cohort designed to 
prospectively measure exposures and monitor early or subclinical disease.  
Repeated levels of recent exposure to lead were measured in blood and 
cumulative exposure to lead was measured by bone K-shell X-ray fluorescence.  
Homocysteine (Hcy), a risk factor for cardiovascular and neurodegenerative 
diseases when elevated, was measured concurrently with blood lead.  Using 
repeated measures mixed effects models, this research demonstrated that an 
interquartile range higher blood Pb level (3 µg/dl) was associated with an 8.1% 
higher Hcy, compared to the percent change in Hcy with a 5-year increase in age 
(3.1%).  We also demonstrated that individuals with diets rich in vitamins B6, B9, 
and B12, mitigated the effect of Pb on Hcy.  This research suggests that 
interventions to reduce blood Pb and increase dietary B-vitamin intake would 
reduce circulating Hcy levels, potentially lowering risk for cardiovascular and 
neurodegenerative disease.   
The second study investigated the role of epigenetic regulation, through 
DNA methylation, and its potential contribution to gene expression changes in 
late-onset Alzheimer’s disease.  In two separate thesis papers, the DNA 
methylomes and transcriptomes of frontal cortex tissues from deceased patients 
with Alzheimer’s disease were mapped and compared to neuropathologically 
xi 
normal controls using genome-wide approaches and bioinformatic analyses.  In a 
proof-of-concept study, the top disease ranked DNA methylation site was 
validated for altered gene expression and protein levels.  A novel biomarker and 
potential mechanism for LOAD pathogenicity with environmental implications was 
proposed. 
This interdisciplinary thesis implemented laboratory biomarker studies, 
population exposure assessment and molecular epidemiology to approach the 





Alzheimer’s Disease and Environmental Exposure to Lead: The 
Epidemiologic Evidence and Potential Role of Epigenetics 
 
From: Bakulski KM, Rozek LS, Dolinoy DC, Paulson HL, Hu H. 2012. Alzheimer’s 
disease and environmental exposure to lead: The epidemiologic evidence and 
potential role of epigenetics. Current Alzheimer’s Research 9: 563-73, reprinted 
with permission for educational use from Bentham Science Press. 
ABSTRACT 
Several lines of evidence indicate that the etiology of late-onset Alzheimer’s 
disease (LOAD) is complex, with significant contributions from both genes and 
environmental factors.  Recent research suggests the importance of epigenetic 
mechanisms in defining the relationship between environmental exposures and 
LOAD.  In epidemiologic studies of adults, cumulative lifetime lead (Pb) exposure 
has been associated with accelerated declines in cognition.  In addition, research 
in animal models suggests a causal association between Pb exposure during 
early life, epigenetics, and LOAD. There are multiple challenges to human 
epidemiologic research evaluating the relationship between epigenetics, LOAD, 
and Pb exposure.  Epidemiologic studies are not well-suited to accommodate the 
long latency period between exposures during early life and onset of Alzheimer’s 
disease.  There is also a lack of validated circulating epigenetics biomarkers and 
retrospective biomarkers of Pb exposure.  Members of our research group have 
shown bone Pb is an accurate measurement of historical Pb exposure in adults, 
offering an avenue for future epidemiologic studies.  However, this would not 
address the risk of LOAD attributable to early-life Pb exposures.  Future studies 
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that use a cohort design to measure both Pb exposure and validated epigenetic 
biomarkers of LOAD will be useful to clarify this important relationship.  
 
Keywords 
DNA methylation; epigenetics; epidemiology, Late-onset Alzheimer’s disease; 
lead exposure; Pb 
 
ALZHEIMER’S DISEASE 
General Alzheimer’s Disease Epidemiology 
Alzheimer’s disease (AD) is a highly prevalent, progressive, and fatal 
neurodegenerative disease associated with aging.  Clinical manifestation of AD 
includes progressive memory impairment and a gradual difficulty performing 
normal activities.  A small percentage of cases, termed early-onset AD (EOAD), 
experience disease onset prior to age 60.  EOAD cases are attributed to highly 
penetrant genetic mutations in amyloid pathway genes including amyloid 
precursor protein (APP) on chromosome 21, presenilin 1 (PSEN1) on 
chromosome 14, and presenilin 2 (PSEN2) on chromosome 1 (Bertram 2009; 
Hardy 1997).   These mutations lead to the accumulation of β-amyloid plaques, a 
pathological hallmark of AD.    
Termed late-onset AD (LOAD), the majority of AD cases are sporadic and 
symptoms manifest after age 60.  Numerous low-penetrant genetic risk factors 
conferring a modest increase in risk of disease have been identified for LOAD, 
the most studied of which is the apolipoprotein ε4 allele (APOE-ε4).  The global 
population prevalence of APOE-ε4 is 22%, while approximately 60% of LOAD 
cases carry at least one allele (Ashford 2004; Kim et al. 2009).  Large, multi-
center genome-wide association studies (GWAS) estimate the population 
attributable risk for APOE variants is 19-35% (Ertekin-Taner 2010).   GWAS have 
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identified additional polymorphisms associated with LOAD risk including genes 
for ABCA7, BIN1, CD2AP, CD33, CLU, CR1, EPHA1, MS4A, and PICALM 
(Harold et al. 2009; Hollingworth et al. 2011; Lambert et al. 2009; Naj et al. 
2011), each associated with small increases in population attributable risk (PAR) 
ranging from 2-9.3% with a combined non-APOE PAR of 31-35%.   Additional 
APOE ε4 dose adjustment reveals 50% of the PAR for LOAD is accounted for by 
known single nucleotide polymorphisms (SNPs) (Naj et al. 2011). While these 
variants are important both for risk assessment and identification of novel 
mechanisms of pathogenesis, they are neither necessary nor sufficient for the 
development of LOAD.  
Twin studies are an important epidemiologic tool for estimating the relative 
contribution of genetics and the environment in disease development.  
Incomplete twin concordance and variable age of onset supports a significant 
role for non-genetic factors in LOAD etiology.   Among monozygotic twin (MZ) 
pairs, approximately 45-67% of twin pairs are concordant for LOAD (Gatz et al. 
1997; Gatz et al. 2006; Nee and Lippa 1999).   Heritability of liability based on 
twin studies is estimated to be 58-79% (Gatz et al. 1997; Gatz et al. 2006).  
Linkage analysis reveals age at LOAD onset is partially genetically linked to 
regions on chromosomes 4 (208 cM) and 10 (139 cM) (Li et al. 2002).   However, 
among a group of MZ pairs in which both twins develop the disease, differences 
in age of onset range from 4 to 16 years (Gatz et al. 1997). Both genetic and 
environmental factors likely contribute to LOAD development.   
Association studies have identified several non-genetic risk factors for 
LOAD, including depression (Saczynski et al. 2010), hypertension (Li et al. 2011; 
Sharp et al. 2011), stroke (Savva and Stephan 2010), diabetes (Li et al. 2011), 
hypercholesterolemia (Li et al. 2011), obesity (Anstey et al. 2011), head trauma 
(Plassman et al. 2000), smoking (Almeida et al. 2002; Li et al. 2011; Rusanen et 
al. 2011), and having greater than 6 siblings (Moceri et al. 2000).  Protective 
factors, those that reduce the risk of developing LOAD or delay the onset of 
LOAD, include physical activity (Laurin et al. 2001; Lindsay et al. 2002), social 
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engagement (Fratiglioni and Wang 2007), mental activity (Fratiglioni and Wang 
2007; Stern and Munn 2010), education (via the cognitive reserve hypothesis) 
(Fratiglioni and Wang 2007; Lindsay et al. 2002), statin use (G Li et al. 2010) , 
non-steroidal anti-inflammatory drug (NSAID) use (Lindsay et al. 2002), 
moderate alcohol consumption (Larrieu et al. 2004; Lindsay et al. 2002), coffee 
consumption (Lindsay et al. 2002), past vaccinations (Verreault et al. 2001), and 
childhood residence in the suburbs relative to the city (Moceri et al. 2000).  In 
particular, nutrition may play a protective role in LOAD onset.  Consumption of 
one meal/week of fish rich in omega-3 fatty acids reduced the risk of developing 
AD by 60% in the Chicago Health and Aging Project (Morris 2009). Individuals 
with plasma vitamin E less than or equal to 21.0 µmol/L had a higher risk of 
incident dementia than individuals with plasma levels greater than or equal to 
25.5 µmol/L (Helmer et al. 2003).  The natural plant polyphenols curcumin and 
green tea epigallocatechin gallate (EGCG) have anti-oxidant and neuroprotective 
properties that may be protective against LOAD (Mandel et al. 2007).  EGCG 
reduces APP translation through modulation of the intracellular iron pool in vitro 
neuroblastoma cell culture (Reznichenko et al. 2006) and AD transgenic mice 
exposed in vivo to EGCG show reduced Aβ plaque density (Rezai-Zadeh et al. 
2005).  In an additional AD transgenic mouse model study, curcumin suppressed 
inflammation and oxidative damage in the brain and lowered levels of soluble Aβ 
and plaques (Yang et al. 2005).    Anthropometric measures of shorter adult knee 
height and arm span may reflect nutritional deficits in childhood (Jeong et al. 
2005) and women in the lowest quartile of arm span in the Cardiovascular Health 
Cognition cohort study had 1.5 times elevated risk of dementia (Huang et al. 
2008). 
Proposed environmental exposures associated with LOAD include 
aluminum (Frisardi et al. 2010; Shcherbatykh and Carpenter 2007), copper 
(Brown 2009; Shcherbatykh and Carpenter 2007), zinc (Shcherbatykh and 
Carpenter 2007), mercury (Gerhardsson et al. 2008), lead (reviewed below), iron 
(Mandel et al. 2007), pesticides (Baldi et al. 2003; Santibanez et al. 2007), 
solvents (Kukull et al. 1995), electromagnetic field (Sobel et al. 1996), and 
5 
particulate matter in air pollution (Calderon-Garciduenas et al. 2004).  
Environmental exposure studies have been underrepresented in the AD 
literature, likely due to the challenges of retrospective exposure assessment in 
older adults.   
 
LEAD (Pb) EXPOSURE 
Overview of Pb Exposure as a Risk Factor 
Zawia and colleagues have published a series of experimental studies on 
rodents and primates demonstrating that Pb exposure in early life results in late-
life neuropathological changes similar to those of AD (reviewed elsewhere in this 
issue of Current Alzheimer’s Research).  This work, coupled with the recognition 
that exposure to Pb in the general population until recently has been high, has 
heightened interest in the epidemiology of Pb exposure and neurodegenerative 
disease.  We discuss trends in Pb exposure and epidemiologic studies that 
provide evidence for the role of Pb as a risk factor for AD. 
Pb Exposure Epidemiology 
One of the greatest environmental health successes of our society was 
the regulatory action to reduce what had been decades of high Pb exposure in 
the US (Grosse et al. 2002).  Between 1976 and 1991, the mean blood Pb levels 
for people in the US dropped 78% from 12.8 µg/dL to 2.8 (Pirkle et al. 1994).  
Since 1991 the standard elevated blood Pb level defining the need for action 
from Pb poisoning in children has been set to 10 µg/dL.  The previously elevated 
mean blood Pb level of 12.8 µg/dL is a sobering testament to the high levels of 
Pb exposure endured by the general US population and other countries in the 
recent past. 
   However, hazardous public health impacts remain despite low mean 
population blood Pb levels.  One issue is that the general reduction in Pb 
exposure is not universal.  Pockets of high Pb exposure remain in certain sectors 
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of the US population where housing was constructed prior to 1950 and at which 
time leaded paint was used (Lanphear et al. 1998; Rabito et al. 2003), or where 
plumbing pipes and solder containing Pb have not yet been replaced (Edwards et 
al. 2009).  Fly ash from municipal waste incineration contains high levels of 
heavy metals including Pb (Jung et al. 2004).  In the high temperatures of the 
trash incineration process, Pb is converted to the volatile PbCl2 compound, which 
can contaminate surrounding areas (Jung et al. 2004).  It is estimated that the 
US has hundreds of defunct Pb battery recycling sites (Nedwed and Clifford 
1997) and Pb/zinc mines and smelters.  The surrounding soil and water of these 
industrial sites are often contaminated with high levels of Pb, leading to human 
exposure (Kaul et al. 1999), and many of these sites are designated Superfund 
sites on the National Priorities List by the US Environmental Protection Agency 
(EPA) (Lewin et al. 1999; von Lindern et al. 2003). In many developing countries 
the combustion of leaded gasoline continues and industrial emissions of Pb have 
been increasing (Meyer et al. 2008; Tong et al. 2000).  Groups of people 
continue to experience high blood Pb levels based on their occupation or 
residential proximity to these hazards. 
The pharmacodynamics of Pb in the human body makes past exposure to 
this heavy metal relevant to current and future health outcomes.  Pb dust is 
inhaled or ingested and absorbed through the lung epithelia or gastrointestinal 
tract respectively. Pb is taken up by divalent metal transporters in the gut, binds 
tightly to heme molecules, and circulates throughout the body via blood.  A small 
percentage of circulating Pb is highly toxic because it is free and bioavailable in 
the plasma (Hernandez-Avila et al. 1998).  Plasma Pb contributes to both soft 
tissue Pb as well as bone Pb deposition (Rabinowitz et al. 1976).  Pb can occupy 
both Ca2+ sites in the hydroxyapatite structure of bones (Barry and Mossman 
1970) and greater than 95% of the adult body burden of Pb is stored in bones 
(Barry and Mossman 1970).   Given that cortical bone turns over at a slow rate of 
approximately 2% per year in healthy adults, Pb can be stored for decades in 
bone (Barbosa et al. 2005; Hu et al. 1998; Rabinowitz 1991).  Storage in bone is 
not a permanent Pb detoxification mechanism as Pb can have direct effects on 
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the cellular components of bone (Pounds et al. 1991), and bone Pb can be 
mobilized in times of higher bone turnover such as during pregnancy, lactation, 
and osteoporosis (Silbergeld et al. 1988).  Individuals born in the US prior to the 
Pb phase out in the 1970s may have accumulated elevated bone Pb stores that 
become mobilized in later life.   
Biomarkers of Pb Exposure 
Whole blood Pb is the most common biomarker of Pb exposure.  The half-
life of Pb in blood is relatively short, approximately 35 days (Rabinowitz et al. 
1976).  This biomarker is best used for quantifying recent environmental 
exposures and mobilization of endogenous Pb (Silbergeld 1991).  Similarly, soft 
tissues also have relatively high turnover of Pb with a mean half-life of 
approximately 40 days, but soft tissue Pb quantification is invasive and not 
typically used for epidemiologic studies (Rabinowitz et al. 1976).   
An expert panel on adult Pb toxicity convened by the US Centers for 
Disease Control concluded that bone Pb levels were the best biomarker of 
cumulative Pb exposure (Hu et al. 2007). Spongy trabecular bone, such as that 
found in the patella, has an intermediate half-life of 5-15 years in adults (Hu et al. 
1995).  More dense cortical bone, as in the tibia, has a much longer half-life of 
10-30 years (Chettle 2005).  Thus, epidemiologic studies measuring Pb in bone 
can quantify a subject’s life history of cumulative Pb exposure.   
Bone Pb levels can be measured either in vivo using Cd109 K-shell X-ray 
Fluorescence (KXRF) (Hu et al. 2007) or by direct, chemical measurement of Pb 
in excised total joint replacement or post-mortem bone samples (Wittmers et al. 
1988).  Measurements with KXRF technology are painless and non-invasive, with 
minimal radiation exposure (Hu et al. 1995).  The KXRF instrument uses low-
level gamma radiation to provoke emission of fluorescent photons from a 
subject’s tibia and patella (Hu et al. 1989).  The photons are detected and 
quantified over a spectrum of wavelengths from which the characteristic emission 
profile of Pb can be extracted (Hu et al. 1995).  Post-mortem bone samples can 
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be acid digested and quantified for Pb levels using inductively coupled plasma 
mass spectrometry (ICP-MS) (Garcia et al. 2001). 
There are several approaches to predicting cumulative Pb exposure in the 
absence of direct bone Pb measures.  The Park model incorporates blood Pb 
and information on subject demographics, medical history, and metabolic 
parameters to predict cumulative Pb exposure (Park et al. 2009).  The Gorell 
system predicts cumulative Pb exposure based on blood Pb levels and 
physiologically based pharmacokinetic (PBPK) models incorporating industrial 
hygienist rated occupational Pb exposure for each job over the duration worked 
(Coon et al. 2006).  Both strategies have been validated with bone Pb measures.   
Pb as a Neurotoxicant and Risk Factor for LOAD 
Pb is a well-known neurotoxicant in children.  Even at relatively low 
(subclinical) levels, epidemiologic studies demonstrate that childhood Pb 
exposure affects IQ and behavior with major impacts on IQ and functioning 
(Fewtrell et al. 2004; Grosse et al. 2002).   
A growing body of toxicological and population-based research indicates 
that cumulative environmental Pb exposure is neurotoxic in adults as well 
(Toscano and Guilarte 2005). Pb exposure is a significant risk factor for 
accelerated declines in cognition (Weisskopf et al. 2004; Wright et al. 2003), an 
effect that a recent CDC panel concluded was likely causal (Shih et al. 2007).  
The Veteran’s Affairs Normative Aging Study (NAS) is a longitudinal cohort of 
men free of disease when recruited in 1963.  Based on data from repeated 
measures of bone Pb, blood Pb, and cognitive tests in the NAS, there are 
significant associations between high Pb exposure and decreased cognition.  
The cognitive domains associated with increased Pb exposure differ depending 
on the time of exposure.  In a cross-sectional analysis, higher blood Pb was 
associated with reduced ability to recall and define words, identify line-drawn 
objects, and difficulty with a perceptual comparison test (Payton et al. 1998).  
Both higher blood and bone Pb were associated with decreased spatial copying 
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skill (Payton et al. 1998).  Higher bone Pb was associated with reduced pattern 
memory (Payton et al. 1998).  Longitudinal analyses confirm that the Pb 
associated declines in cognitive function are greater than changes observed with 
normal aging alone (Schwartz et al. 2000).  Also in the NAS, functional genetic 
polymorphisms in the δ-aminolevulinic acid dehydratase (ALAD) and 
hemochromatosis (HFE) genes modify the association between Pb and cognition 
measured by the Mini-Mental State Exam (MMSE), where variant carriers have 
more pronounced cognitive deficits associated with Pb exposure (Wang et al. 
2007; Weuve et al. 2006). Future research may study the ecological association 
between geographic regions with elevated Pb exposure and prevalence of 
LOAD.   
Pb is also a risk factor for increased hippocampal gliosis measured by 
magnetic resonance spectroscopy in the NAS (Weisskopf et al. 2007), an 
abnormality associated with LOAD development.  Molecular epidemiology 
studies show cumulative Pb exposure is associated with an increased risk of 
amyotrophic lateral sclerosis (Kamel et al. 2005; Kamel et al. 2003; Kamel et al. 
2002) and Parkinson’s Disease (Weisskopf et al. 2010), suggesting that Pb 
exerts a significant neurodegenerative effect.   This effect may have specificity 
through epigenetic change as a pathogenic mechanism.   
Toxicological studies are consistent with the epidemiologic research.  
Early life Pb exposure in animal models is associated with latent APP pathway 
dysregulation.  Rats exposed to Pb in early life showed increased expression of 
APP mRNA and elevated Aβ aggregation without changes in α-, β-, or γ-
secretases at 20 months of age (Basha et al. 2005a; Basha et al. 2005b).  
Similarly, primates exposed to Pb during the first 2 months of life only had 
significant adverse brain changes at 23 years of age when compared to their 
unexposed counterparts (Wu et al. 2008a).  Pb exposed primates had increased 
amyloidogenesis, senile plaque deposition, and up-regulation of key proteins in 
the amyloid processing pathway, such as APP and beta-site APP-cleaving 
enzyme 1 (BACE1) (Wu et al. 2008a).   
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OVERVIEW OF EPIGENETICS 
Literally meaning “above the genome,” the epigenome comprises the 
heritable changes in gene expression that occur in the absence of changes to the 
DNA sequence itself.  Epigenetic mechanisms include chromatin folding and 
attachment to the nuclear matrix, packaging of DNA around nucleosomes, 
covalent modifications of histone tails, and DNA methylation.  The influence of 
regulatory small RNAs and micro RNAs on gene transcription is also increasingly 
recognized as a key mechanism of epigenetic gene regulation (Morris 2011).  
Epigenetic mechanisms are important in growth and cellular differentiation 
(Jones and Taylor 1980).  Epigenetic change can be stochastic (Feinberg and 
Irizarry 2010) or internally orchestrated as part of aging (Fraga and Esteller 
2007).  Longitudinal change in global and gene-specific DNA methylation clusters 
within families, suggesting that there is genetic control of methylation status 
(Bjornsson et al. 2008).  Inappropriate epigenetic changes are associated with 
many diseases including cancers (Esteller 2008), Rett syndrome (Horike et al. 
2005), Beckwith-Wiedemann syndrome (DeBaun et al. 2002) and other 
imprinting disorders.  Environmental signals can trigger epigenetic responses 
and may be an important mechanism by which environmental exposures are 
associated with disease (Faulk and Dolinoy 2011).  Furthermore, epigenetic 
mechanisms may play an important role in the developmental origins of adult 
health and disease (DOHaD) by providing a mechanism underlying the latent 
effects of adverse fetal, infant, and childhood environments on late-life chronic 
disease (Barker 2004; Hanson et al. 2011; Wadhwa et al. 2009).   
Epigenetic Epidemiology and Alzheimer’s Disease 
Epigenetic epidemiology is the study of the effects of heritable epigenetic 
changes on the occurrence and distribution of diseases in populations (Jablonka 
2004).  This research includes both trans-generational and intra-individual 
cellular epigenetic inheritance systems.  Epigenetic changes are associated with 
epidemiologic risk factors such as aging (Calvanese et al. 2009; Fraga 2009) and 
environmental exposures (Faulk and Dolinoy 2011), as well as psychiatric 
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outcomes (Sananbenesi and Fischer 2009) and neurodegeneration (Urdinguio et 
al. 2009).   
Evidence for the role of epigenetics in AD pathogenesis is found in human 
studies of various tissues, animal models, and cell culture (2010; Mastroeni et al. 
2011; Mill 2011).  Global changes associated with AD have been observed in 
DNA methylation, miRNAs, and histone modifications.  A human post-mortem 
case-control study identified global DNA hypomethylation in the entorhinal cortex 
of AD subjects by quantifying the percentage of positive 5-methylcytosine 
neuronal nuclear immunoreactivity (Mastroeni et al. 2008).  Within a single MZ 
twin pair discordant for AD, DNA from the temporal neocortex neuronal nuclei 
was hypomethylated in the AD twin compared to their cognitively normal twin 
using similar methods to the previous study (Mastroeni et al. 2009).  An AD case-
control study in the post-mortem human parietal lobe cortex revealed differential 
regulation of miRNAs including miR-204, miR-211, and miR-44691 using a 
custom µParaflo array (Nunez-Iglesias et al. 2010).  Age-matched AD cases 
have increased neuronal global phosphorylation of histone 3 relative to controls 
determined by immunolabeling in the hippocampus, a histone modification that 
suggests mitotic activation (Ogawa et al. 2003).   
Given that epigenetics play an important regulatory role in gene 
expression, epigenetic dysregulation of important AD tau and amyloid processing 
pathway genes may point to a potential mechanism for AD disease progression. 
In experiments where neuroblastoma cells were cultured under low folate and 
vitamin B12 conditions, PSEN1 and BACE1 were hypomethylated, mRNA 
expression of BACE1 and PSEN1 was significantly induced, and Aβ production 
was increased (Fuso et al. 2005).  Addition of S-adenosyl methionine (SAM) was 
able to restore BACE1 and PSEN1 expression to baseline levels, though DNA 
methylation reversal was incomplete (Fuso et al. 2005).  An additional study 
using human neuroblastoma cells and male rat brain tissue shows APP mRNA 
expression is repressed by thyroid hormone (T3) sensitive histone modifications 
(Belakavadi et al. 2011).  Treatment with T3 decreases H3K4 methylation and H3 
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acetylation at the APP promoter, leading to APP silencing that was reversed with 
histone deacetylase (HDAC) and histone lysine demethylase inhibitors 
(Belakavadi et al. 2011).   
There have been several candidate-gene methylation studies in LOAD 
cases and controls.  In a post-mortem brain study of 26 controls and 44 LOAD 
cases with varying degrees of disease severity, no differences were seen in DNA 
methylation in regions associated with Microtubule Associated Protein Tau 
(MAPT), PSEN1, and APP, nor were differences detected between frontal cortex 
and hippocampal DNA (Barrachina and Ferrer 2009). Investigation of 6 familial 
AD frontal cortex and cerebellum brain samples revealed no methylation at the 
APP promoter in any case in either brain region (Brohede et al. 2010).  These 
studies were limited by a candidate-gene approach and highlight the need for 
genome-wide assessment of DNA methylation. 
It is critical that epigenetic epidemiology studies of AD epigenetics 
consider age as an independent predictor of epigenetic change as age-specific 
epigenetic drift has been observed at AD related loci among healthy normal 
controls.  In a set of control parietal cortex samples, the promoter of APP was 
hypomethylated in individuals greater than 70 years of age relative to younger 
subjects (Tohgi et al. 1999a).  DNA methylation upstream of the MAPT gene also 
varied with age in the control parietal cortex and was associated with an age-
related decline in MAPT gene expression (Tohgi et al. 1999b).  Specifically, 
MAPT promoter CpG dinucleotides located in the Sp1 transcriptional activator 
binding site were hypermethylated with age, while CpG dinucleotides located 
within the GCF transcriptional repressor binding region were hypomethylated 
with age (Tohgi et al. 1999b).  Another study of post-mortem cerebral cortex in 
125 subjects ranging from 17 weeks of gestation to 104 years of age measured 
methylation by MethyLight PCR at candidate tag loci for 50 genes selected for 
their relevance to LOAD, CNS differentiation, and cancer.  CpG sites in the 
promoters of eight genes showed robust linear increases in DNA methylation 
across the lifespan (Siegmund et al. 2007).  An additional study examined 
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prefrontal cortex samples across a 30 year age range and noted that the average 
DNA methylation in promoters of MTHFR and APOE increased by 6.8% across 
the age range, while control samples decreased by 10.6% with age (Wang et al. 
2008).  Given the likely epigenetic drift, clinical samples should be carefully 
matched on age.  
Epigenetics and Heavy Metals, with a Focus on Pb 
Epigenetic alterations have been observed following exposure to 
environmental metals (Salnikow and Zhitkovich 2008), including arsenic, nickel, 
chromium, cadmium, and Pb.  Perhaps the heavy metal most studied in the field 
of cancer epigenetic epidemiology is arsenic.  In a population-based study of 351 
individuals with bladder cancer, elevated toenail arsenic measurements were 
associated with increased tumor sample promoter methylation of RASSF1A and 
PRSS3 tumor suppressor genes (Marsit et al. 2006).   Nickel, chromium, and 
cadmium epigenetics research has largely been in toxicologically based in vitro 
experiments.  A cell line of human lung bronchoepithelial cells treated with nickel 
chloride show global histone modification changes including decreased H2A, 
H2B, H3, and H4 acetylation and increased H3K9 dimethylation (Ke et al. 2006).   
When the same cell line is treated with chromium, the cells exhibit increased 
H3K9 dimethylation at the MLH1 gene promoter region, which correlates with 
decreased MLH1 mRNA expression (Sun et al. 2009).  Cadmium exposure in a 
rat liver cell line initially reduces DNA methyltransferase activity and global DNA 
methylation, but after 10 weeks of prolonged exposure, the cells show significant 
increases in DNA methyltransferase and global DNA methylation above the 
baseline (Takiguchi et al. 2003). 
Evidence suggests that Pb, in particular, may play a role in epigenetics 
throughout the life course.  In a study of 103 mother-infant pairs, maternal 
cumulative Pb exposure was inversely associated with offspring umbilical cord 
genomic DNA methylation of Alu retrotransposable elements (Pilsner et al. 
2009).  Similarly, bone Pb levels were inversely associated with peripheral blood 
genomic DNA methylation of LINE-1 retrotransposons in 517 elderly men from 
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the NAS (Wright et al. 2010).  Individuals exposed to extremely high levels of Pb 
(51-100 µg/dL blood Pb) had higher methylation in the promoter of the p16 tumor 
suppressor gene (Kovatsi et al. 2010).  Research is needed to expand this early 
epidemiologic work on global and candidate gene DNA methylation to more 
comprehensively understand specific pathways influenced by Pb exposure in 
humans.  
Animal studies have investigated the relationship between Pb exposure 
and epigenetics.  Early life exposure to Pb in primates causes dysregulation of 
biological pathways important to LOAD pathogenesis in late life and is associated 
with reduced DNA methyltransferase 1 (DNMT1) activity (Wu et al. 2008a).  Rat 
pheochromocytoma cells exposed to Pb show dose dependent decreases in 
global methylation and decreases in APP promoter methylation at 4 CpG sites 
(YY Li et al. 2010).  These changes were associated with increases in APP 
mRNA and Aβ protein levels (YY Li et al. 2010).  Toxicological and 
epidemiological studies suggest that Pb exposure may be associated with 
epigenetic change, but further research is needed. 
DATA INTEGRATING ALZHEIMER’S DISEASE, EPIGENETICS, AND Pb 
EXPOSURE 
Alzheimer’s and Pb Exposure are Associated with Changes in One-Carbon 
Metabolism, the Substrate for DNA Methylation 
De novo and maintenance DNA methylation is dependent on available 
methyl (-CH3) groups.  One-carbon metabolism reactions are reversible and 
deficiencies in methyl donors can cause DNA hypomethylation.  For example, 
mice given diets deficient in the methyl donor choline showed lower global brain 
methylation (Niculescu et al. 2006) and elevated expression of APP, consistent 
with promoter hypomethylation (Niculescu et al. 2005).  Epidemiologic studies 
indicate that AD patients have altered circulating levels of one-carbon 
metabolism members including homocysteine (HCY), SAM, folate, and vitamin 
B12.  Elevated HCY is associated with increased risk of developing AD and 
15 
increased rate of disease progression among individuals with the disease. 
Prospective data from the Framingham Heart Study show that each standard 
deviation increase in log transformed plasma total HCY levels was associated 
with an adjusted relative risk of dementia of 1.8 (95% CI: 1.3-2.5) eight years 
after the HCY measurement (Seshadri et al. 2002).   AD patients in the Oxford 
Project to Investigate Memory and Ageing have increased serum HCY relative to 
cognitively normal control subjects (n=164) and the individuals with the greatest 
disease progression over the subsequent three years had the highest original 
HCY levels (Clarke et al. 1998).  SAM is a methyl-donor molecule that is 
hydrolyzed to form HCY, the substrate for DNA methylation.  AD patients also 
have decreased cerebrospinal fluid SAM relative to cognitively normal controls 
(Bottiglieri et al. 1990).   
 Several proteins in the one-carbon metabolism cycle may be disturbed by 
Pb exposure because elemental Pb reacts with free sulfhydryl groups on 
proteins. HCY metabolism may be directly inhibited by Pb binding to the 
sulfhydryl group in HCY.  Furthermore, HCY is transsulfurated into cysteine by 
cystathionine β-synthase (CBS) and CBS has two sulfhydryl groups with which 
Pb can react. There is also evidence for Pb’s involvement in methionine 
processing.  Rats developmentally treated with Pb have impaired long-term 
potentiation (LTP), memory, and synaptic plasticity.  Co-treatment with SAM and 
Pb increases LTP relative to Pb treatment alone and reduces circulating blood 
Pb levels (Cao et al. 2008) .  Similarly, neuroblastoma cells exposed to Pb 
experience viability loss, glutathione antioxidant depletion, membrane lipid 
peroxidation, DNA damage, and apoptosis; pretreatment with a methionine 
derivative reduces these harmful effects (Chen et al. 2011). 
Pb exposure and HCY levels are linked in cross-sectional epidemiologic 
studies. In the Baltimore Memory and Aging Project involving greater than 1,000 
adults, higher blood Pb was associated with higher HCY (Schafer et al. 2005).  
Analyses from the 1999-2002 National Health and Nutrition Examination Survey 
(NHANES) showed HCY was strongly associated (OR=1.92) with peripheral 
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arterial disease (PAD) (Guallar et al. 2006).  Subsequent analysis showed the 
original association was actually due to confounding from smoking, blood Pb and 
cadmium levels, and impaired renal function (Guallar et al. 2006).  This suggests 
that the association between HCY and chronic disease may be driven by 
environmental exposures.  
Animal Model Studies Linking Pb Exposure, Epigenetics, and 
Amyloidogenesis 
A series of rat and primate model studies conducted by the Zawia 
research group collectively demonstrate that early life Pb exposure reduces DNA 
methyltransferase activity and specifically alters the regulation of many AD 
pathway related genes including APP and BACE1 that are known to be CpG rich.   
Rats exposed to Pb from post natal day (PND) 1 through PND 20 experienced a 
transient increase in APP mRNA expression in cortical brain tissue, which 
returned to basal levels at 1 year, and later resurged at 20 months of age in the 
absence of continued exposure (Basha et al. 2005b).  The observed late-life rise 
in APP mRNA was accompanied by elevated Aβ, suggesting that early life Pb 
exposure may have long-term effects on amyloidogenesis in late life (Basha et al. 
2005b).  In a follow-up study on the same tissues, investigators noted the effects 
on Aβ formation and aggregations were not due to changes in protein levels of 
APP processing secretases (Basha et al. 2005a).  In a third study using  the 
early-life exposed rat brain tissues, elevated oxidative DNA damage measured 
by cerebral 8-hydroxy-2’-deoxyguanosine (8-oxo-dG) was observed in the 
exposed animals (Bolin et al. 2006). Local 8-oxo-dG is associated with 
hypomethylation at adjacent CpG sites (Cerda and Weitzman 1997).  Direct 
oxidation of 5-methylcytosine to 5-hydroxymethylcytosine may be part of active 
DNA demethylation (Wu and Zhang 2010).  Analogous primate experiments by 
Zawia et al. are consistent with these rodent findings. Primates exposed in early 
life to Pb had elevated levels of the A peptide, 8-oxo-dG DNA, and mRNA from 
APP and BACE1 on autopsy 23 years later relative to controls, suggesting Pb is 
involved in LOAD-like pathology (Wu et al. 2008a).  Brain tissue from these 
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exposed primates also had 20% reduced DNA methyltransferase 1 activity (Wu 
et al. 2008a) and lower methylation at the promoter of APP (Wu et al. 2008b).  In 
vivo animal model studies spanning multiple organisms support an integrated 
role of Pb exposure and epigenetics in amyloidogenesis.  
  
CHALLENGES TO LOAD EPIDEMIOLOGIC RESEARCH INTEGRATING 
EPIGENETICS AND Pb EXPOSURE 
Human epidemiologic research integrating LOAD, environmental exposure 
to Pb, and epigenetics faces many challenges.  Clinical criteria for AD include 
progressive impairment in memory in the absence of motor, sensory, or 
coordination deficits (McKhann et al. 1984).  However, the standard of diagnosis 
for AD requires the pathologic post-mortem identification of Aβ plaques and tau 
neurofibrillary tangles.  Epidemiologic studies can take advantage of predictive 
and diagnostic biomarkers, including a panel of plasma signaling proteins (Ray et 
al. 2007), cerebrospinal fluid protein analyses (De Meyer et al. 2010), magnetic 
resonance imaging (MRI) volumetric and structural measures (Jack et al. 1992), 
and positron emission tomography (PET) neuroimaging of metabolic rate and Aβ 
pathology (Klunk et al. 2004; Minoshima et al. 1995).  However, these research 
methods require additional validation to become routine early detection methods 
(Dubois et al. 2007).   
Another concern in environmental epidemiology is that the length of time 
between exposure and disease onset. Barker first introduced the hypothesis that 
early-life conditions could be linked to late life chronic disease, otherwise known 
as the developmental origins of health and disease (DOHaD) hypothesis (Barker 
and Osmond 1986).  Fetal or childhood exposures have been associated with 
adverse health outcomes including impaired glucose tolerance (Ravelli et al. 
1998) and hypertension (Barker et al. 1990; Bergvall et al. 2007).  Indeed, 
several early life events related to growth, metabolism, and cognitive reserve 
have been associated with LOAD  (Miller and O'Callaghan 2008).  AD risk is 
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increased with limited education and income, and both factors are associated 
with poor early life environment and growth (Borenstein et al. 2006).  Middle life 
risk factors including obesity (Whitmer et al. 2005), limited physical activity (Rovio 
et al. 2005), and diabetes (Luchsinger et al. 2001) are shared between AD and 
cardiovascular disease.  Low birth weight and intrauterine growth restriction are 
related to metabolism, fat distribution, and insulin resistance at mid-life and it has 
been suggested that these early-life events may be associated with AD as well 
(Landrigan et al. 2005; Lester-Coll et al. 2006; Ross et al. 2007).  However, 
LOAD is a chronic disease of old age and a prospective developmental exposure 
study could not feasibly follow an early life cohort for 75 years with our current 
late stage diagnostic measures.  Additionally, retrospective exposure 
assessment is difficult.  The human body has efficient detoxification and 
clearance mechanisms for many toxicants and many chemicals do not 
bioaccumulate in the human body.  There is an acute need to develop 
biomarkers that correspond to prior toxicologic exposures.   
Finally, an additional roadblock is that brain specific epigenetic 
measurements are only possible post-mortem.  Molecular epidemiology research 
of toxicant induced disease is strengthened when performed with relevant tissue 
samples.  Brain tissue collection is invasive and not possible longitudinally on live 
subjects.  Model animal research and epidemiology studies of human pre-
mortem available tissues such as skin, blood, colon, etc. are necessary to fill in 
stages of disease tissue not available through end of life epidemiologic brain 
banks.   
POTENTIAL APPROACHES TO STUDY Pb EXPOSURE, EPIGENOMICS, 
AND ALZHEIMER’S DISEASE EPIDEMIOLOGY 
To best understand the relationship between Pb exposure (both early-life 
and later life) and LOAD, studies should take advantage of available biomarkers 
of Pb and technologic advances in epigenetic measurements.  Bone Pb levels 
are a strong predictor of negative health outcomes including elevated risks for 
hypertension (Cheng et al. 2001; Hu et al. 1996; Korrick et al. 1999), ischemic 
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heart disease (Jain et al. 2007), and mortality (Weisskopf et al. 2009), but the 
relationship between cumulative Pb exposure and LOAD has not been assessed.  
Cumulative Pb exposure of LOAD subjects can be measured either non-
invasively in vivo using K-x-ray fluorescence (Hu et al. 2007) or by direct 
measurement of Pb in bone samples (Wittmers et al. 1988).  At Alzheimer’s 
Disease Research Centers (ADRCs) where LOAD subjects consent to brain 
tissue donation on autopsy, it would be most ideal to directly measure Pb in 
samples of cranial bone obtained at the time of brain harvesting.  Measurement 
of Pb in the cranium is highly correlated with a weighted average of skeletal Pb 
levels, as well as the level of Pb in tibia bone (Hu et al. 1990), the latter being the 
bone most commonly measured in epidemiologic studies of chronic Pb toxicity 
(Hu et al. 2007). Sampling cranial bone Pb would make it possible to 
concurrently study LOAD epidemiology, brain tissue epigenetics and cumulative 
Pb exposure in post-mortem case-control studies. 
 Circulating epigenetic biomarkers would be useful to conduct case-control 
studies of Pb exposure (by in vivo KXRF) with live subjects.  Post-mortem 
Alzheimer’s disease brain tissue epigenetic studies are expanding, but use of this 
tissue collected at end of life is not feasible to track within individual changes 
over time as in longitudinal epidemiological aging cohort studies.  Biologically-
available biomarkers would allow for repeated epigenetic measures throughout 
the disease course.  Epigenetic markers in white blood cells (WBC) have been 
used as biomarkers in other diseases.  Global DNA methylation has been 
associated with several cancers, myelodysplastic syndrome, and schizophrenia 
and thus does not appear to be a disease specific biomarker. Gene-specific 
methylation data and risk factor methylation data are more limited and results are 
inconsistent (Terry et al. 2011).  Larger, prospective cohort studies are needed to 
determine whether WBC gene-specific epigenetics will be informative with AD 
and with Pb exposure (Figure 1.1). Upon epigenetic biomarker development, 
cohort studies could integrate and target distinct age groups.  Birth cohorts could 
investigate the role of in utero and postnatal Pb exposure on AD biomarkers to 
test the hypothesis suggested by animal research (Wu et al. 2008b) that early life 
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is a critical window for Pb’s influence on developmental reprogramming.  Mid-life 
cohorts could focus on later exposure periods and could incorporate traditional 
AD risk factors such as hypertension status and education achieved.  Late-life 
cohorts would involve the best AD and mild cognitive impairment (MCI) 
diagnostic tools and study the role of cumulative lifetime Pb exposure. 
 Finally, epidemiologic data needs to be incorporated with epigenetic 
studies on ADRC brain bank tissues.  Epigenetic changes are associated with 
age (Wang et al. 2008), sex (Anway et al. 2005), exposures (Dolinoy et al. 2007), 
and diseases (Waterland and Garza 1999).  Alzheimer’s disease specific 
epigenetic change may need to be extracted from a noisy background of age-
specific epigenetic drift, sex-specific epigenetic marks, co-morbidity disease 
changes, and a lifetime of environmental exposures. The majority of existing 
studies of brain epigenetics focus on CpG islands and the application of array-
based approaches that only cover a portion of the genome, largely in genic 
regions.  Rapid advances in technology and reduction in costs have made new 
approaches using next-generation sequencing (NGS) feasible for larger sample 
sizes.  These new approaches have been lauded as unbiased but criticized as 
relative (rather than quantitative) measures of DNA methylation.  The depth of 
genome coverage will be able to provide the large amount of information needed 
to detect subtle changes from multiple sources.  Integration of these data with 
ongoing studies of biomarkers in other neurodegenerative diseases and in non-
diseased aging populations will help elucidate the specific epigenetic changes 
associated with LOAD, providing a foundation for prevention and treatment of 




Figure 1.1. Conceptual diagram describing the relationship between 
environmental exposures, including to the heavy metal lead, with the 
development of late-onset Alzheimer’s disease. There is a complex interplay of 
genetics and epigenetic programming.  Epidemiologic cohort studies can be 
designed to study different stages in the life course leading to disease 
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Background: Epidemiologic studies suggest that elevated circulating level of 
homocysteine (Hcy), a one-carbon metabolite, is a risk factor for cardiovascular 
and neurodegenerative diseases.  Although a few cross-sectional studies have 
evaluated the influence of environmental toxicant exposures on Hcy levels, 
longitudinal studies and studies of the interplay of environmental and dietary 
factors are lacking. 
Objectives: We examined the association of recent and cumulative exposure to 
lead with Hcy levels cross-sectionally and longitudinally.  We also determined 
whether lead exposure’s association with Hcy varied by dietary intake of nutrients 
involved in one-carbon metabolism (folate and vitamins B6 and B12). 
Methods: We followed 1,056 of the Normative Aging Study men (age 50-97 at 
visit 1) over 4 study visits (2,301 total observations) at which concurrent 
measures of blood lead and Hcy were collected.  We determined baseline 
cumulative dose of lead via Cd109 K-shell X-ray fluorescence of the tibia and 
patella bones. We estimated cross-sectional differences in Hcy across levels of 
Pb exposure measures using generalized linear models.  We also used mixed 
effects models to estimate differences in rate of change in Hcy over time 
associated with Pb exposure.   
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Results: Higher exposure to lead was associated with higher Hcy levels.  An 
interquartile range (IQR) increment in tibia bone lead concentration (14µg/g) was 
associated with 3.64% higher Hcy at visit 1 (95% CI= 1.37-5.97).  Similar results 
were found at other visits, but tibia Pb was not associated with trajectory in Hcy 
over time.  An IQR increment in blood lead concentration (3 µg/dl) was 
associated with 8.14% higher Hcy (95% CI: 6.16-10.16) at visit 1, similar to the 
results at other visits. To put these findings in context, in our data, a 5-year 
increment in age corresponded to a 3.14% increase in Hcy (95% CI=2.88-7.87).  
The association between blood lead and Hcy was significantly larger among 
participants with lower dietary intakes of vitamins B6, B12, and folate.   
Conclusion: Increasing levels of lead exposure were associated with elevated 
Hcy, and this relationship was stronger in individuals with low dietary folate, B6, 
and B12. Increased intake of folate, B6, and B12 may be an effective intervention 
on lead’s effects on Hcy.   
KEYWORDS: aging, folate, homocysteine, lead exposure 
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INTRODUCTION 
 The post-war baby boom and lengthening life spans are fueling an 
unprecedented growth in the population of older adults worldwide, with 
widespread implications for stress on public health and medical infrastructures.  
Thus, increasing numbers of older adults are at risk of chronic diseases that 
require care and monitoring over decades.  Several chronic diseases, including 
cardiovascular disease (CVD) and neurodegenerative diseases, share a 
common risk factor, elevated homocysteine (Hcy), which is measured in the 
blood or cerebrospinal fluid.  Relatively little is known about the causes of 
elevated Hcy; in particular, the potential influence of environmental toxicant 
exposures and their interplay with dietary factors.  Research on the regulation of 
Hcy may result in opportunities for intervention prior to onset of chronic disease.   
Homocysteine (Hcy) 
 Hcy is a thiol-containing amino acid that is highly reactive and thus short-
lived in the body (Jocelyn 1972).  It is an intermediate in the one-carbon 
metabolism cycle, formed in the production of methionine, an important methyl 
donor for epigenetic modifications to nucleic acids and proteins (FIGURE 2.1).  
Though physiologically normal cellular processes produce and require Hcy at low 
levels, elevated Hcy is associated with toxicity.  Accessible cysteinyl residues in 
cellular proteins can react with free Hcy, forming Hcy-protein thiol-thiol 
interactions, altering native protein conformation and function.  In addition, free 
Hcy can cleave accessible disulfide bridges, damaging native protein 
confirmations (Krumdieck and Prince 2000). Biochemical damage is based on 
the duration and concentration of exposure to Hcy.  Long-lived proteins can 
accumulate irreversible Hcy-related damages, making these mechanisms 
especially relevant to the chronic diseases and morbidity of aging.   
Elevated Hcy is a risk factor for both CVD and neurodegeneration.  In 
epidemiologic studies, moderately elevated Hcy is associated with CVD.  In a 
meta-analysis of 30 retrospective or prospective studies, reduced plasma Hcy 
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was protective against ischemic heart disease (IHD) (OR=0.89 for 25% lower 
Hcy), and stroke (OR=0.81) (Collaboration 2002).  Similarly, a 5-μmol/L increase 
in Hcy corresponded to elevated odds of IHD (OR=1.23) and stroke (OR=1.42) in 
a meta-analysis of 20 prospective studies (Wald et al. 2002). The suggested 
mechanisms linking Hcy and cardiovascular outcomes include impaired 
endothelial elasticity and the production of reactive oxygen species (Perla-Kajan 
et al. 2007).   
 Elevated Hcy is also associated with decline in multiple cognitive domains.  
In the Veteran’s Affairs Normative Aging Study (NAS) of older men, higher 
baseline Hcy was associated with reduced spatial copying and verbal recall over 
a three-year follow-up period (Tucker et al. 2005).  Data from the Oxford Health 
Aging Project show high Hcy is associated with declines in general cognitive 
function as measured by the Mini-Mental Status Exam (MMSE) over a ten-year 
period (Clarke et al. 2007).  In a two-year follow-up study in Korea, incidence of 
dementia increased across ascending quintile of Hcy at follow-up (Kim et al. 
2008).  In the Sacramento Area Latino Study on Aging, higher baseline Hcy was 
associated with increased risk of both incident dementia and cognitive 
impairment in the absence of dementia over the subsequent 4.5 years of follow-
up (Haan et al. 2007).  Hcy is also an important risk factor for Alzheimer’s 
disease (Seshadri et al. 2002).   
Circulating Hcy can be lowered with dietary interventions, primarily 
therapy with folic acid, vitamin B12, and vitamin B6  (Appel et al. 2000).  Several 
randomized control trials have evaluated the effects of these therapies on cardio- 
and cerebrovascular events, their results have been mixed.  A meta-analysis of 
seventeen trials of individuals with preexisting cardiovascular or renal disease 
showed no differences between the Hcy-lowering treatment group and control 
group with respect to coronary heart disease, stroke, cardiovascular events, or 
all-cause mortality (Mei et al. 2010).  Dietary changes can reduce Hcy, but in 
individuals with pre-existing conditions, hypothesized improvements in health 
outcome do not seem to occur with the reduction (Mei et al. 2010).   
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Lead Exposure 
 The heavy metal lead (Pb), is a well-established and ubiquitous toxicant.  
The molecular mechanisms of lead’s toxicity in the human body are numerous 
but incompletely characterized.  Pb binds free sulfhydryl groups on proteins and 
can alter protein conformation and activity (Needleman 2004). Pb can form 
protein complexes in the kidney’s proximal tube, which lead to poor blood 
pressure regulation and cardiovascular problems (Goyer 1989).  Pb can also 
compete with or replace other divalent cations including calcium and iron.  In the 
central nervous system, rodent model research indicates lead exposure reduces 
synaptic plasticity and hippocampal long-term potentiation (Toscano and Guilarte 
2005).  It also results in a cascade of molecular changes including reduced 
cAMP and protein kinase A activity, altered MAPK signaling, and disruption of 
CREB phosphorylation (Toscano and Guilarte 2005).  Pb and Hcy both 
independently exert toxicity in part by binding to free sulfhydryl groups and 
damaging proteins.   
Exposure to Pb is linked to numerous diseases and negative health 
outcomes throughout the lifespan.  In late life, lead exposure, even at low levels 
experienced in the community, is related to CVD, as measured through 
hypertension (Cheng et al. 2001), heart rate variability (Park et al. 2006), and 
clinical CVD outcomes (Navas-Acien et al. 2007).  Lead exposure is also 
associated with poor cognition and cognitive decline in aging populations (Shih et 
al. 2007; Weuve et al. 2009).  
Lead Exposure and Homocysteine 
Previous studies have demonstrated a relationship between Pb and Hcy 
at single time points.  In the Baltimore Memory Study, blood Pb and plasma Hcy 
were significantly correlated with each other (Pearson’s unadjusted r=0.27) 
(Schafer et al. 2005).  Similarly, in Pakistan, a cross-sectional survey of persons 
aged 18-60 years, an increase of 1 μg/dL log blood Pb was associated with an 
increase of 0.09 μmol/L log Hcy after multivariable adjustment (Yakub and Iqbal 
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2010).  In a third cross-sectional study, this time in Vietnam and Singapore, an 
increase of 1μg/dl log blood lead was associated with an increase of 0.04μmol/l 
log Hcy among occupationally exposed 449 workers (mean age=39; mean blood 
Pb= 22.7 μg/dl) (Chia et al. 2007).   
One reason that lead exposure and elevated Hcy are associated with 
many of the same negative health outcomes is that lead exposure elevates Hcy.  
For example, in the 1999-2002 National Health and Nutrition Examination Survey 
(NHANES), Hcy was associated with peripheral arterial disease (PAD) (OR of 
PAD in the highest quintile of Hcy relative to the lowest was 1.92, p-trend=0.004), 
however the association disappeared following adjustment for blood lead and 
calcium levels as well as kidney function (OR=0.89, p-trend=0.87) (Guallar et al. 
2006).  This research suggests the Hcy may be a marker of exposure to other 
toxicants, rather than the toxic agent itself. 
 Pb and Hcy levels may be mechanistically linked.  Several proteins in the 
homocysteine processing one-carbon metabolism cycle (FIGURE 2.1) contain 
sulfhydryl groups that may be potential reaction sites for lead (Schafer et al. 
2005).  Cystathionine β-synthase (CBS) catalyzes the breakdown of Hcy into 
cysteine.  CBS has two sulfhydryl groups that may be subject to reaction with 
lead, potentially interfering with the enzyme’s ability to transsulfurate Hcy into 
cysteine (Schafer et al. 2005).  In addition, Hcy contains a sulfhydrl group and 
lead may directly inhibit its metabolism.  There is also evidence for the protective 
effect of methionine on lead toxicity (Chen et al. 2011).  It is hypothesized that Pb 
could directly influence the levels of Hcy in the body. 
The association reported between lead and Hcy is plausible and 
supported by compelling data, but it requires further epidemiologic investigation 
in an additional population.  Thus far, only one study has tested the Pb-Hcy 
relationship in a community-exposed population of older adults.  There are 
currently no studies evaluating the relevant window of Pb exposure’s effect on 
Hcy.  Studies of cumulative Pb exposure and Hcy are needed to fill this gap.  In 
45 
addition, there are no data indicating whether the association of Pb exposure 
with Hcy can be mitigated (or worsened) with intake of B vitamins.   
Objectives 
 The goal of this study was to evaluate the relationship of lead exposure to 
plasma Hcy in a population of community-exposed older men.  We tested the 
hypothesis that recent exposure to Pb (meausured by blood Pb) is associated 
with concurrent Hcy levels.  Next, we evaluated whether people who have 
changes in their blood Pb over time also have corresponding changes in their 
Hcy levels.  We also tested whether those with a diet low in methyl donors 
(folate, vitamin B6, and vitamin B12) are more susceptible to the effects of Pb 
exposure on Hcy.  Finally we evaluated the relationship of cumulative Pb dose 
(tibia and patella bone Pb) and Hcy in comparison to acute/recent Pb exposure. 
METHODS 
Study Population 
In 1963, 2,280 men in the greater Boston area between the ages of 21 
and 80, and representing a range of educational and occupational backgrounds, 
were enrolled in the Veteran’s Affairs Normative Aging Study (NAS) (Bell et al. 
1972).  All participants were free of disease at the onset of the study and 
participated in health assessments every three to five years that expanded in 
scope over time.  Blood lead measurements began in 1977 and bone lead 
measurements began in 1991.  Homocysteine was first measured in 1993.  At 
each study visit, age, smoking status, medication use, physical activity, and 
dietary intake were assessed.    
In the study of Hcy, up to six repeated measures of Hcy from 1,080 men 
for a total of 2,941 observations were available.  Bone lead data was missing for 
301 individuals and there were a total of 779 subjects across 2,252 observations 
that had bone lead data and Hcy measures. Approximately three years after the 
bone lead assessment, the first Hcy was measured. Concurrent blood lead data 
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was missing from 23 participants and there were 1,056 individuals with 2,301 
observations of Hcy and blood Pb.   In an additional analysis of the changes in 
blood Pb and Hcy, a subset of the main dataset was used.  At least two repeated 
measures of blood lead and concurrent Hcy were available from 747 men for a 
total of 1,830 repeated observations. The majority of blood lead measurements 
(>99%) were made within 30 days of Hcy measurements. The Human Subjects 
Institutional Review Boards at the Harvard School of Public Health, the 
Department of Veterans Affairs Outpatient Clinic in Boston, the Brigham and 
Women’s Hospital, and the University of Michigan Medical School approved this 
study. 
Plasma Homocysteine Measures  
 Fasting blood plasma was collected during each clinic visit and frozen at 
negative 80ºC.  Samples were analyzed at the Jean Mayer US Department of 
Agriculture Human Nutrition Research Center on Aging.  Total Hcy was 
measured via fluorescence detection with high-performance liquid 
chromatography (HPLC) (Araki and Sako 1987).  Hcy detection methods have 
been previously described in detail (Tucker et al. 2005).  Plasma folate levels 
below 3 ng/mL were considered low (LSRO 1984). Plasma B6 levels at 30nmol/L 
were considered adequate (US RDA, NIH Office of Dietary Supplements).  
Plasma B12 below 250 pg/mL was considered low (US RDA, NIH Office of 
Dietary Supplements).  Participants with low nutrient status were included in the 
analysis. 
Lead Exposure Measures 
 Lead levels can be measured in various tissue types across the body to 
reflect different exposure times.  Blood lead levels indicate recent exposure (with 
a half-life of approximately 30 days) (Hu et al. 1998).  Blood lead levels included 
in this analysis were measured up to six times between 1993 and 2011 via 
graphite furnace atomic absorption with Zeeman background correction. 
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 Bone lead was measured in two bone types (tibia and patella) through 
Cd109 K-shell x-ray fluorescent (KXRF) spectroscopy using methods previously 
described (Hu et al. 1996). The half-life for lead in cortical tibia bone is estimated 
at 48.6 years in the NAS (Wilker et al. 2011).  The trabecular patella bone has a 
shorter half-life for lead (between 10-15 years) (Hu et al. 1998).  The primary 
statistical analyses were performed using tibia Pb, while patella Pb was used as 
a secondary sensitivity analysis.   
Dietary Measures 
 Annual average diet was assessed with the semi-quantitative Willett Food 
Frequency Questionnaire using methods described previously (van de Rest et al. 
2009).  Before each study visit, participants were mailed the questionnaire.  Their 
responses were checked for completeness at the study visit.  The questionnaire 
assesses frequency of consumption of 126 items on a scale ranging from never 
to ≥2 times per day. Three one-carbon metabolism dietary factors were 
measured without supplements and were used in the current study (folate, 
vitamin B6, and vitamin B12).  Nutrient quantification based on FFQs 
administered after August, 1997 were adjusted to consider folate fortification in 
the US.  Total calorie intake-adjusted nutrient residuals (Willett et al. 1997) 
(Willett et al. 1997) were calculated for each individual and included in the 
models. 
Statistical Analysis  
 All analyses were performed in R Statistical Software (version R 2.15.0).  
Univariate descriptive statistics were calculated for each variable.  We also 
estimated bivariate associations between Hcy, and the three lead exposure 
measures and additional covariates were also calculated.   
We assessed the associations between blood Pb and concurrent Hcy 
using multivariable-adjusted linear models.  Because the distribution of Hcy 
levels is skewed, we natural log-transformed the variable Hcy. Thus, the 
exponentiated parameter estimates from these models are directly interpreted as 
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the percentage difference in Hcy per unit increment in predictor.  We adjusted 
these analyses for several sets of covariates.  All analyses were adjusted for the 
following “core covariates”: age, education, smoking status, alcohol consumption, 
and body mass index (BMI) (Schafer et al. 2005).  The following plasma levels of 
one-carbon metabolism related compounds were considered the “plasma 
sensitivity covariates”: plasma PLP (a measure of vitamin B6), vitamin B12, and 
folate.  Finally, dietary measures were categorized as the “dietary sensitivity 
covariates”: intakes of total energy and calorie adjusted residuals for vitamin B6, 
vitamin B12, and folate.  We tested for non-linear trends using generalized 
additive models with penalized splines in the mgcv R package.   
Using the repeated measures of Hcy and linear mixed effects models with 
random intercepts, we compared rates of change in Hcy (as percentage change 
from baseline Hcy) by level of lead biomarker.  We modeled interaction terms 
between time and baseline age to capture the trajectories of Hcy over the follow-
up period.  Several error covariance matrices were considered, but they did not 
improve model fit, so no within-subject correlation was used. All models were 
adjusted for Core Covariates, Plasma Sensitivity Covariates, and Dietary 
Sensitivity Covariates, similar to the concurrent exposure models.  In addition, all 
models included a cross-product term between time and baseline age.  The 
inclusion of other time-covariate cross-products did not change the results. 
We used “change-change” models to assess whether change in Pb level 
over time was associated with concomitant changes in Hcy.  In these models, we 
restricted the analyses to individuals with at least two measures of Pb and Hcy 
(747 individuals, 1,830 observations).  We regressed change in blood Pb on 
change in Hcy, adjusting for the core covariates.   
To assess the potential modification of the association between Pb and 
Hcy by key nutrients, we fit models stratified by median plasma or dietary levels 
of folate and vitamins B6 and B12.  We used methods by Payton et al. (Payton et 
al. 2003) to test for differences in the effect of lead on Hcy between the high and 
low nutrient strata.  This permits other covariate-Hcy associations to vary across 
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the strata, associations that may influence the stratum-specific Pb association.  
In addition, however, we fit models, incorporating all observations that included a 
cross-product term between each Pb marker measure and nutrient measure.   
Additional analyses were performed to determine whether the effects of 
cumulative lead dose were mediated through current blood lead levels.  Our 
secondary aim was to determine whether lead-associated changes in Hcy were 
associated with recent exposure measured by blood lead or cumulative dose 
measured by tibia lead.  We used mixed effects core covariate models containing 
tibia Pb, both tibia Pb and blood Pb, and blood Pb alone as a basic mediation 
analysis.    
RESULTS 
 The univariate descriptive statistics for subjects with blood Pb levels are 
presented in Table 1.  These values are similar to those for the population with 
tibia bone lead measures.  The geometric mean Hcy level in this population was 
10.2 nmol/ml (GSD= 1.3) (TABLE 2.1).  Mean (SD) blood, tibia bone, and patella 
bone lead levels were 4.4(2.5) µg/dl, 21(13) µg/g, and 29.9(19.5) µg/g, 
respectively.  Similar to the general US population at this time, blood lead levels 
decreased across study visits.  In general, this population was elderly (age 70.9 
(7.3)), overweight (BMI 28(4)), educated (64.2% with some post-high school 
education), moderate-heavy drinkers (20.6% with more than 2 drinks per day), 
and former smokers (66.2%).   
At visit one, log(Hcy) was positively correlated with blood Pb, tibia bone 
Pb, and patella bone Pb (respectively Pearson’s r=0.28 p=2x10-16; r=0.15 
p=2x10-5; r=0.16, p=3x10-5) (Supplemental Figure 2.1).   The bivariate 
associations between Hcy and other covariates before and after age-adjustment 
at study visit 1 are listed in Table 2.2.  Hcy was positively associated with 
increasing linear trend in categories of blood Pb, tibia bone Pb, patella Pb, age, 
alcohol consumption, and smoking status.  Hcy was inversely associated with 
plasma PLP (B6), B12, folate and dietary B6 levels.  Similar associations were 
50 
observed at the other study visits (data not shown).  A notable exception is that 
smoking was only associated with Hcy at study visit one.   Similar results are also 
observed in the population with tibia bone Pb levels (n=774) (data not shown).  
The bivariate associations between covariates and blood Pb as well as tibia bone 
Pb are also presented in Table 2.2.  Blood Pb was positively associated with age 
and alcohol intake.  Blood Pb was negatively associated with increased 
education, plasma B6, plasma B12, plasma folate, dietary B6, and dietary B12.  
Tibia bone Pb was positively associated with smoking status (current smokers 
with higher exposure) and tibia bone Pb was negatively associated with 
increased education, plasma B6, plasma folate, and dietary B6.   
 After adjustment for age, education, alcohol, smoking, and BMI (Core 
Covariates) an IQR increment in blood Pb (3 ug/dl) at visit 1 was associated with 
an 8.0 percent increase in Hcy (95% CI: 6.0-10.0).  By comparison, a 5-year 
increment in age was associated with a 3.2 percent increase in Hcy (95% CI=2.0-
4.4) (FIGURE 2.2A).  The percent difference in Hcy at visit 1 between never 
smokers and current smokers was 14.0 (95% CI: 5.6-23.1).  The difference in 
Hcy between never smokers and former smokers was not statistically significant.    
Next we added to the model plasma factors that influence Hcy metabolism.  After 
further adjustment for the plasma sensitivity covariates (plasma PLP, B12 and 
folate), an IQR increment in blood Pb was associated with 6.4% increase in Hcy 
(95% CI: 4.5-8.3), while after further adjustment for the dietary sensitivity 
covariates (core covariates plus total energy consumption, dietary B6, B12, and 
folate), an IQR increment in blood Pb was associated with 5.6 in Hcy (95% CI: 
1.4-9.9).  These results were consistent across the 4 study visits (FIGURE 2.2A).   
Results from the mixed effects models of the repeated blood Pb and Hcy 
measures were consistent with those from the models based on single visits 
(TABLE 2.3).    Plasma B6, plasma B12, plasma folate, and dietary B6 were 
significant negative predictors of log(Hcy).  In the core model, a 3 ug/dl (IQR) 
increase in blood Pb is associated with 6.0% increase in Hcy (95% CI: 4.6-7.5).   
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The adverse association between blood Pb and Hcy was stronger among 
men whose dietary intake of vitamin plasma B6, B12, or folate fell below the 
median B6: 2.24 mg/day, B12: 6.185 mcg/day, folate: 343 mcg/day) (FIGURE 
2.4).  Results were similar albeit weaker for the plasma vitamin measures.  None 
of the blood lead estimates for men with the higher vitamin levels was 
significantly different from the corresponding estimates for men with the lower 
vitamin levels.  Data was stratified by median plasma level (B6: 64.1 nmol/L, 
B12: 447.5 pg/mL, folate: 11.4 ng/mL) or median dietary levels (B6: 2.24 mg, 
B12: 6.185 mcg, folate: 343 mcg).   However, when we modeled the interaction 
between blood Pb and the nutrients using cross-product terms, the interactions 
corresponding to dietary B6, dietary folate, and plasma folate were statistically 
significant (p-values for interaction: 9.6x10-5, 0.0016, and 0.024 respectively), 
and the interaction corresponding to dietary B12 was borderline significant (p-
value for interaction: 0.051).  
Among the 747 men with two or more measures of blood Pb and Hcy, 
blood Pb levels generally declined over time (mean) but this decline was variable 
(SD or range).  Changes in Hcy generally “tracked” changes in blood Pb, with a 
1-μg/dL drop in blood Pb corresponding to a 5% drop in Hcy, but this association 
was not statistically significant (Supplemental Tables 2.1 and 2.2).   
Higher cumulative exposure to Pb, as measured by tibia bone lead 
concentration, was also significantly associated with increased plasma Hcy.  
Using all four study visits, tibia bone Pb was a significant predictor of log(Hcy) (p-
value =0.0012) (TABLE 2.4).  Similarly, at visit 1 alone, tibia Pb predicted 
log(Hcy) (p-value=0.016).  Next we looked at each visit individually using linear 
regression with three sets of covariates.  Similar to the blood lead analysis, after 
adjusting for the Core Covariates (age, education, alcohol, smoking, and BMI) an 
IQR change in tibia bone Pb (14 ug/g) at visit 1 was associated with a 3.6 
percent increase in Hcy (95% CI: 1.4-6.0) (FIGURE 2.2B).  After further 
adjustment for plasma PLP, B12 and folate, an IQR change in tibia Pb was 
associated with 2.4 percent increase in Hcy (95% CI: 0.2-4.6).  Finally in the 
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dietary sensitivity model, an IQR change in tibia Pb was associated with 2.5% 
increase in Hcy (95% CI: -0.3-5.4).  Similar results were observed across the four 
study visits. 
While cumulative exposure to lead was associated with consistently higher 
plasma Hcy over the course of follow-up, it was not associated with the degree to 
which plasma Hcy changed over time (TABLE 2.5).  On average, Hcy levels 
increased by about 1.2% per year of follow-up.  An IQR increment in tibia Pb (14 
µg/g) corresponded to a negligible 0.02% slower percentage change in Hcy over 
time (95% CI: XX). 
There were no significant differences in the concurrent effect of bone Pb 
on Hcy between persons with low and high plasma or dietary B vitamins or folate.  
In a subset of individuals (n=221) with at least three repeated visits with dietary 
information (n=691 observations), we tested for a long term dietary influence on 
Hcy.  We averaged dietary intake of folate and vitamins B6 and B12 over three-
four visits and used mixed effects models to test for dietary associations with 
Hcy.  In this smaller set of individuals, tibia Pb was no longer a significant 
predictor of Hcy and we did not observe a long term dietary trend (Supplemental 
Table 2.3). 
To determine whether the association between cumulative exposure to Pb 
and Hcy was mediated by current exposure to Pb, we further adjusted the 
analyses of tibia Pb for blood Pb as a predictor (TABLE 2.6). Adding blood Pb to 
the model removed the association between tibia Pb and Hcy.  We see similar 
results when we restrict the dataset to just visit one and compare the linear 
multivariate models containing (1) core covariates and tibia Pb, (2) core 
covariates, tibia and blood Pb, and (3) core covariates and blood Pb 
(Supplemental Table 2.4).  Tibia Pb is an significant predictor of Hcy at visit 
one, but it drops out of the model with the addition of blood Pb.  This suggests 
that the association between tibia Pb and Hcy may be mediated by blood Pb.     
DISCUSSION 
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 This cohort study examined the association between Pb exposure and 
circulating Hcy levels in a population of elderly community-dwelling men in the 
greater Boston area.  Increased current blood Pb exposure was associated with 
greater Hcy levels.  These effects were stronger in individuals with low dietary 
vitamins B6, B12, and folate as well as plasma folate.  Greater cumulative 
exposure to Pb, measured in the tibia and patella bones, was associated with 
higher levels of Hcy.  Further analyses revealed that these results may be 
mediated through current blood Pb and that Hcy responds to acute Pb dose. 
The present finding that Pb exposure is associated with Hcy levels is 
consistent with prior epidemiological studies.  The Baltimore Memory Study 
examined the cross-sectional association between Pb and Hcy in a population of 
1,037 adults (mean age= 59) with similar blood Pb and Hcy to our study.  The 
analysis observed a 1.0 ug/dL increase in blood lead was associated with a 0.43 
μmol/L increase in Hcy in males, but no association was observed with tibia Pb 
(Schafer et al. 2005).  Among 872 adults in Pakistan age 18-60, with mean blood 
Pb 11.65± 5.5 μg/dl, an increase of 1 μg/dl log blood Pb was cross-sectionally 
associated with an increase of 0.09 μmol/l log Hcy (Yakub and Iqbal 2010).  In a 
group of 276 workers occupationally exposed to Pb in Vietnam, blood lead and 
Hcy were associated (Pearson’s correlation=0.255, p<0.01) (Chia et al. 2007).  
Our research has confirmed the association between lead exposure and Hcy 
demonstrated in the above studies.  However, these studies did not examine 
longitudinal change in Hcy and they did not assess how the association might be 
influenced by intake of folate and B-vitamins. 
 The results of this study are plausible given that Pb and Hcy share toxic 
mechanisms.  Both form stable disulfide bonds with protein cysteine residues, 
potentially altering protein function.  In particular, albumin (the dominant protein 
in blood) Cys34 has a low pKa that readily reacts with metals and Hcy (Carter 
and Ho 1994). In addition, both are associated with inflammation (Hcy through 
NF-kB activation of IL-8 and MCP-1 (Perla-Kajan et al. 2007); and Pb through 
cytokine production (Heo et al. 1996)).  Given the independent cell culture and 
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animal model evidence on each toxicant (Pb and Hcy), our epidemiological 
observations on the associations between Pb and Hcy, with interactions with B-
vitamins, are plausible.  Studies are needed to examine the health effects of 
combined exposure to Pb and these vitamins, and the degree to which they are 
mediated by Hcy. 
 The current analyses are influenced by a few limitations of the data. First, 
there may be error in the measurement of Hcy.  The time of day of blood draw for 
Hcy measures was not standardized.  In healthy individuals over a 24-hour 
period, Hcy levels showed a daily rhythm characterized by an evening peak and 
nighttime low (Bonsch et al. 2007).  Whole blood genomic DNA methylation 
varies throughout the day and is inversely correlated with Hcy levels (Bonsch et 
al. 2007).  Unstandardized Hcy collection times in our study would have biased 
our results towards the null hypothesis of no association between Hcy and Pb.  In 
addition, plasma measures of Hcy assess the pool of Hcy released after 
reduction of all disulfide bonds in the sample.  Total Hcy does not include 
homocysteine thiolacetone (a product of misincorporation of Hcy into proteins 
and subsequent error-editing) or Hcy bound to protein by an amide bond (Perla-
Kajan et al. 2007).  These Hcy groups are potentially toxic and may not be 
correlated with plasma concentrations of Hcy (Perla-Kajan et al. 2007). 
Another potential weakness of this study is the limited power to detect 
interactions.  This problem is exacerbated in our study due to missing nutrient 
data and smaller sample sizes in dietary models.  The change-change analyses 
also have limited power as participants were lost to follow-up over time.   
Epidemiologic studies that identify mediators linking exposure and 
outcome strengthen the model’s biological plausibility and potential causal 
relationship (Hafeman 2011).  In this study, we measured blood Pb as a mediator 
of tibia Pb.  Our results are based on the assumption that there are no 
unmeasured confounders of the causal effect of the mediator (blood Pb) on the 
outcome (Hcy) (Cole and Hernan 2002). With these caveats in mind, our analysis 
incorporating blood Pb and tibia Pb suggest that the influence of Pb exposure on 
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Hcy is fairly immediate and thus that recent exposure to Pb (measured in blood) 
may be driving the association between Pb and Hcy.  Despite cumulative 
exposure, interventions that lower acute blood Pb levels may be an effective 
strategy to lower Hcy. 
The current study is strengthened by the use of repeated measures of Hcy 
and blood Pb as well as repeated measures in Hcy with baseline bone Pb.  This 
allows us to look at longitudinal changes in Hcy with Pb exposure, not simply 
cross-sectional associations.  This study is the first to examine the Pb-Hcy 
relationship while examining plausible dietary interactions, namely folate and 
vitamins B6 and B12. 
Since Pb exposure is related to elevated Hcy levels, toxicology studies are 
needed to determine the mechanism and potential reversibility of Pb and 
disturbed Hcy metabolism.  Based on the current study, dietary intervention with 
folate and vitamins B6 and B12 may be a potential option to remediate elevated 
Hcy high Pb exposed individuals.   
In the 1999-2002 US National Health and Nutritional Examination Study 
(NHANES), Hcy was cross-sectionally associated with peripheral arterial disease 
(PAD), but adjustment with blood Pb, Cd, smoking, and glomerular filtration rate 
removed the Hcy association (Guallar et al. 2006).  This suggests that Pb and 
Hcy levels are related and are associated with cardiovascular effects.  Future 
research may test this association and the association with cognitive decline in 
cohort studies.   
 In conclusion, we report a significant association between blood, patella, 
and tibia Pb levels with higher levels of plasma Hcy in a group of older men.  The 
association corresponding to blood Pb was strongest, suggesting that circulating 
lead may influence circulating Hcy through its metabolism, even at very low 
levels of exposure.  The effects of chronic lead exposure are also supported by 
these results.   
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 Diet may modify the association between blood Pb and Hcy.  The adverse 
effect of blood lead on Hcy may be worse in the presence of low folate, vitamin 
B6, and vitamin B12 intake (equivalently: the adverse effect of low folate intake 
on Hcy may be worse in the presence of lead, even for very modest levels of 
lead exposure).  Altered Hcy levels, such as those observed in the range here, 
may increase risk for cardiovascular and neurodegenerative disease and 
measures should be taken to reduce blood lead levels and improve dietary 







Table 2.1. Univariate Statistics: Characteristics of individuals with complete Hcy and blood Pb (2234 obs, 1048 
individuals).  Mean (S.D.), except where noted. 




1056 747 400 98 

















10.2(1.3) 0(0) 10.1(1.3) 0(0) 10.2(1.3) 0(0) 10.5(1.3) 0(0) 10.8(1.3) 0(0) 
Blood Pb (μg/dl) 4.4(2.5) 0(0) 4.9(2.7) 0(0) 4.2(2.3) 0(0) 3.6(2.2) 0(0) 3.4(2.2) 0(0) 
Age (years) 70.9(7.3) 0(0) 69(7.4) 0(0) 71.3(6.9) 0(0) 74(6.5) 0(0) 76.4(5.9) 0(0) 
Education 
< HS [n(%)] 
HS [n(%)] 
Some college [n(%)] 
College [n(%)] 


































































≤ 2 drinks/day [n(%)] 





















BMI 28(4) 0(0) 28(3.9) 0(0) 28.2(4) 0(0) 27.9(4.2) 0(0) 27.5(3.7) 0(0) 
Tibia Pb (μg/g)   21.4(13.5) 285(27)       
Patella Pb (μg/g)   30.6(20.1) 289(27.4)       
Plasma B6 (nmol/l) 93.8(92.5) 27(1.2) 87.5(87.2) 12(1.1) 97(93.7) 9(1.2) 99.2(93.5) 5(1.2) 114.9(125.5) 1(1) 
Plasma B12 (pg/ml) 490(235.8) 26(1.1) 466.4(222) 21(2) 493.4(244.1) 2(0.3) 519.9(230.5) 3(0.8) 593.4(289.4) 0(0) 
Plasma Folate (ng/ml) 14.2(11.7) 35(1.5) 11(7) 30(2.8) 14.8(12.9) 2(0.3) 19.4(15.2) 3(0.8) 22.2(14.7) 0(0) 

















Dietary B6 (w/o supp) (mg) 2.4(1) 104(4.5) 2.3(0.9) 49(4.6) 2.4(0.9) 25(3.3) 2.4(1.1) 22(5.5) 2.4(1.1) 8(8.2) 
Dietary B12 (w/o supp) (mcg) 7.5(4.8) 104(4.5) 7.9(5.5) 49(4.6) 6.9(3.8) 25(3.3) 7.4(4.4) 22(5.5) 8.1(5) 8(8.2) 
Dietary Folate (w/o supp) 
(mcg) 
379.1(179) 1034(44.9) 344(150.5) 794(75.2) 356.5(164) 210(28.1) 418.5(195) 22(5.5) 451.2(218.4) 8(8.2) 
* 






Table 2.2. Bivariate statistics based on visit 1. Characteristics of individuals with complete Hcy and blood Pb (1056 
individuals).  

















Blood Pb (ug/dl) 







6E-23 3<x≤5 347(32.9) 10.1(1.3)  10.4 4.4(0.5) 21.1(12.3) 
> 5 342(32.4) 11.1(1.4)  11.6 8(2.4) 27.4(16.4) 
Tibia Pb (ug/g) 








15<x≤23 248(23.5) 10.1(1.3)  10.5 4.6(2.3) 19.2(2.3) 
> 23 256(24.2) 10.7(1.3)  11.1 6.2(3.2) 35.7(13.3) 
Missing 285(27) 10.2(1.3)  10.6 4.8(2.6) NaN(NA) 
Patella Pb 
(ug/g) 








20<x≤34 258(24.4) 9.8(1.3)  10.2 4.5(2.4) 18.6(8) 
>34 253(24) 11(1.3)  11.3 6.3(3.2) 32.5(15.6) 
Missing 290(27.5) 10.1(1.3)  10.6 4.8(2.6) 13.6(12.5) 
Age Tertile 







0.4 66-71 327(31) 9.9(1.3)  10.3 4.9(2.8) 21.8(12.3) 
72-97 374(35.4) 10.7(1.3)  10.8 5(2.8) 26(16.3) 
Education 








HS 303(28.7) 10.2(1.4)  10.7 5.2(2.9) 24.7(15.9) 
Some College 288(27.3) 10.1(1.3)  10.6 4.8(2.7) 20.3(11) 
College 202(19.1) 9.9(1.3) 10.3  4.5(2.3) 18.9(11.3) 
> College 183(17.3) 10.2(1.3)  10.7 4.4(2.8) 17(9.4) 
Smoking Status 







0.002 Former 698(66.1) 10.1(1.3)  10.6 4.8(2.6) 22(13.6) 
Current 62(5.9) 11.2(1.3)  12.0 5.8(3.2) 22.1(11.5) 
Two Drinks/Day 








Yes 222(21) 10.8(1.4)  11.5 5.7(2.9) 21.2(12.1) 
BMI 







0.3 25≤x<30 574(54.4) 10.1(1.3)  10.6 4.8(2.7) 21.8(14.3) 
≥30 266(25.2) 10.1(1.3)  10.6 4.8(2.8) 20.4(13.3) 
Plasma B6 
(nmol/L) 







2E-05 ≥30 936(88.6) 10(1.3)  10.4 4.7(2.6) 20.6(13.2) 
Missing 12(1.1) 9.5(1.2)  9.7 5.3(2.8) 30.7(12.4) 
Plasma B12 
(pg/mL) 







2E-01 ≥ 250 953(90.2) 9.9(1.3) 10.3  4.8(2.7) 21.2(13.5) 















4E-03 ≥ 3 1002(94.9) 10(1.3)  10.4 4.8(2.7) 21.1(13.2) 
Missing 30(2.8) 10.3(1.4)  10.8 4.7(2.2) 28.6(21.5) 
Total Energy 
Consumption 







0.6 ≥2300 247(23.4) 10.2(1.3)  10.7 4.7(2.8) 20.8(13.6) 
Missing 70(6.6) 10.1(1.3) 10.4  4.8(2.4) 21.4(10.5) 
Dietary B6 (mg) 







0.05 ≥1.7 233(22.1) 10.6(1.3)  11.2 5.3(2.8) 22.7(15) 
Missing 49(4.6) 10.1(1.4)  10.4 4.8(2.5) 20.2(10.9) 
Dietary B12 
(mcg) 







0.06 ≥2.4 47(4.5) 10.6(1.4)  11.3 5.6(2.9) 25(14.7) 
Missing 49(4.6) 10.1(1.4)  10.4 4.8(2.5) 20.2(10.9) 
Dietary Folate 
(mcg) 







0.2 ≥400 189(17.9) 9.9(1.3)  10.2 4.6(2.5) 21.1(14.7) 






Table 2.3. Concurrent Pb exposure is associated with plasma homocysteine:  Mixed effects model, random intercept only.  
Equivalent to cross-sectional model taking into account correlated nature of observations from the same individual.  Linear 
mixed effects model of log(Hcy)t = b0 + b1[blood Pb]t + covariates.  Continuous variables have been centered so the 
intercept is interpretable. 
 
Core Model* Plasma Model** Diet Model*** 
 
2301 obs from 1056 indiv 
R2=0.10 
2240 obs from 1033 
 R2=0.16 
1241 obs from 779 indiv 
 R2=0.13 
 
Beta(SE) p-value Beta(SE) p-value Beta(SE) p-value 
(Intercept) 2.30(0.015) 0 2.30(0.014) 0 2.29(0.017) 0 
Blood Pb (per µg/dl) 0.0195(0.0023) 4E-17 0.0159(0.0023) 6E-12 0.0197(0.0035) 2E-08 
Age 0.0091(0.00084) 2E-26 0.0105(0.00085) 2E-33 0.0118(0.0012) 3E-22 
Education 
(reference>hs) 
-0.0127(0.013) 0.3 -0.0157(0.013) 0.2 0.00255(0.017) 0.9 
Alcohol 
Consumption 
0.0576(0.015) 2E-04 0.0572(0.015) 0.0002 0.0713(0.02) 0.0005 
Former Smoker 0.0176(0.017) 0.3 0.0148(0.016) 0.4 0.0123(0.019) 0.5 
Never Smoker 0.0690(0.032) 0.03 0.0646(0.031) 0.04 -0.0077(0.042) 0.9 













Dietary B6 Residual 
    
-0.0310(0.014) 0.03 
Dietary B12 Residual 
    
-0.00308(0.0021) 0.1 
Dietary Folate 
Residual     
3.03e-05(6.4e-05) 0.6 
Total Energy Intake 
    
-1.64e-05(1.1e-05) 0.1 
*Core model adjusts for blood Pb, age, bmi, education, smoking status, and alcohol consumption. 
**Plasma model adjusts for core model covariates and plasma B6 (PLP), B12, and folate. 






Table 2.4. Cumulative exposure is associated with plasma homocysteine:  Mixed effects model, random intercept only.  




Visits 1-4 Visit 1 
 
2158 observations from 777 individuals 
R2=0.6 
777 obs from 777 individuals 
R2=0.061 
 
β(SE) p-value β(SE) p-value 
(Intercept) 2.32(0.016) 0 2.29(0.02) 0 
Tibia Pb 0.00215(0.00066) 0.001 0.00256(0.00081) 0.002 
Age 0.00921(0.00094) 4E-22 0.00526(0.0015) 0.0007 
High School -0.0148(0.015) 0.3 -0.036(0.022) 0.09 
Two Drinks/Day 0.0675(0.017) 8 E-05 0.0817(0.025) 0.001 
Former Smoker 0.00934(0.019) 0.6 0.0291(0.022) 0.2 
Current Smoker 0.0422(0.035) 0.2 0.143(0.047) 0.002 






Table 2.5. Longitudinal mixed effects models: Log(hcy) is outcome and tibia pb is main predictor.  Continuous covariates 
have been mean adjusted so that the intercept can be interpreted as the log(hcy) at the mean of those covariates and 
when dummy variables =0.  Four visits of tibia Pb and Hcy have been used.  Random intercept and slope. 
 Core Model* Plasma Sensitivity Model** Diet Sensitivity Model*** 
 n= 2158, R2=0.0811 n= 2106, R2=0.114 n= 1328, R2=0.098 
 β (SE) p-value β (SE) p-value β (SE) p-value 
Intercept 2.28(0.017) 0 2.25(0.019) 0 2.24(0.022) 0 
Tibia Pb 0.00255(0.00077) 0.0009 0.00254(0.00076) 0.0009 0.00214(0.001) 0.04 
Time Since Baseline 0.0123(0.0014) 2E-18 0.0149(0.0015) 1E-23 0.0178(0.0022) 6E-15 
Baseline Age 0.0049(0.0015) 0.0009 0.005(0.0014) 0.0006 0.00665(0.0021) 0.001 
Education -0.0186(0.014) 0.2 -0.0211(0.014) 0.1 -0.00374(0.018) 0.8 
Alcohol Consumption 0.0701(0.017) 4E-05 0.0684(0.017) 6E-05 0.0748(0.022) 0.0008 
Former Smoker 0.00509(0.019) 0.8 0.00736(0.018) 0.7 0.0034(0.021) 0.9 
Current Smoker 0.0301(0.036) 0.4 0.031(0.035) 0.4 -0.00147(0.045) 0.9 
BMI 0.00131(0.002) 0.5 0.000636(0.002) 0.8 0.00288(0.0024) 0.2 
Plasma B6   -0.000165(5.8e-05) 0.004   
Plasma B12   -6.4e-05(1.8e-05) 0.0005   
Plasma Folate   -0.00159(4e-04) 7E-05   
Dietary B6     -0.0284(0.014) 0.04 
Dietary B12     -0.000564(0.0018) 0.8 
Dietary Folate     7.84e-05(6.4e-05) 0.2 
Total Energy Intake     -3.03e-05(1.1e-05) 0.005 
Baseline Age * Time 0.000881(0.00022) 8E-05 0.000901(0.00022) 5E-05 0.000675(0.00031) 0.03 
Tibia Pb * Time -1.72e-05(0.00011) 0.9 -3.24e-05(0.00011) 0.8 3.77e-05(0.00015) 0.8 
*Core model adjusts for tibia Pb, baseline age, bmi, education, smoking status, alcohol consumption, time since baseline, 
baseline age*time since baseline, and tibia Pb*time since baseline. 
**Plasma model adjusts for core model covariates and plasma B6 (PLP), B12, and folate. 






Table 2.6. Basic mediation analysis.  All visits main effect of tibia Pb with and without current blood Pb adjustment.  Note: 
Tibia Pb is no longer significant after adjusting for blood Pb.   Research Question:  Does cumulative exposure to Pb 
influence Hcy levels, independent of current exposure to Pb? 
 
Tibia Only Blood and Tibia Blood Only 
 
n=1766 obs, n=771 indiv n=1766 obs, n=771 indiv n=1766 obs, n=771 indiv 
 
R2=0.0711 R2=0.104 R2=0.104 
 
Beta(SE) p-value Beta(SE) p-value Beta(SE) p-value 
(Intercept) 2.3(0.017) 0 2.3(0.017) 0 2.3(0.016) 0 




0.0183(0.0028) 4E-11 0.0194(0.0026) 8E-14 
Age 0.00715(0.001) 2E-12 0.00886(0.001) 2E-17 0.00922(0.00098) 2E-20 
Education (>hs 
reference) 
-0.0148(0.015) 0.3 -0.0171(0.015) 0.3 -0.014(0.015) 0.4 
Alcohol Consumption 0.0794(0.018) 1E-05 0.0682(0.018) 0.0001 0.0676(0.018) 0.0001 
Former Smoker 0.00525(0.019) 0.8 0.0101(0.019) 0.6 0.0119(0.019) 0.5 
Current Smoker 0.0606(0.037) 0.1 0.0505(0.036) 0.2 0.0521(0.036) 0.2 





FIGURE 2.1. One-Carbon Metabolism Pathway.  Homocysteine can be elevated 
in conditions of low folate, low B6, or low B12. The sulfhydryl groups on several 
proteins, including Cystathionine β-synthase (CBS), in the one-carbon 
metabolism pathway are potential sites for lead’s interferences. Abbreviations 
Used: Adenosine (Ado), S-adenosylmethionine (SAM), S-adenosylhomocysteine 
(SAH), Glutathione (GSH), Glutamate (Glu), Glycine (Gly), Tetrahydrofolate 
(THF), Methionine Transferase (MT), Betaine-Homocysteine S-Methyltransferase 









Figure 2.2. The adjusted cross-sectional association between Pb exposure and 
homocysteine.  Y-axis: With an IQR increase in Pb exposure (blood: 3 ug/dl; tibia 
Pb: 14 ug/g), corresponding percent increase in plasma Hcy.  X-axis: Visit 
number.  Results from cross-sectional multivariate linear regression models.  
Core covariates are age, blood Pb, education, smoking status, alcohol status, 
and BMI.  Plasma sensitivity covariates include the core model plus plasma PLP, 
B12, and folate.  Diet sensitivity model includes the core covariates and the total 
energy consumed and the dietary adjusted residuals for B6, B12, and folate.  (A) 














































































































































Figure 2.3. Longitudinal core model. Tibia Pb.  Data has been centered on the 
mean continuous variables so intercept can be interpretable. Tibia Pb exposure 
quartiles are defined at baseline: 













Baseline Tibia Pb Predicts Hcy Over Time















Highest Tibia Quartile >27 ug/g
Tibia Pb 18-27 ug/g
Tibia Pb 12-18 ug/g




Figure 2.4. Adjusted association between Pb and homocysteine stratified by 
nutrient status.  Y-axis: Percent change in Hcy with an IQR increase in Pb 
biomarker.  Analyses stratified by level of B6, B12 or folate measured in either 
plasma or dietary FFQ.  Longitudinal mixed effects regression of Pb exposure 
(either blood or tibia bone) on log(homocysteine). *High group is significantly 
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Supplemental Table 2.1. Visits 1-2 all samples, linear regression, split by change in blood Pb n=747 
 
No Change Blood Pb Increase in Blood Pb 















(Intercept) -1.29(0.9) 0.15 -0.42(0.68) 0.83 0.449(0.55) 0.41 -0.0266(0.36) 0.94 
delta 
  
0.0578(0.15) 0.7 0.0995(0.11) 0.34 0.0401(0.053) 0.45 
bage.c 0.172(0.13) 0.18 0.0326(0.084) 0.7 0.0287(0.065) 0.66 0.0598(0.046) 0.2 
as.factor(hs)1 0.0937(0.45) 0.83 0.378(0.41) 0.34 -0.515(0.33) 0.12 -0.138 (0.22) 0.54 
as.factor(twodrink)1 -0.312(0.58) 0.59 0.762(0.5) 0.13 -0.147(0.38) 0.7 0.072(0.27) 0.79 
as.factor(smkcat)2 -0.628(0.49) 0.2 -0.294(0.47) 0.53 -0.285(0.36) 0.42 -0.341(0.24) 0.16 
as.factor(smkcat)3 -1.18(1.1) 0.27 -1.62(1) 0.11 -1.39(0.83) 0.095 -1.31(0.55) 0.017 
bmi.c -0.0405(0.047) 0.39 0.0123(0.053) 0.82 0.0385(0.042) 0.36 0.00542(0.027) 0.84 
timebase 0.0543(0.27) 0.047 0.0844(0.15) 0.56 0.135(0.12) 0.26 0.168(0.086) 0.051 






Supplemental Table 2.2: All visits, all samples, mixed effects.  n=747 with 1245 observations The average change in Hcy 
over the average time interval (3.9 years). 
 Delta Change from Baseline Model  Adjacent Change Model 
 N=747 indiv, n=1245 obs  N=747 indiv, n=1245 obs 
 R2=0.0482  R2=0.022 
 Beta(SE) p-value  Beta(SE) p-value 
(Intercept) 0.263(0.23) 0.26 (Intercept) 0.337(0.26) 0.2 
delta 0.133(0.042) 0.0015 d.adj.bpb 0.0475(0.045) 0.29 
bage.c 0.0125(0.023) 0.59 age.c 0.0469(0.013) 0.00043 
as.factor(hs)1 0.0286(0.19) 0.88 as.factor(hs)1 -0.0231(0.18) 0.9 
as.factor(twodrink)1 -0.163(0.24) 0.49 as.factor(twodrink)1 0.104(0.21) 0.63 
as.factor(smkcat)2 -0.557(0.23) 0.013 as.factor(smkcat)2 -0.435(0.19) 0.024 
as.factor(smkcat)3 -1.53(0.49) 0.0018 as.factor(smkcat)3 -1.35(0.45) 0.003 
bmi.c 0.00321(0.024) 0.89 bmi.c 0.0117(0.021) 0.59 
timebase.c 0.134(0.026) 1.9e-7 d.adj.time 0.0722(0.054) 0.18 






Supplemental Table 2.3: Secondary analysis, long-term dietary trend in tibia model 
 
Core Model: Just Individuals with At Lead 
3 Waves of Dietary Information 
Dietary Model on Invididuals With At Least 3 
Waves of Dietary Data 
 
n=691 obs, n=221 indiv 
R2=0.81 
n=691 obs, n=221 indiv 
R2=0.088 
Variable Beta(SE) p-value Beta(SE) p-value 
(Intercept) 2.31(0.032) 0 2.31(0.032) 0 
tib.c 0.00163(0.0012) 0.16 0.00167(0.0012) 0.15 
age.c 0.0131(0.0019) 4.4E-12 0.0135(0.0019) 1.6E-12 
as.factor(hs)1 -0.0302(0.028) 0.28 -0.0278(0.028) 0.32 
as.factor(twodrink)1 0.0364(0.033) 0.27 0.038(0.033) 0.25 
as.factor(smkcat)2 0.00264(0.035) 0.94 0.00674(0.036) 0.85 
as.factor(smkcat)3 0.0946(0.071) 0.18 0.0869(0.071) 0.22 
















***note, when we subset only the people with 3 or 4 dietary measures (n=221 individuals across 691 observations), tibia lead is no longer a 






Supplemental Table 2.4: Mediation analysis, visit 1. 
 
Tibia Only Blood and Tibia Blood Only 
 
n=771 n=771 n=771 
 









(Intercept) 2.27(0.02) 0 2.27(0.02) 0 2.26(0.019) 0 




0.0241(0.0039) 1E-09 0.0252(0.0036) 9E-12 
Age 0.00551(0.0016) 0.0005 0.00587(0.0015) 0.0001 0.00625(0.0014) 2E-05 
Education (>hs 
reference) 
-0.0408(0.022) 0.06 -0.0495(0.021) 0.02 -0.0463(0.021) 0.03 
Alcohol 
Consumption 
0.0881(0.025) 0.0004 0.0598(0.025) 0.02 0.0588(0.025) 0.02 
Former Smoker 0.0326(0.023) 0.2 0.0403(0.022) 0.07 0.0419(0.022) 0.06 
Current Smoker 0.144(0.047) 0.002 0.134(0.046) 0.004 0.136(0.046) 0.003 





   
Supplemental Figure 2.1. Bivariate scatterplots for the unadjusted associations 
between lead measurement and Hcy at visit 1.  Red line is the linear regression 
line of best fit and the blue lines are the 95% confidence intervals.  (A) Tibia lead 
(n=774). (B) Patella lead (n=774). (C) Blood lead (n=1048).  
 
Supplemental Figure 2.2. Blood Pb restricted plasma and diet. *Restrict 
analysis to only individuals with both plasma and dietary measures.  (Visit 1 
n=774, visit 2 n= 382, visit 3 n= 65, visit 4 n=0) 











Visit 1: Complete Tibia Data















































































Restricted to Individuals with Both Plasma and Diet Measures

































































Research Chapter 2 
Genome-wide DNA Methylation Differences Between Late-Onset 
Alzheimer’s Disease and Cognitively Normal Controls in the Human Frontal 
Cortex 
FROM: Bakulski KM, Dolinoy DC, Sartor MA, Paulson HL, Konen JR, Lieberman 
AP, Albin RL, Hu H, Rozek LS. 2012. Genome-wide DNA methylation differences 
between late-onset Alzheimer’s disease and cognitively normal controls in the 
human frontal cortex. Journal of Alzheimer’s Disease. 29: 571-588, reprinted for 
educational purposes from IOS Press. 
ABSTRACT 
Evidence supports a role for epigenetic mechanisms in the pathogenesis 
of late-onset Alzheimer's disease (LOAD), but little has been done on a genome-
wide scale to identify potential sites involved in disease.  This study investigates 
human post-mortem frontal cortex genome-wide DNA methylation profiles 
between 12 LOAD and 12 cognitively normal age- and gender-matched subjects.  
Quantitative DNA methylation is determined at 27,578 CpG sites spanning 
14,475 genes via the Illumina Infinium HumanMethylation27 BeadArray.  Data 
are analyzed using parallel linear models adjusting for age and gender with 
empirical Bayes standard error methods.  Gene-specific technical and functional 
validation is performed on an additional 13 matched pair samples, encompassing 
a wider age range. Analysis reveals 948 CpG sites representing 918 unique 
genes as potentially associated with LOAD disease status pending confirmation 
in additional study populations.  Across these 948 sites the subtle mean 
methylation difference between cases and controls is 2.9%. The CpG site with a 
minimum false discovery rate located in the promoter of the gene 
Transmembrane Protein 59 (TMEM59) is 7.3% hypomethylated in cases.  
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Methylation at this site is functionally associated with tissue RNA and protein 
levels of the TMEM59 gene product. The TMEM59 gene identified from our 
discovery approach was recently implicated in Amyloid Precursor Protein post-
translational processing, supporting a role for epigenetic change in LOAD 
pathology.  This study demonstrates widespread, modest discordant DNA 
methylation in LOAD-diseased tissue independent from DNA methylation 
changes with age.  Identification of epigenetic biomarkers of LOAD risk may 
allow for the development of novel diagnostic and therapeutic targets.   





Dementia and Alzheimer’s Disease  
  Worldwide changes in demography are leading to a rapid increase in the 
numbers of older adults at risk for dementia. Accordingly, the global prevalence 
of dementia is expected to quadruple from an estimated 35.6 million cases in 
2010 to 115.4 million cases in 2050 (International 2010).  The global financial 
burden of dementia in 2010 was $604 billion (US dollars) including direct medical 
bills, formal social care, and informal care provided by unpaid caregivers 
(International 2010).   
Alzheimer’s disease (AD), a progressive, fatal neurodegenerative disease, 
is the most prevalent form of dementia.  Less than two percent of AD cases 
represent early-onset AD (EOAD) (Bird 2005) defined by disease onset prior to 
age 60 and genetic mutations in amyloid-β precursor protein (AβPP), presenilin-1 
(PSEN-1), or presenilin-2 (PSEN-2) genes (Bertram 2009; Hardy 1997).  
Mutations in these genes dysregulate the AβPP pathway and directly lead to 
amyloid-β (Aβ) plaque accumulation, a major pathological hallmark of AD.   
The remaining vast majority of cases are sporadic, termed Late-Onset 
Alzheimer’s Disease (LOAD) because they manifest symptoms after age 60.  
Approximately 60% of LOAD cases carry at least one apolipoprotein ε4 allele 
(APOE-ε4), while the global population prevalence of the allele is only 
approximately 22% (Ashford 2004; Kim et al. 2009).  Pooled data on LOAD from 
recent, collaborative, large genome-wide association studies (GWAS) reported 
the population attributable risk for APOE variants was between 19% and 35% 
(Ertekin-Taner 2010).   GWAS also identified additional LOAD risk alleles (CLU, 
PICALM, BIN1, CR1, ABCA7, MS4A, EPHA1, CD33, CD2AP) that contribute 
added risk in population subsets (Harold et al. 2009; Hollingworth et al. 2011; 
Lambert et al. 2009; Naj et al. 2011).  These risk factor genotypes are neither 
necessary nor sufficient for LOAD development.  Twin studies revealed 
incomplete concordance (Gatz et al. 1997; Nee and Lippa 1999) and variable 
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age on onset (Li et al. 2002) even among monozygotic pairs, highlighting the 
complex etiology of LOAD.  These observations underscore the likely importance 
of non-genetic factors in LOAD etiology and spurred recent investigations of the 
epigenetics of AD.  
Epigenetics and Alzheimer’s Disease 
Epigenetics is the study of heritable changes in gene expression that 
occur without changes to the underlying DNA sequence.  Methylation (Maunakea 
et al. 2010) and hydroxymethylation (Jin et al. 2011) at the 5’ site on cytosines in 
cytosine-guanine (CpG) dinucleotides are important epigenetic modifications 
associated with gene expression in the human brain.  Specific marks distinguish 
brain regions (Hernandez et al. 2011; Ladd-Acosta et al. 2007) and epigenetic 
differences in human brain tissues have been associated with such neurological 
diseases as schizophrenia and bipolar disorder (Mill et al. 2008).  Epigenetics is 
also a mechanism by which environmental exposures can translate to human 
disease (Dolinoy and Jirtle 2008; Suter and Aagaard-Tillery 2009).  
In AD cases lacking highly penetrant genetic susceptibility, the etiology of 
amyloid dysregulation is not well understood.  Altered epigenetic regulation of tau 
and amyloid processing genes has been observed across multiple brain regions 
and is a potential mechanism for disease (Barrachina and Ferrer 2009; Tohgi et 
al. 1999a; Tohgi et al. 1999b).  Human post-mortem case-control studies 
observed global hypomethylation in the entorhinal cortex of AD subjects 
(Mastroeni et al. 2008) and in the temporal neocortex neuronal nuclei of an AD 
monozygotic twin relative to their cognitively normal twin (Mastroeni et al. 2009).  
Evidence for epigenetic involvement in AD pathogenesis spans human studies in 
various tissues, animal models, and cell culture, and was recently reviewed 
(2010; Mastroeni et al. 2011; Mill 2011).   
 Significant transcriptome-wide gene expression differences have been 
observed between brain tissues of LOAD cases and controls (Loring et al. 2001; 
Miller et al. 2008).  However, previous AD research on DNA methylation as a 
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regulator of gene expression evaluated DNA methylation at 5’ promoter regions 
of a few candidate genes selected based on a priori hypotheses about AD 
molecular mechanisms. The current research provides a semi-unbiased, 
quantitative, genome-wide discovery of locations of DNA epigenetic differences 
in human frontal cortex brain tissue between LOAD cases and controls, which 
allows for identification of novel disease-associated genes.  The gene identified 
in this study that best distinguished cases and controls was technically validated 
using an additional sensitive and quantitative method of DNA detection.  This 
mark was also validated using a second population of samples.  The functional 
significance of this DNA methylation mark was further confirmed by gene 
expression and protein quantification assays.   
MATERIALS AND METHODS 
Sample Acquisition 
 The NIA funded Michigan Alzheimer’s Disease Center (MADC) 
(P50AG008671; PI: Sid Gilman) maintains a well-clinically characterized cohort 
of Alzheimer’s disease and cognitively normal control subjects, many of which 
agreed to participate in autopsy and donated to the MADC Brain Bank. Upon 
autopsy, each left hemisphere was fixed in 10% neutral formalin for 
neuropathological diagnosis.  The right hemisphere was sectioned coronally, 
flash frozen, and archived in MADC freezers at -80ºC. Frozen tissue blocks 0.5 
cm3 (50-90 mg) in size were dissected at -20ºC from the mid-frontal gyrus of the 
frontal lobe and provided for this study.  MADC frozen tissues were previously 
used in high quality expression (Hong et al. 2008; Pan et al. 2007) and proteomic 
studies (Pan et al. 2007).    
Twelve age- and gender- matched pairs of LOAD cases (clinical diagnosis 
and Braak Score ≥ 4) and controls (clinically confirmed and Braak Score ≤ 2) 
were used for the genome-wide discovery phase of the project and for gene-
specific technical validation.  An additional thirteen matched pairs were included 
in the population validation phase, which included gene-specific DNA 
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methylation, gene expression, and protein quantification studies. The 
demographic characteristics of all 50 brains included in this study are described 
in Table 3.1.   Post-mortem intervals in hours for AD cases used in the Discovery 
Set were as follows: 3, 4, 7, 7, 7.75, 8, 8.75, 9, 11, 12, 14, 24.  Post-mortem 
intervals in hours for controls used in the Discovery Set were as follows: 6, 6, 
13.5, 14, 17, 18, 18, 18, 19.3, 20.5, 21.25, 24.5.  Gray matter for DNA 
methylation, expression, and protein analysis was excised from the tissue 
sample and used in this study and vascular lesions were avoided.   
DNA Isolation and APOE Genotyping  
DNA was extracted from all 25 matched pair samples using the Promega 
Maxwell Tissue DNA Kit (Madison, WI) according to manufacturer’s instructions.  
APOE genotyping was assayed using the Applied Biosystems TaqMan method 
(Foster City, CA) according to manufacturer’s instructions using the ABI 7900 HT 
machine (Christensen et al. 2008).    
Genome-wide DNA Methylation Discovery 
 DNA was bisulfite-treated using the Zymo EZ DNA Methylation Kit 
(Orange, CA) with a modified thermal cycling protocol (98ºC for 10 minutes, 64ºC 
for 17 hours).  Genome-wide DNA methylation was assessed with the Infinium 
HumanMethylation27 BeadArray (Illumina) performed at the University of 
Michigan DNA Sequencing Core facility in accordance with manufacturer’s 
instructions and previously published (Bibikova et al. 2009).  Six cases and six 
control samples were randomly applied to each of two 12-sample arrays to avoid 
biasing case-control differences by batch effect.  BeadArrays were imaged using 
the Illumina BeadArray Reader.  Image processing and intensity data extraction 
are standard components of the BeadScan software that is associated with the 
BeadArray Reader. The Illumina BeadStudio Software generated percent 
methylation estimates (beta values) for each probe set based on Cy3 and Cy5 
fluorescence intensities.  Data was background normalized and exported for 
further processing.   
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Statistical Methods for Bead Array 
All statistical analysis was performed with the R Statistical Software 
(version 2.10.1).  CpG sites that failed on 10% of samples were not included in 
subsequent analyses.  Linear models adjusting for age and gender were fit 
across all CpG sites using the limma package (version 3.2.3). As is standard in 
microarray analyses, empirical Bayesian variance methods were incorporated to 
site-specific moderated t-tests (Smyth 2004).  The linear model used for each 
individual CpG site was as follows:  
% Methylation = β0
 + β1(Case Status) +β2(Age) + β3(Sex) 
Top hits by case status were identified by p-values < 0.05 and false 
discovery rates were calculated.  Additional analyses were performed on the top 
hit.  We compared the basic linear model above to a model containing PMI using 
an F-test.  We also compared the R2 goodness of fit of two simple linear 
regression models containing only either PMI or Case Status as predictors.   
Samples were hierarchically clustered by the single linkage method across 
the top 26 hits by case status.  Positional gene set enrichment analysis was 
performed using Gene Set Enrichment Analysis (GSEA) to determine statistical 
over-representation of disease specific epigenetic marks within chromosomal 
cytogenic bands containing at least 15 genes (Subramanian et al. 2005).  
Enrichment in promoter and 3’UTR regulatory motifs of disease associated 
genes was determined by GSEA (Xie et al. 2005).  Biological processes and 
molecular functions associated with LOAD gene lists were established using 
Gene Ontology (Ashburner et al. 2000). 
Gene-Specific DNA Methylation Validation 
Site-specific methylation technical (of the original 12 Discovery Set 
matched pairs) and population (of an additional 13 matched pairs with an 
expanded age range) validation of the top CpG hit was determined by bisulfite-
pyrosequencing on the Qiagen Pyromark MD instrument (Valencia, CA). Using 
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Pyromark Assay Design Software, a custom pyrosequencing assay was 
designed to include the two CpG sites present on the Illumina array (Target IDs 
cg01182697 and cg20793071). This amplicon is located in the promoter of the 
gene that most statistically distinguished LOAD cases and controls on the 
Illumina array. Primers were complementary to bisulfite treated DNA in regions 
without CpG nucleotides (Table 3.2).  The region of interest was amplified by 
bisulfite-PCR with the following thermal cycling protocol: 15 minute activation at 
95ºC, 45 cycles of 30 second denaturation at 94ºC, 30 second annealing at 
55ºC, and 1 minute extension at 72 minutes, followed by a final extension for 10 
minutes at 72ºC.  Serial dilutions of 100% methylated and unmethylated controls 
were used to test for any bias in amplification for each assay.  Internal bisulfite 
conversion quality controls were incorporated at original sequence non-CpG 
cytosines by including C nucleotides in the dispensation order, which should be 
fully converted to T’s following bisulfite treatment.   
Incorporation of either a T (for an unmethylated cytosine) or C (for a 
methylated cytosine) at each CpG provides a quantitative measure for 
consecutive CpG sites throughout the region sequenced. The level of 
methylation for each CpG within the target region of analysis was quantified 
using the Pyro Q-CpG Software.  Primers and pyrosequencing assay file 
information including nucleotide dispensation orders and sequences to analyze 
are in Table 3.2.  
Gene Expression 
Functional relevance of top methylation marks distinguishing Alzheimer’s 
disease cases and controls was assessed via SYBR green Real Time PCR gene 
expression assays.  RNA was extracted from all 25 matched pair samples using 
an adjacent portion of the same gray matter sample used for DNA.  RNA was 
extracted using the Qiagen RNeasy Lipid Tissue Kit (Valencia, CA), following 
homogenization with the Qiagen Tissue Lyser instrument.  Assays were 
designed using Genscript software (Piscataway, NJ).  cDNA was generated with 
the Bio Rad iScript cDNA Synthesis Kit (Hercules, CA) and the primers are listed 
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in Table 3.3. Quantitative PCR assays were run with the iQ SYBR Green 
Supermix (Bio Rad) on the CFX96 C1000 Thermal Cycler (Bio Rad). CFX 
Manager software (Bio Rad) was used to determine the threshold cycle (CT) and 
perform inter-plate normalizations.  CT values relative to β-actin levels were used 
to compute a fold change between matched pairs. A subset of samples was 
analyzed on the Affymetrix GeneChip Human Genome U133 Plus 2.0 Array in 
the University of Michigan Sequencing Core using standard protocols.  We 
determined that β-actin is a suitable control in these samples as gene expression 
of β-actin did not differ by case control status at any of the 6 probe sets included 
in the Affymetrix Array (p-values: 0.13, 0.18, 0.23, 0.43, 0.48, 0.77).  Gene 
expression data were evaluated for normality using R Statistical Software.  To 
determine if higher methylation values were associated with decreased 
expression of target genes, Spearman correlation coefficients were calculated 
between CpG methylation (as measured by pyrosequencing) and the expression 
level data.   
Protein Quantification 
 Adjacent portions of the same 25 matched-pair, gray matter tissue used 
for DNA were homogenized and protein extracted in Thermo Scientific RIPA 
buffer (Burlington, Ontario).  Protein concentration was quantified using the 
Thermo Scientific Pierce BSA assay (Burlington, Ontario).  Protein (25 ug) was 
loaded on 10% SDS-polyacrylamide gels for Western Blot analysis.  
Transmembrane protein 59 antibody was purchased from Novus Biologicals 
(Littleton, CO) and Transmembrane protein 59 control protein was purchased 
from OriGene (Rockville, MD).  The blots were imaged on the VersaDoc 5000MP 
instrument (Bio Rad) with Quantity One densitometry software (Bio Rad) under a 
consistent, constrained area.  The levels of Transmembrane protein 59 were 
standardized to the corresponding tubulin band. 
RESULTS 
Genome-Wide Descriptive Statistics 
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DNA was extracted from the frontal cortex of 25 age- and gender-matched 
LOAD case and control human post-mortem pairs (Table 3.1). Sixteen pairs 
were male and nine pairs were female.  LOAD cases and controls did not differ 
by age (p-value = 0.68).  The mean post-mortem interval (PMI) was 12.8 hours, 
ranging from 3-28 hours. Controls had significantly longer PMI than LOAD cases 
(p-value=0.0004).  The mean number of years in storage was 11.8, ranging from 
2-21 years.  Cases and controls did not statistically differ in the number of years 
in storage (p=0.07). 
In the Discovery Set, a randomly selected subset of 12 matched pairs 
ranging in age from 69-95 (mean age 79.8) were analyzed for genome-wide DNA 
methylation using the Illumina Infinium HumanMethylation27 BeadArray.  The 
BeadArray represented 27,578 CpG sites corresponding to 14,475 unique genes.  
The average number of CpG sites per gene was 1.9, and 92.0% of CpG sites 
were within 1000 bp of a transcription start site.  CpG sites within CpG islands 
were overrepresented on the array, as 72.5% of sites were within CpG islands.  
The average number of CpG sites per sample with Illumina detection p-values 
greater than 0.05 (considered failing) was 71.1 (range 11-360 sites).  CpG sites 
that failed on more than 2 samples (>10% samples) were not included for further 
analyses (n= 171 sites). 
  The global distribution of 5’-cytosine modifications at all CpG sites 
measured by the array was bimodal, and the distribution of methylation levels 
was very similar between cognitively normal controls (Figure 3.1A) and 
Alzheimer’s disease cases (Figure 3.1B).  There was a large cluster of sites that 
had less than 10% methylation (15,735 in controls and 15,619 in AD cases) 
based on the mean of each group of 12 samples.  A second cluster of sites was 
modified between 75% and 100% (5,226 sites in controls and 5,162 sites in AD 
cases).   
Of the 27,578 sites on the array, 25,380 sites were located in promoter 
regions as defined within 1,000 bp of a transcription start site.  Only 2,198 sites 
were outside of known promoters.  Promoter CpG sites had a median of 5.1% 
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methylation (IQR= 2.1-5.2) while non-promoter sites had a median of 59.7% 
methylation (IQR=11.0-84.0). This observation did not depend on AD case 
status.  On the array, 20,006 sites were located within CpG islands and 7,572 
sites were outside of CpG islands.  CpG island sites had a median methylation of 
3.2% (IQR = 1.7-9.6) and non-CpG island sites had 74.6% median methylation 
(IQR=45.5-85.4).  This did not depend on AD case status. Our discovery set of 
24 samples ranged in age from 69-95 years (Table 3.1), and age was an 
important predictor of methylation. There were 2,416 sites and 2,227 unique 
genes associated with age (based on a p-value of 0.05).  Of these sites, 1,294 
were hypermethylated with increasing age and 1,122 were hypomethylated with 
age.  The top 25 CpG sites associated with age among controls are listed in 
Table 3.4.  
Alzheimer’s Disease-Specific Results 
 Following age and gender adjusted linear fit models with empirical 
Bayseian standard error adjustments, 948 CpG sites representing 918 unique 
genes were significantly associated with AD case status (based on p-value of 
0.05).  Among these 948 sites, the maximum mean methylation difference 
between AD cases and controls was 19.5% at a CpG site 249 base pairs from 
the predicted TSS of C21orf56 on chromosome 21 (cases 34.8% methylated vs. 
controls 15.9% methylated).  The mean observed disease specific methylation 
difference across the 958 sites was 2.9% (IQR=0.88-4.2).   
The top 26 autosomal CpG sites distinguishing cases and controls (as 
defined by FDR) are depicted in a heatmap (Figure 3.2).  Samples clustered on 
case status with the exception of two control samples.  One of those controls was 
the oldest control subject in the study at 94 years of age.  The top 25 CpG sites 
that were significantly different by case status are outlined in Table 3.5.    
Gene ontology analysis of the top 958 disease specific sites revealed 
hypermethylation in several molecular functions and biological processes 
associated with transcription.  The top 10 molecular functions enriched for 
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hypermethylation with AD cases were RNA polymerase II transcription factor 
activity (Figure 3.3A), RNA binding, GTPase regulator activity, cytokine binding, 
DNA binding, lyase activity, ATPase activity, transcription factor activity, and 
nucleoside triphosphatase activity. Similarly, the top 10 biological processes 
associated with hypermethylation were nucleic acid metabolic process, DNA 
replication, regulation of nucleic acid metabolism, regulation of DNA dependent 
transcription, regulation of RNA metabolic process, regulation of cell cycle, DNA 
dependent transcription, positive regulation of RNA metabolic process, DNA 
metabolic process, RNA biosynthetic process, and nervous system development. 
  Hypomethylation was enriched at functions and processes related to 
membrane transport and protein metabolism.  The top 10 molecular functions 
associated with hypomethylation in AD cases are electron carrier activity, cation 
transmembrane transporter activity, metal ion transmembrane transporter 
activity, enzyme binding, rhodopsin-like receptor activity, cation channel activity, 
integrin binding, phosphoric ester hydrolase activity, G-protein coupled receptor 
activity, and peptidase activity.  The top 10 biological processes associated with 
hypomethylation in LOAD cases were carboxylic acid metabolic processes 
(Figure 3.3B), organic acid metabolic process, biosynthetic process, cation 
transport, nitrogen compound metabolic process, amine metabolic process, 
negative regulation of developmental process, programmed cell death, 
apoptosis, and anti-apoptosis.   
 Several promoter and 3’ UTR regulatory binding motifs were enriched in 
the disease associated gene list.  Hypermethylation in LOAD cases was 
observed in genes containing binding site motifs for transcription factors POU3F2 
(p-value < 0.001) and HOXA4 (p-value=0.004), and microRNAs MIR-9 (p-value = 
0.002), MIR-518C (p-value < 0.001), MIR-1 (p-value=0.025), and MIR-326 (p-
value=0.019).  Genes containing MIR-140 (p-value = 0.04) and NFE2 (p-
value=0.019) motifs were hypomethylated in LOAD cases.   
 Positional gene set analysis of the 958 disease associated CpG sites 
identified enrichment of hypomethylation at the chromosomal location19q13 
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(Normalized Enrichment Score (NES) = 1.24), in cytogenetic band region where 
the APOE gene is located (Kim et al. 2009).  In addition, hypermethylation in 
LOAD cases was seen at 19q13 (NES= -0.72), a candidate location for genetic 
linkage with LOAD (Wijsman et al. 2004).  We visually identified broad regions of 
altered methylation in AD brains compared to control brains (Figure 3.4).  These 
include the p-arm of chromosome 14 and distal q-arm of chromosome 3 
(hypomethylated in AD brains compared to control brains) and the p-arms of 
chromosomes 10 and 17 (hypermethylated in AD brains compared to control 
brains).  Chromosome 15 had the highest density of observed disease-specific 
methylation differences.   
 We checked the list of disease specific hits identified with the BeadArray 
for genes known to be associated with AD.  There were two CpG sites on the 
array corresponding to each of the following genes: ABCA7, APOE, AΒPP, 
BACE1, BDNF, BIN1, CD2AP, CD33, CLU, CR1, EPHA1, MAPT, MS4A6A, 
PICALM, PSEN2, and TOMM40.  There was one site representing PSEN1 on the 
array and this site was associated with AD (Cases mean methylation = 1.6%, 
Controls mean methylation = 2.6%; p-value=0.034; cg11490446).  Gene 
expression of the probe set for PSEN1 at exon 2 differed by case status based 
on the results of the Affymetrix gene expression array (probe 207782_s_at, p-
value = 0.0076, fdr = 0.35).  The Spearman correlation coefficient linking 
expression of this gene expression probe set and methylation measured by the 
Illumina BeadArray is -0.61 (pvalue=0.0014).  AD cases were less methylated 
and had higher expression of this probe. There was no difference gene 
expression in the other five probe sets for PSEN1.   One of the two sites 
corresponding to EPHA1 was associated with hypermethylation with age (p-value 
= 0.029; cg02376703).  One of the two sites associated with PSEN2 was 
associated with hypomethylation with age (p-value = 0.030; cg25514304).  The 
remaining CpG sites within LOAD candidate genes were not associated with 
differential methylation by case status or age. 
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 We also assessed known human imprinted genes for their association 
with AD, focusing on CpG sites located within Differentially Methylated Regions 
(DMRs) (Choufani et al. 2011).  The Illumina array contains 10 sites in the DMR 
for DIRAS3, 8 sites each for PLAGL1 and GNAS, 7 sites for ZIM2, 4 sites for 
PEG10, 3 sites for PEG3, 2 sites for MEST, and 1 site each for the genes 
GRB10, KCNQ1, and SNURF.  One of the sites in the DMR for DIRAS3 was 
more highly methylated in AD cases (43.4%) than controls (38.5%) (p-value = 
0.024; cg21808053).  One of the sites in the DMR for GNAS was hypomethylated 
with age among controls (p-value = 0.012; cg21625881) and the site for KCNQ1 
was hypermethylated with age (p-value = 0.023; cg27119222). 
Gene-Specific Results 
 After adjusting for age and sex, the highest ranking site (FDR = 0.36, p-
value = 0.000013) associated with LOAD was a CpG site upstream of 
Transmembrane Protein 59 (TMEM59).  TMEM59 is responsible for post-
translational glycosylation of AΒPP and leads to retention of AΒPP in the Golgi 
apparatus (Ullrich et al. 2010).  AD cases had 7.3% lower methylation at 
TMEM59 than controls, and this difference was more profound in older subjects 
(Figure 3.5A).  Methylation of TMEM59 was significantly associated with age in 
cases relative to controls (p-value=0.013).  In a second TMEM59 model, we 
added PMI as a predictor and compared the goodness of fit of the two nested 
models using an F-test.  PMI did not improve the model fit and PMI is not a 
statistically significant predictor of methylation at the TMEM59 site.  In a simple 
linear regression model with Case Status as the only predictor of TMEM59 
methylation, the model fit R2 was 0.597.  The model fit R2 with PMI as the only 
predictor was 0.132.   
The methylation findings were technically validated by pyrosequencing a 
single assay containing both CpG sites from the Illumina array that were 
associated with TMEM59. The CpG density 1000 bp flanking the top hit on either 
side is 1.5%.  Pyrosequencing the original 24 discovery samples confirmed the 
difference between cases and controls at TMEM59 was 2.7% (Figures 3.5B and 
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3.5D).  Methylation was again associated with age in cases relative to controls in 
the technical validation (p-value=0.0084).  Pyrosequencing of an additional 26 
matched pair samples across an expanded younger age range (61-94) confirmed 
the age-associated reduction in methylation (p-value-0.0022), and the 
association with AD case status was not statistically significant at an alpha of 
0.05  (p-value = 0.088) (Figure 3.5C). 
 We determined expression levels of TMEM59 at four points along the 8 
exon transcript (Figure 3.6A) (including the beginning, end, and two middle sites) 
to functionally validate the DNA methylation results with the TMEM59 gene.  At 
the four locations along the transcript that were assayed by real time PCR, 
controls had lower RNA expression levels than cases (Figure 3.6B).  For the first 
assay on the transcript, AD cases had 24.9% higher expression (fold change 
1.33; p-value 0.0013).  For two assays in the middle of the transcript, AD cases 
had 20.5% (fold change 1.26; p-value 0.0071) and 28.3% (fold change 1.40; p-
value 0.056) higher expression.  The assay at the end of the transcript showed 
AD cases to have 21.5% (fold change 1.27; p-value-0.0036) higher expression 
than controls.  DNA methylation and RNA expression were negatively correlated 
at TMEM59 (Spearman correlation coefficient = -0.274, p-value = 0.0083).   
 To further investigate the functional implications of the observed DNA 
methylation and gene expression differences of TMEM59, we measured the 
protein levels by Western blot in the full set of 25 case brains and 25 control 
brains.  No differences were observed for the full length 36 kDa protein (p-
value=0.68) (Figure 3.6C), but AD cases had reduced levels of a shorter protein 
that was also bound by the antibody specific for the C-terminus of TMEM59 (p-
value=0.040) (Figures 3.6C, 3.6E).  The quantity of shorter protein was 
associated with age (Figure 3.6D).   
DISCUSSION 
We performed a genome-wide, semi-unbiased quantitative comparison of 
frontal cortex DNA methylation from age- and gender-matched LOAD cases and 
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controls.  The CpG site most strongly associated with case status was located in 
the promoter region of TMEM59, a gene recently implicated in Alzheimer’s 
disease pathogenesis (Ullrich et al. 2010). This gene is involved in the post-
translational modification of Amyloid Precursor Protein (AβPP) and causes 
retention of AβPP in the Golgi apparatus (Ullrich et al. 2010).  The magnitude of 
methylation difference at this site between cases and controls was very modest 
(7.3% difference using the Illumina array), but the direction of association was 
confirmed using an alternate method of DNA methylation detection (2.7% 
difference using pyrosequencing).  In an expanded population including a higher 
number of younger cases and controls, an interaction between age and case 
status was detected.  Thus, age modifies the association between disease status 
and methylation.  There was not a primary association between case status and 
methylation when the younger population was included.  In the original sample of 
LOAD cases and controls, TMEM59 DNA methylation levels corresponded to 
functional changes in TMEM59 gene expression.  LOAD cases had lower 
methylation and higher expression of TMEM59 than control samples.  No 
differences in the level of the full length TMEM59 protein were observed between 
cases and controls; however a smaller protein that bound theTMEM59 antibody 
was significantly higher in controls. This TMEM59 protein size pattern is 
consistent with the TMEM59 control protein lysate. The shorter protein may 
represent a proteolytic product of the full length protein.  The shorter protein is 
approximately 17 kDa, which could also be consistent with translation of an 
alternative RNA transcript beginning at exon 5 of the TMEM59 gene.  The 
observed differences in protein expression levels are consistent with epigenetic 
regulation.  Further molecular research is needed to better understand the gene 
expression and protein regulation and potential role of DNA methylation at this 
site. 
Well-studied genes known to be involved in AD pathogenesis or identified 
through GWAS for genetic association with LOAD were largely not associated 
with disease-specific DNA methylation differences in this study. A notable 
exception was PSEN1, which was modestly hypomethylated in LOAD cases.  
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Consistent with previous human post-mortem tissue studies, PSEN1 showed 
very low levels of methylation in our population (Siegmund et al. 2007).  Here, 
LOAD cases had reduced DNA methylation that was associated with increased 
PSEN1 gene expression, suggesting the DNA methylation change may be 
functional at this site. Studies in mice and neuroblastoma cell lines demonstrate 
that PSEN1 gene expression is regulated by DNA methylation at specific 
promoter CpG sites and this regulation depends on B vitamin availability (Fuso et 
al. 2011).  The correlation between DNA methylation and gene expression in our 
study support the cell line and mouse model findings.  The Illumina 
HumanMethylation27 BeadArray platform used in this study also allowed for 
discovery of novel gene associations with AD.  For example, methylation change 
was observed within the DMR for the imprinted gene, DIRAS3.  Genomic 
imprinting in Alzheimer’s disease is a potential mechanism to explain 
epidemiological parent-of-origin inheritance observations(Fallin et al. 2011; 
Mosconi et al. 2011). 
Greater than 900 genes (6% of genes featured on the array) were 
differentially methylated by case status after adjusting for age and gender.  
Overall, the disease related methylation effect size (2.9%) was relatively modest, 
and the global methylation distributions of AD cases and controls were similar.  
Together these findings suggest that DNA methylation may play a role in LOAD 
and the individual effects at each CpG site may be subtle.  The magnitude and 
absolute number of DNA methylation changes observed in this study are 
consistent with previous reports in the literature performed on candidate gene 
subsets.  In a case-control study of prefrontal cortex DNA methylation of twelve 
genes, only two genes were associated with AD status and the differences in 
methylation were less than 10% (Wang et al. 2008).   
Gene set enrichment analysis revealed key patterns in the identified set of 
disease associated CpG sites. First, gene ontology analysis showed 
hypermethylation of genes involved in transcription and DNA replication, while 
membrane transporters were hypomethylated.  Second, hypermethylation was 
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enriched at genes containing POU3F2 binding motifs.  POU3F2 is a transcription 
factor critical in central nervous system development that regulates Nestin gene 
expression, a protein important for radial axon growth (Jin et al. 2009). Third, 
positional analysis showed hypomethylation with case status at 19q13 and 
hypermethylation at 19p13, cytogenic band regions genetically linked with AD 
(Kim et al. 2009; Wijsman et al. 2004).   
LOAD cases and control sample groups were similar with respect length 
of time in storage, but LOAD cases had shorter PMI then control samples (p-
value = 0.0004).  During PMI, samples may be exposed to damaging lower pH 
conditions and higher temperatures where enzymes may be active.  PMI was not 
a significant confounder at the TMEM59 site, however, PMI may be a factor at 
other specific locations throughout the DNA methylome.   
 This study measured genome-wide DNA methylation differences between 
LOAD case and control subjects aged 69 to 95.  Across this relatively short age 
range, DNA methylation was associated with age at over 2,400 CpG sites, 
representing more than 8% of the sites on the BeadArray.  Both hyper and 
hypomethylation was observed.  Previous studies have observed global 
hypomethylation with age in the brain (Pogribny and Vanyushin 2010), but gene-
specific studies of aging and methylation have noted varying patterns (Siegmund 
et al. 2007).  These results further support age as an important covariate to 
consider in statistical models of DNA methylation in late life. 
 Age is a major factor in epigenetic change in the brain (Hernandez et al. 
2011), potentially confounding or modifying disease specific associations. In a 
study of cerebral cortex DNA from gestation to 104 years of age, eight of fifty loci 
showed increases in methylation through late life and two sites presented 
changes suggestive of an acceleration of age-related change in a subset of 
samples with LOAD (Siegmund et al. 2007).  Additional evidence supports 
increased age-dependent epigenetic drift with disease.  In LOAD prefrontal 
cortex samples representing a 30 year age range, an age-specific epigenetic drift 
was more prominent among cases compared to controls.  The average 
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methylation in promoters of MTHFR and APOE increased by 6.8%, while control 
samples decreased with age by 10.6% (Wang et al. 2008).   
Cultured cells can potentially have very different epigenetic profiles than 
primary cells as an artifact of growth in culture (Smiraglia et al. 2001), and thus 
use of primary human frontal cortex tissue is a strength of this study.  DNA 
methylation is brain region specific and greater differences have been seen 
between the cerebellum and cortex regions than by sex, age, post-mortem 
interval, race, or cause of death (Ladd-Acosta et al. 2007).  This study 
consistently used frontal cortex tissue because of its role in advanced AD.  As 
with many studies of epigenomic, transcriptomic, or proteomic changes in the 
human brain, the tissue samples represented populations of mixed cell types, an 
important limitation, which may have resulted in attenuated effects.  Epigenomes 
are cell type specific (Lister et al. 2009; Maunakea et al. 2010), and brain cell 
types have different roles in AD (Selkoe 2001).  The AD brain has an active 
changing cell population including neuronal loss and glial activation (Akiyama et 
al. 2000) that may in part be responsible for the observed results. DNA 
methylation data, however, was not enriched in inflammatory mediators, which 
would have supported changes due to gliosis. This study considered brain region 
specific methylation and as epigenomic platforms require lower input DNA 
amounts, future research may be able to also consider cell type specific 
changes.   
Results from large DNA methylome and transcriptome maps of the human 
brain suggest that intragenic CpG sites rather than promoter CpG islands may 
better correlate with transcription (Maunakea et al. 2010). The genome-wide sites 
included on the Illumina Infinium HumanMethylation27 BeadArray are more likely 
to be located within promoter region CpG islands.  Important methylation events 
located elsewhere throughout the genome would be missed using this platform 
and may be included in future research utilizing alternative technologies. 
These results must be interpreted with caution because this study had a 
small sample size relative to the large number of CpG site comparisons and the 
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magnitude of observed methylation differences between LOAD cases and 
controls was moderate.  The results from the array were technically validated at 
the top CpG site, but it is not clear whether this observation will be consistent 
across populations.  While a small study, we identified modest DNA methylation 





Figure 3.1. Mean percent methylation frequency distribution of the Discovery Set 
of 12 cognitively normal control samples (A) and 12 Alzheimer’s disease cases 





Figure 3.2. Hierarchical clustering heatmap of the Discovery Set top 26 
autosomal CpG loci associated with late-onset Alzheimer’s disease (LOAD) 
case/control status after adjusting for sex and age.  Green represents 
hypermethylation in LOAD cases and red represents hypomethylation in cases.  
Horizontal color bars at the top refer to the age, sex, and case status of the 
sample.  In the Case Status color bar, light green represents control samples and 
dark green represents LOAD cases.  For sex, female is light pink and male is 
dark blue.  In the age panel, black represents ages 91-95, darkest gray 86-90, 
medium gray 81-85, light gray 76-80, lightest gray 71-75, and white represents 
ages 66-70.  Vertical color bars on the left refer to the CpG island and promoter 
status of the CpG sites.  In the CpG island bar, dark purple represents sites 
within CpG islands and light purple represents sites outside of CpG islands.  In 
the promoter bar, dark orange represents sites within promoter regions and light 




Figure 3.3. Discovery Set gene set enrichment analysis plots. (A)  Genes 
associated with RNA polymerase II transcription factor activity molecular function 
were hypermethylated in LOAD cases relative to controls (p-value = 0.013).  (B) 
Genes associated with carboxylic acid metabolic biological processes were 
hypomethylated in LOAD cases relative to controls (p-value= 0.013). 
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Figure 3.4. Human chromosome ideogram in black.  Distribution of CpG sites 
featured on the Illumina HumanMethylation27 BeadArray is below the 
chromosomes in blue. Distribution of CpG sites that were significantly associated 
with late-onset Alzheimer’s disease (LOAD) in the Discovery Set are above the 
ideograms.   Green represents hypermethylation with LOAD status.  Red 
represents hypomethylation with LOAD status. 
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Figure 3.5. Methylation upstream of the TMEM59 gene.  (A) Percent methylation 
by age and case status (Late-Onset Alzheimer’s Disease cases in red; Controls 
in blue).  Data from the Illumina HumanMethylation27 BeadArray. (B) Age vs. 
percent methylation bisulfite-pyrosequencing technical validation data of original 
24 samples run in duplicate in the Discovery Set.  (C) Age vs. percent 
methylation bisulfite pyrosequencing of Discovery Set 24 samples plus 26 
additional population validation samples run in duplicate. (D) A representative 





Figure 3.6. Functional validation of observed DNA methylation differences for 
TMEM59, a gene involved in the post-translational modification of Amyloid 
Precursor Protein (AΒPP).  (A) TMEM59 is located on chromosome 1 and is 
transcribed on the reverse strand.  The reference sequence mRNA is yellow.  
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Predicted alternative isoforms are in blue. (B) Boxplot of TMEM59 gene 
expression by Q-PCR in the Discovery Set. Two-sample t-test between cases 
and controls were all statistically significant (exon 1 p-value=0.0013; exons 1-2 p-
value=0.0071; exons 3-4 p-value=0.0036, exons 7-8 p-value=0.0083) (C) Boxplot 
of relative protein levels of TMEM59 in the Discovery Set plus an additional 26 
validation samples.  Paired t-tests did not reflect case specific differences for the 
full length protein (p-value=0.68), while the shorter protein fragment was 
significantly lower in AD cases (p-value=0.040).  (D) Levels of the shorter 
TMEM59 protein fragment as a function of age.  (E) Representative western blot 
image of TMEM59 protein expression in controls and AD cases 1-3 representing 
identical exposures of the same gel.  No differences were detected between AD 
and controls for full length TMEM59 protein based on case status, but the levels 
of the TMEM59 shorter proteins were reduced in AD cases.  These shorter 




Table 3.1. Study population mean demographics by case status.  Range is 
provided in parentheses.   
 LOAD Cases Cognitively Normal Controls 


























Braak Stage 4.7 (2-6) 4.8 (2-6)  1.3 (1-2) 1.5 (1-2) 


















9.6 (3-24) 9.5 (3-27.5) 16.3 (6-24.5) 16.0 (5-28) 









Age of onset 69.1 (59-78)  NA NA 








# Years from 
Diagnosis to 
Death 
5.1 (1-12) 5.2 (1-12) NA NA 
APOE Genotype 
  2/2 
  2/3 
  2/4 
  3/3 
  3/4 
  4/4 




































Table 3.2. Pyrosequencing assay information. 
Gene Sequence 5 – 3’  
TMEM59  




Sequencing Primer AATAGATTATATTTTGTAAAAGAA 
Dispensation Order ATATCGATCGAGGATGTTGATCGAG 
Sequence to Analyze TAATAAYGAAGGGGATTTGTTTTAYGAGTTAGTATATATGGTGTAAAT 
 
 
Table 3.3. Primer sequences for gene expression QPCR assays. 
Gene Sequence 5’ – 3’ 
TMEM59 Exon 1  
Forward Primer TGACTCGGTCTTGGGTGATA 
Reverse Primer TCTTCCTTAGGGTAGGTGTGC 
TMEM59 Exons 1-2  
Forward Primer GGGCCTGTCAGTTGACCTAC 
Reverse Primer CTGCAACCTCTCTGACATGC 
TMEM59 Exons 3-4  
Forward Primer GAACAACTTATGTCCCTGATGC 
Reverse Primer CGTCATCGGCTTGAAGATAA 
TMEM59 Exons 7-8  
Forward Primer TCCTCTCGGTGATGGTATTG 
Reverse Primer TCAGCTTCTCAGAGGGAACA 
Β-actin  
Forward Primer TGCTATCCAGGCTGTGCTAT 








Table 3.4. CpG sites differentially methylated with age among cognitively normal controls (Discovery Set, Age 69-94).Beta 












Chromosome Biological Description 
1 DNAI2 0.441288 1.08E-05 714 FALSE 17 
Dynein intermediate polypeptide 2; axonemal;. Function in microtubule motor 
activity. 
2 ECM2 0.453176 3.85E-05 717 FALSE 9 
Extracellular matrix protein 2 precursor. Function in integrin binding and cell-
matrix adhesion 
3 UNQ689 0.409188 1.39E-04 991 FALSE 4 hypothetical protein LOC401138 
4 C3 0.262665 1.52E-04 680 FALSE 19 
Complement component 3 precursor. Function in acylation-stimulating protein 
cleavage in innate immune response 
5 OSMR 0.25763 2.10E-04 404 TRUE 5 
oncostatin M receptor. Role in cell proliferation and cell surface linked signal 
transduction 
6 MEG3 -0.45638 2.15E-04 NA TRUE 14 Predicted gene from GNOMON 
7 GLO1 0.238369 2.36E-04 480 TRUE 6 
glyoxalase I.  Role in zinc ion binding, lyase activity in carbohydrate metabolism 
and antiapoptosis. 
8 CRNN 0.295641 2.50E-04 167 FALSE 1 Hypothetical protein LOC49860.  Tumor-related protein. 
9 SF3B2 -0.16749 2.92E-04 484 TRUE 11 splicing factor 3B subunit 2 
10 PIK3C2B 0.221434 3.22E-04 164 FALSE 1 
phosphoinositide-3-kinase; class 2; beta polypeptide.  Role in intracellular 
signaling cascade 
11 RIBC2 0.226036 3.68E-04 126 TRUE 22 RIB43A domain with coiled-coils 2.  Synonym C22orf11 
12 CCDC74B 0.230644 3.71E-04 1015 FALSE 2 hypothetical protein LOC91409 
13 C20orf77 0.622206 6.42E-04 605 TRUE 20 hypothetical protein LOC58490 
14 C9orf112 0.530497 6.84E-04 317 TRUE 9 hypothetical protein LOC92715 
15 LCE1B 0.388947 7.51E-04 1310 FALSE 1 late cornified envelope 1B Role in epidermal differentiation complex 2A 
16 SFRS11 0.36302 7.59E-04 1480 FALSE 1 Splicing factor p54. Nucleic acid binding and nuclear mRNA splicing 
17 SLC18A2 0.055023 8.92E-04 275 TRUE 10 
solute carrier family 18 (vesicular monoamine); member 2. Vesicle monoamine 
transporter type 2. 
18 PAPPA -0.21564 1.07E-03 204 FALSE 9 
pregnancy-associated plasma protein A preproprotein.  Insulin-like growth 
factor dependent IGF binding protein. 
19 FIGNL1 0.64861 1.08E-03 599 TRUE 7 fidgetin-like 1  ATP binding nucleoside-triphosphatase activity 
20 NMT1 -0.08842 1.10E-03 285 TRUE 17 N-myristoyltransferase 1 
21 VAMP5 -0.28073 1.13E-03 492 TRUE 2 
vesicle-associated membrane protein 5 (myobrevin).  Role in vesicle-mediated 
transport, myogenesis, and cell differentiation 
22 FLJ33641 0.634 1.20E-03 974 FALSE 5 hypothetical protein LOC202309 
23 DVL3 0.40801 1.21E-03 580 TRUE 3 dishevelled 3.  Kinase activity. Role in nervous system development. 
24 C20orf4 -0.15153 1.22E-03 250 TRUE 20 hypothetical protein LOC25980 








Table 3.5. Table of the 25 CpG sites most significantly differentially methylated by AD case status (Discovery Set). 













1 TMEM59 63.03 70.30 1.32E-05 1339 FALSE 1 APP post-translational glycolytic processing 
2 ATG10 8.16 5.59 1.97E-04 197 TRUE 5 Autophagy 
3 C9orf138 85.53 77.88 2.08E-04 47 TRUE 9 Hypothetical Protein 
4 CPNE9 4.76 6.33 4.43E-04 549 TRUE 3 Copine-like protein 
5 RELB 36.40 45.75 5.68E-04 470 TRUE 19 
reticuloendotheliosis viral oncogene homolog 
B 
6 C9orf138 68.36 57.60 8.92E-04 406 TRUE 9 Hypothetical Protein 
7 PLA2G3 45.95 37.03 9.66E-04 488 FALSE 22 Phospholipase A2 
8 DHFRL1 6.41 4.41 1.08E-03 511 TRUE 3 Hypothetical Protein 
9 MBD3L1 16.33 11.98 1.08E-03 141 FALSE 19 Methyl-CpG binding domain protein 3-like 
10 RSN 2.37 2.85 1.37E-03 698 TRUE 12 
Restin isoform a. Intermediate filament 
associated protein 
11 OTUD5 22.39 18.53 1.53E-03 232 TRUE X Hypothetical Protein 
12 TUBB2B 7.58 10.50 1.53E-03 494 TRUE 6 
Tubulin, beta polypeptide paralog. Microtubule 
associated. 
13 NTN2L 7.63 4.97 1.59E-03 159 TRUE 16 
Netrin 2-like. Structural molecule, axon 
guidance. 
14 GPR142 90.60 88.52 1.64E-03 237 FALSE 17 Signal transduction 
15 TSCOT 55.93 62.95 1.65E-03 498 TRUE 9 Thymic stromal co-transporter 
16 IL2RG 67.12 60.80 1.70E-03 88 FALSE X Interleukin 2 receptor, gamma precursor.   
17 BNC1 39.63 48.20 1.86E-03 NA TRUE 15 
Zinc finger protein basonuclin. Metal ion 
binding.   
18 HERC5 2.57 1.43 1.91E-03 108 TRUE 4 Cyclin-E binding protein 1.   
19 SLC36A3 73.03 80.25 2.18E-03 203 FALSE 5 Proton/amino acid transporter 3 
20 DYNC2LI1 4.44 3.05 2.21E-03 24 TRUE 2 Dynein 2 light intermediate chain 
21 SLC7A3 10.20 6.88 2.32E-03 208 TRUE X Cationic amino acid transporter 
22 FGF5 4.24 5.70 2.36E-03 544 TRUE 4 Fibroblast growth factor 5 
23 CAMP 92.62 89.57 2.53E-03 284 FALSE 3 Cathelicidin antimicrobial peptide 
24 CNN1 13.81 9.18 2.59E-03 92 TRUE 19 Caloonin 1. Calmodulin binding 
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Research Chapter 3 
An integrated analysis of genome-wide RNA expression and DNA 
methylation in late-onset Alzheimer’s disease and neuropathological 
controls 
ABSTRACT 
Introduction: Spontaneous, neurodegenerative, late-onset Alzheimer’s disease 
(LOAD) is associated with aberrations in brain gene expression.  Recent studies 
have observed dysregulation of epigenetic mechanisms, such as DNA 
methylation, but the association of gene expression with these marks in disease 
tissue is unknown.  Gene expression analysis in conjunction with DNA 
methylation mapping provides insight into the mechanisms of LOAD. 
Research: To investigate the potential epigenetic regulation of gene expression 
in LOAD, we evaluated the human frontal cortex of 11 cases of LOAD and 12 
cognitively normal controls.  We measured genome-wide RNA gene expression 
using the Affymetrix U133A Plus 2.0 Array and DNA methylation using the 
Illumina HumanMethylation 27K BeadArray.  We performed validation of X 
specific loci. 
Results: After adjusting for age and sex, there were 176 probe sets (145 unique 
genes) distinguishing gene expression of LOAD cases and controls (FDR<0.1, p-
value<3.3x10-4).  Of these, 76.7% were down-regulated in LOAD, including the 
statistically top five genes DUSP16, ERICH1, ESF1, PTPRF, and RNBP1.  
Among the genes where expression was associated with LOAD (p-value<0.05), 
DNA methylation and gene expression were correlated at 151 genes.  Positive 
(47.7%) and inverse (52.3%) associations were observed between gene 
expression and DNA methylation.   
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Conclusions: LOAD case and control samples differed by RNA expression 
levels and relatively few (7.2%) of those differences were correlated with DNA 
methylation.  Among genes with correlated DNA methylation and gene 
expression, positive and negative associations were observed with approximately 
equal frequencies.  Integrated genome-wide analyses of DNA methylation and 
RNA gene expression provide a functional molecular signature of LOAD and 
suggest novel sites for disease biomarker development.   




Alzheimer’s disease (AD) is a fatal neurodegenerative disease that affects 
over five million people in the United States. It is the sixth leading cause of death 
across all ages and the prevalence is rising (Alzheimer's Association 2011).  AD 
is characterized by two neuropathologies: β-amyloid (Aβ) plaques and tau 
neurofibrillary tangles (NFT).  Highly penetrant genetic mutations in the Aβ 
production pathway account for approximately 2% of AD cases, termed early-
onset AD (EOAD) cases (Bird 2005).  The remaining 98% of AD cases manifest 
symptoms after age 55 and are termed late-onset AD (LOAD) cases. Genome-
wide association studies reveal genetic risk factors for LOAD that are neither 
necessary nor sufficient to cause disease.   LOAD risk is associated with 
polymorphisms in the apolipoprotein E4 (APOE ε4), ABCA7, BIN1, CD2AP, 
CD33, CLU, CR1, EPHA1, MS4A4A and PICALM genes (Harold et al. 2009; 
Hollingworth et al. 2011; Lambert et al. 2009; Naj et al. 2011).  The combined 
population attributable fraction (PAF) for these multiple genetic risk factors is 
0.50, even after adjusting for APOE ε4 dose (Naj et al. 2011).  Thus, LOAD risk 
may be conferred through an interaction of external factors with genetic risk 
factors through gene-environment interactions or epigenetic modifications.  
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In LOAD, where genetic determinants confer only partial risk, Aβ and NFT 
pathways may be dysregulated through epigenetic mechanisms.  Epigenetics 
refers to heritable changes in gene expression that do not involve changes to the 
underlying DNA sequence.  Recent evidence suggests age-related changes in 
candidate gene methylation, such as upstream of Microtubule Associated Protein 
Tau (MAPT) in post-mortem human brain tissue (Tohgi et al. 1999).  Striking 
disease-specific differences however, have not been consistently detected in 
promoter CpG island regions of Aβ and NFT candidate genes (Barrachina and 
Ferrer 2009).  Newer research investigates non-canonical disease pathways, 
including cellular protein translation.  For example, AD samples from the parietal 
and prefrontal cortex were hypermethylated in the promoter regions of nucleolar 
rRNA genes (Pietrzak et al. 2011), coinciding with reduced ribosomal activity that 
has been observed with LOAD.   
To better understand the etiology of LOAD and the pathogenic processes, 
mapping the more complete epigenetic signature of disease is an important 
emerging area of research (Bakulski et al. 2012a).  Recent work from our 
research group has broadened the targeted pathway approach to examine 
genome-wide DNA methylation in LOAD (Bakulski et al. 2012a; Bakulski et al. 
2012b).  DNA methylome studies in LOAD brain tissues suggest widespread, yet 
modest DNA methylation changes associated with both age and disease 
(Bakulski et al. 2012b).  DNA methylation change is apparent, but the functional 
implications of the observed epigenetic marks have not yet been determined.  
LOAD cases and controls have been classified based on their differential 
gene expression profiles in post-mortem brain tissues.  For example, studies of 
gene expression by brain region in AD indicate significant dysregulation beyond 
the Aβ and NFT pathways (Kong et al. 2011).  Expression levels of ceramide 
fatty acid processing genes including ASMas, NSMass2, and GALC were 
upregulated in the brains of AD subjects (Filippov et al. 2012).  Changes in gene 
expression may also be at the center of hippocampal-dependent memory and 
corresponding deficiencies in AD.  For example, hippocampal neurons derived 
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from AD transgenic mice had reduced expression of activity-induced CREB-
dependent genes, which was reversible with expression of CREB-regulated 
transcription coactivator 1 (Crtc1) (Saura 2012).  Transcriptome profiles of AD 
and controls suggest AD brain tissues have increased expression of broad 
markers of chronic inflammation, cell adhesion, cell proliferation, and protein 
synthesis, as well as downregulation of signal transduction, energy metabolism, 
stress response, synaptic vesicle synthesis and function, calcium binding, and 
structural proteins (Loring et al. 2001).  The factors responsible for these broad 
gene expression changes are not clear.  In order to understand the etiology of 
LOAD, we move upstream in the LOAD course and investigate the regulation of 
the LOAD transcriptome, controlled in part through the epigenome. 
Recent individual gene studies have underscored the strengths in 
analyzing matched epigenetic and gene expression data in AD.  The candidate 
gene, peptidyl-prolyl cis/trans isomerase (Pin1), was examined in human 
peripheral blood mononuclear cells of 60 matched LOAD and control samples 
(Arosio et al. 2012).  Pin1 promoter DNA methylation had a modest reduction 
(8%) and increased gene expression (74%) in LOAD (Arosio et al. 2012).  A 
second example involves the Aβ A4 precursor protein-binding family A member 2 
(APBA2) gene implicated in Aβ production.  In primary rat cortical neurons, 
expression of Apba2 was reduced with promoter DNA methylation at a location 
7-120 base pairs upstream of the transcription start site (TSS) (Hao et al. 2012).  
An integrated analysis of observed DNA methylation and previously published 
RNA-seq expression was performed on a human cell line expressing the 
Swedish mutation of APP (APP-sw) and it revealed three potential gene sites 
(CTIF, NXT2, and DDR2) where DNA methylation and RNA expression were 
correlated (Sung et al. 2011).  These results are promising, but cell lines have 
distinct epigenetic profiles from primary tissue (Smiraglia et al. 2001) and cell 
lines engineered with EOAD mutations are not adequate models for spontaneous 
LOAD. Previous studies show that analyses incorporating both epigenetic and 
gene expression data can be very useful (Sartor et al. 2011).  Research using 
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primary human brain tissue in LOAD is needed to characterize the connection 
between DNA methylation and gene expression on a genome-wide scale.   
Here we utilize whole genome approaches to interrogate both gene 
expression and DNA methylation profiles in LOAD cases and controls to identify 
potential functional relationships between epigenetic patterns and disease status. 
First, human post-mortem frontal cortex samples from LOAD and 
neuropathologically normal control subjects are assessed for gene expression 
profiles.  Next, we combined gene expression data with DNA methylation results 
in the same samples.  Identification of genes with disease-specific gene 
expression differences that are correlated with DNA methylation changes support 
an emerging role of epigenetics in LOAD. 
Results 
Gene expression results.  
Gene expression in the frontal cortex was measured in 11 LOAD cases 
and 12 cognitively normal controls using the Affymetrix GeneChip Human 
Genome U133 Plus 2.0 Array. The array features 54,675 probe sets representing 
20,722 unique gene ids. The mean expression level across LOAD and controls 
was 4.73 and it ranged from 1.75 to 14.25. 
After adjusting for age and sex, site-specific expression values were 
compared between cases and controls.  The DUSP16 (dual specificity 
phosphatase 16) gene transcript distinguished LOAD cases and controls with the 
greatest statistical significance (p-value= 8.85*10-7, FDR= 0.0316, log(2) fold 
change: -0.913).  DUSP16 was down-regulated in LOAD, as were the next eight 
statistically significant genes with strongest association with LOAD status (Figure 
4.1).  These top nine genes (DUSP16, ERICH1, ESF1, PTPRF, FNBP1, RBM4, 
JMJD1C, LUC7L3, and RBM25) were down-regulated in AD case samples with 
an average of -1.18 log(2) fold change.  Three of the top nine genes were RNA 
splicing regulators (RBM4, LUC7L3, RBM25).   
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The top 25 probesets that differentiated cases and controls at a false 
discovery rate of 0.033 are listed in Table 4.1.  Twenty-two of the top 25 genes 
(88%) (DUSP16, ERICH1, ESF1, PTPRF, FNBP1, RBM4, JMJD1C, LUC7L3, 
RBM25, NUPL1, TCF25, UBXN4, CDC42BPA, CCAR1, ZNF37A, BRD4, EIF5B, 
LIMA1, ZFHX4, SMARCA4 , MYO6, CHAF1A) were down-regulated in LOAD.  
Three of the top 5 genes (12%) (SYTL4, DPYSL3, and LOC100505875) were up-
regulated in LOAD.    
Overall, there were 176 probe sets (146 unique genes) distinguishing 
LOAD cases and controls at a false discovery rate of less than 0.1 (p-
value<3.2x10-4) (Supplemental Table 4.1).  The log(2)fold change between 
cases and controls in these probe sets ranged from -1.98 to 1.72.  Forty-one 
(23.9%) of these probe sets were up-regulated in LOAD, while 135 (76.7%) were 
down-regulated in LOAD. The normalized expression of the top 176 sites is 
illustrated in a heatmap of using Ward’s hierarchical clustering methods and the 
maximum distance function (Figure 4.2).  Cases and controls are separated into 
two column clusters and the probeset rows separate into two groups based on up 
and down regulation with disease.  These 176 probesets also distinguish cases 
and controls when using Principal Component Analysis.  Principal component 
analysis (PCA) is a dimension reduction tool to reduce multiple correlated 
variables to linearly uncorrelated variables.  When data were restricted to probe 
sets that were differentially expressed according to LOAD status (n=176), PCA 
was an effective visualization strategy.  The first principal component described 
67.2% of the variance and the second principal component described 9.5% of the 
variance (Figure 4.3A). PCA on the 176 probe sets associated with LOAD (FDR 
<0.1), clustered samples by LOAD case and control (Figure 4.3B).  The heatmap 
and the PCA plot illustrate that these 176 probesets together are markers of 
LOAD case/control status in these samples.   
To examine whether these differences observed between AD cases and 
controls were due to disease-specific changes in expression or changing cell-
type populations, we incorporated publicly available cell-type specific data from 
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the NCBI Gene Expression Omnibus (GEO).  We combined GEO data from 
embryonic stem cell-derived neuronal precursor cells (NPC) and astrocytes with 
our own AD case and control data.  We used a follow-up heatmap to plot the 
expression levels at the original 176 probesets we found to distinguish cases and 
controls alongside the expression at those sites in NPC and astrocyte cells 
(Supplemental Figure 4.1).  At these 176 sites, NPC and astrocyte cells were 
separated into two cell-type clusters.  NPC and astrocytes did not cluster with AD 
cases or controls however, and the embryonic stem cell-derived data displayed 
greater range in gene expression change than our data.   
To test whether there were biological patterns in the group of genes that 
were found to be different in expression between LOAD cases and controls, we 
used the software, LRpath, developed by the National Center for Integrative 
Biomedical Informatics (NCIBI) (Sartor et al. 2009).  LRpath is a program that 
runs gene set enrichment testing using logistic regression on the full list of genes 
and associated p-values.  We used LRpath to calculate overrepresentation 
among our top expression hits in gene ontology terms (biological processes and 
molecular functions), cytogenic bands, transcription factor targets, and miRNA 
targets.  We observed down-regulation of 92 gene ontology biological processes 
at p<0.01 (FDR<0.1). The top fifteen biological processes that are decreased in 
LOAD are listed in Table 4.2 and the full list is in Supplemental Table 4.2.   Nine 
processes were at false discovery rates < 0.002: synaptic transmission, 
transmission of nerve impulses, cell-cell signaling, oxidative phosphorylation, 
regulation of synaptic plasticity, regulation of transmission of nerve impulse, 
cellular respiration, regulation of neurological system process, neurotransmitter 
transport, and regulation of neuronal synaptic plasticity. Similarly, we observed 
enrichment of 348 gene ontology biological processes in the genes with 
increased expression in AD cases (p-value<0.01, FDR<0.1).  The top fifteen 
biological processes that are increased in LOAD are listed in Table 4.3 and the 
full list is in Supplemental Table 4.3.  The top nine were translational elongation, 
defense response, immune response, innate immune response, inflammatory 
response, response to biotic stimulus, response to other organism, activation of 
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immune response, and regulation of immune response at false discovery rates < 
4*10-7.   The results for gene ontology molecular functions were similar to the 
results for 77 significantly up and 79 down regulated biological processes 
(Supplemental Tables 4.4 and 4.5, respectively). 
Genes differentially expressed in LOAD were also enriched in specific 
transcription factor targets, microRNA targets, and cytogenic bands.  Reduced-
expression in LOAD was associated with 17 transcription factors (Supplemental 
Table 4.6) including the top five: NRSF_01, NMYC_01, CREB_01, 
CREBP1CJUN_01, and MEIS1BHOXA9_02.  Over-expression in LOAD was 
associated with the following six transcription factors NFKAPPAB_01, 
NKX22_01, OCT_C, PBX1_01, HOXA3_01, and CREL_01 (Supplemental 
Table 4.7).  Genes targets associated with three microRNAs were over-
expressed in LOAD (mir-506, mir-124, mir-433) and genes under-expressed in 
LOAD were enriched in binding for three microRNAs (mir-129-5p, mir-185, and 
mir-328) (Supplemental Tables 4.8 and 4.9, respectively).  Among genes with 
higher expression in LOAD, 32 cytogenic bands were enriched, including the top 
five: 7p13-p12, 17p13, 4q25, 10p12.31, and 1q25 (Supplemental Table 4.10).  
Across genes with lower expression in LOAD, 33 cytogenic bands were enriched, 
including the top five: 16p13.3, 10p11.2, 8p23, 12p12.3, 8p21.3 (Supplemental 
Table 4.11).   
Expression-Methylation 
To test the extent to which DNA methylation was associated with the 
observed LOAD gene expression differences, we linked genome-wide gene 
expression and DNA methylation data from the same samples.  DNA methylation 
data was generated using the Illumina Infinium HumanMethylation27 BeadArray 
(Bakulski et al. 2012b).  We assessed combined methylation and expression at 
2,094 Entrez gene IDs (Figure 4.4).  These 2,094 genes had RNA expression 




Across these 2,094 genes, we tested whether DNA methylation was 
correlated with gene expression.  At 151 genes (7.2% of genes tested), DNA 
methylation and gene expression were significantly correlated (Pearson 
correlation test p-value<0.05).  Among the 151 correlated sites, 79 (52.3%) 
represented the canonical, inverse association between DNA methylation and 
gene expression.  Conversely, 72 (47.7%) represented non-canonical, positive 
correlation between DNA methylation and gene expression. Pearson correlation 
values ranged from -0.62 to 0.68 across these significantly correlated sites.  
Among the 151 DNA methylation and RNA expression correlated sites, 81 
(53.6%) genes had higher methylation in LOAD and 70 (46.4%) had lower 
methylation in LOAD (Figure 4.5A).  Similarly, 86 (57%) had higher expression in 
LOAD and 65 (43%) had lower expression (Figure 4.5B) 
Significant differences in methylation levels between LOAD cases and 
controls were observed at 24 of the 151 DNA methylation-gene expression 
correlated sites (15.9%), after adjusting for age and sex (p-value<0.05) (Table 
4.4).  These 24 sites had significant disease-specific differences in DNA 
methylation, gene expression, and correlated methylation-expression values.  
Canonical, inverse correlation was observed at the following 17 genes (70.8% of 
24 genes with significant methylation differences): ARHGAP15, PTAFR, 
FAM122C, SNX20, MKNK1, PSEN1, PMP2, CDC42EP3, PLD5, SKI, GPR34, 
TP53TG5, WWTR1, CATSPERG, PARVG, PPP1R3B, and IFI16.  Non-
canonical, positive correlation between DNA methylation and gene expression 
was observed at 7 (29.2%) of sites: TMPO, SERPINH1, PSMB2, ITGAM, 
MED12, OLFML2B, and NACC2.  The first 9 genes with significant disease-
specific differences in DNA methylation, gene expression, and correlated 
methylation-expression are illustrated in scatter plots in Figure 4.6 and the 
remaining 15 genes are in Supplemental Figure 4.2. 
To test whether the genes with correlated expression and methylation 
values shared common biological pathways, we again performed gene set 
enrichment analysis using LRpath software.   We uploaded the Pearson’s 
 
124 
correlation test p-values corresponding to the correlations between the 2,094 
genes with linked RNA expression and DNA methylation data.  We observed 
enrichment at the cytogenic bands across DNA methylation and RNA expression 
correlated genes: 17p11.2, 14q24.3, 16q22.1, 11q23.3, 6p21.2, and 19p13.3, as 
shown in the circos plot (Figure 4.7).  We also observed transcription factor 
binding site enrichment at CEBPA_01, OCT1_05, GFI1_01, EVI1_06, MEF2_02, 
OCT1_01, NCX_01, PAX4_03, USF_C, GATA1_01, HAND1E47_01, PAX3_01, 
FOXO3_01, and COUP_01.  The following microRNA targets were enriched 
among the correlated DNA methylation and RNA expression sites: mir-342-3p, 
mir-215, mir-192, mir-455-5p, mir-300, mir-488, and mir-142-3p.  171 biological 
processes were enriched, including the top ranked twelve: protein 
deubiquitination, protein modification by small protein removal, NK-kappB import 
into nucleus, regulation of NF-kappaB import into nucleus, negative regulation of 
axonogenesis, ion membrane transport, regulation of transcription factor import 
into nucleus, microtubule depolymerization, positive regulation of protein 
ubiquitination, nuclear-transcribed mRNA catabolic process, mRNA catabolic 
process, and positive regulation of ligase activity.   
Discussion 
 LOAD is a complex disease involving multiple physiological changes that 
are evident in post-mortem pathology. Known genetic risk factors are responsible 
for only approximately half of the risk of LOAD disease initiation and progression 
(Naj et al. 2011).  We interrogated the gene expression changes associated with 
disease and an epigenetic gene expression regulator.  DNA methylation changes 
have been observed in LOAD, but the function of DNA methylation as a 
biomarker or potential mechanism of disease with gene expression implications 
had not been well characterized. We compared frontal cortex genome-wide RNA 
expression and DNA methylation profiles of LOAD cases and neuropathology-
confirmed controls.   Tissues were acquired on autopsy and nucleic acid samples 
were analyzed using array-based methods. We identified genes where 
expression was correlated with DNA methylation and where there were 
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differences by disease status.  These observations support a potential functional 
role for DNA methylation in LOAD at a subset of genes.   
First, using frontal cortex tissue, we identified discordant gene expression 
in LOAD.  We identified a subset of genes that were associated with LOAD 
where expression of samples clustered by case status.   These genes also 
differentiated NPC and astrocyte cell lines, which clustered separately from post-
mortem samples.  The majority of genes altered in LOAD were repressed in the 
disease samples. Across the entire gene set, the biological processes synaptic 
plasticity and transmission of nerve impulse were down-regulated in LOAD, while 
immune-related responses were up-regulated in LOAD.  These findings are 
consistent with the current understanding of LOAD pathogenesis.  In a novel 
analysis of genes with altered expression in LOAD, we integrated gene 
expression and DNA methylation data to test the role of DNA methylation in 
disease RNA changes.  Seven percent of genes with altered expression in LOAD 
were correlated with DNA methylation levels.  Gene expression varies with 
disease and DNA methylation may regulate the expression changes at a subset 
of genes.    
A handful of identified genes have previously been implicated in LOAD 
and in cognitive changes.  Specifically, we found reduced gene expression of 
ERICH1 in LOAD.  Copy number variation within the ERICH1 gene was 
previously associated with intra-extradimensional set shifting (IED) domain on 
the CANTAB cognition test (Need et al. 2009).  We also observed 
downregulation of formin binding protein 1 (FNBP1) in LOAD samples.  FNBP1 
was previously shown to be downregulated in blood mononuclear cells of AD 
subjects (Maes et al. 2007).  FNBP1 is implicated in endocytosis and cellular 
trafficking and protein processing.  Further, we observed reduced expression of 
PTPRF.  AD pathogenesis is associated with abnormal autophagy and PTPRF 
binds PTPσ, an autophagic phosphatase (Martin et al. 2011).   
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The gene expression probe set which best distinguished LOAD cases and 
controls was associated with DUSP16 (dual specificity phosphatase 16).  
DUSP16 is a member of a family of proteins that catalyse the inactivation of 
mitogen-activated protein kinase (MAPK).   MAPK plays a role in long term 
potentiation (LTP) of neurons (English and Sweatt 1997).  The p38 MAPK 
pathway is involved in tau pathology in AD (Johnson and Bailey 2003) and has 
been targeted for AD treatment (Munoz and Ammit 2010).   In addition, RBM4 
was downregulated in LOAD in our study.  RBM4 is a splice factor that interacts 
with an intronic element for MAPT and stimulates tau exon 10 inclusion (Kar et 
al. 2006).  RMB25 and LUC7L3 are also splice factors that were downregulated 
in LOAD in our study.  Dysregulation of splicing factors could have widespread 
downstream effects for neurodegenerative disease (Licatalosi and Darnell 2006).   
Previous research has performed transcriptome array analysis on LOAD 
cases and controls in the neocortex and found a large number of genes with 
divergent disease gene expression with wide-ranging physiological functions 
(Tan et al. 2010).  Among the genes that were associated with LOAD (FDR<0.1), 
we observed 77% were down-regulated in gene expression with LOAD.  
Similarly, Maes et al. found of the 942 genes with 2-fold differential change in AD 
blood mononuclear cells relative to controls, 87% were downregulated and only 
13% were upregulated in AD (Maes et al. 2007).  Research has looked at 
genetics as a driver of gene expression differences.  A previous genome-wide 
gene expression study in Alzheimer’s disease linked SNP data with transcript 
levels (Webster et al. 2009), and found that ~5% of transcripts had correlation 
between expression profiles and genotypes that could distinguish LOAD cases 
and controls.  Results from our study suggest that a similar level of genes with a 
altered expression (7% of genes) are correlated with DNA methylation levels.  
The current paper is the first study, that we are aware of, to examine the 
association between DNA methylation and gene expression in LOAD on a 
genome-wide scale.  Future research may integrate genetics, transcriptomics, 
and epigenomics for a more complete understanding of gene regulation in LOAD.   
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A limitation of cross-sectional research, such as this, is that causal 
relationships cannot be inferred.  Later work will be able to study the time course 
of the DNA methylation and gene expression associations observed here.  
Further, LOAD is characterized by neuronal loss (Coleman and Flood 1987) and 
glial cell activation (Mattson 2004).  Changing cell type populations may be 
responsible for these observations and future work could identify the cell type 
specific DNA methylation and gene expression patterns.   
GWAS studies estimate that known genetic LOAD risk alleles confer a 
combined population attributable fraction of 0.5 (Naj et al. 2011).  Additional risk 
genotypes may be discovered, but the remaining risk likely results from 
environmental exposures and an interaction of genetic and environmental 
factors, which have been historically understudied.  Epigenetics represents an 
important intersection of genes and environment.  By identifying new candidate 
areas of epigenetic and gene expression variability with LOAD, this research 
provides the groundwork for future studies in environmental and genetic 
susceptibility to LOAD.  LOAD research may increasingly consider a combined 
gene-environment paradigm.   
Materials and Methods 
Sample ascertainment.  The Michigan Alzheimer’s Disease Center (MADC) 
(P50AG008671; PI: Henry Paulson) followed a clinically characterized cohort of 
Alzheimer’s disease and cognitively normal control subjects.  Many subjects (and 
legal care-givers) consented to autopsy and donated to the MADC Brain Bank.  
Diagnoses were neuropathologically confirmed using Braak and Reagan scoring 
in the left hemispheres.  The right hemispheres were coronally sectioned, flash 
frozen, and archived at -80ºC.  For the current study, frozen tissue blocks from 
the mid-frontal gyrus of the frontal lobe were dissected at -20ºC.  MADC frozen 
tissues were previously used in high quality DNA methylation (Bakulski et al. 
2012b), expression (Hong et al. 2008; Pan et al. 2007), and proteomic studies 
(Pan et al. 2007).   
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Samples were eligible for the current study if neuropathology confirmed 
the diagnosis and if the subjects were at least 60 years old at death.  The MADC 
Brain Bank had 98 eligible LOAD cases (Braak Score ≥ 4) and 39 controls (Braak 
Score ≤ 2). Twelve gender- and age- (+/- 2 years) matched pairs of LOAD cases 
and controls were generated randomly, without replication.  The population 
characteristics of both sets of samples used in the current study are described in 
Table 4.5.  This human subjects study was approved by the Institutional Review 
Board of the University of Michigan Medical School.   
DNA and RNA isolation.  Gray matter free of vascular lesions was selected 
from the tissue blocks. DNA and RNA were isolated from adjoining tissues in all 
25 matched pairs.  DNA was extracted according to manufacturer’s instructions 
using the Maxwell Tissue DNA Kit (Promega, AS1030).  Tissue was 
homogenized with the TissueLyser II (Qiagen, 85300) and total RNA was 
extracted using the RNeasy Lipid Tissue Mini Kit (Qiagen, 74804).   
Transcriptome-wide RNA expression.  RNA from the twelve case-control pairs 
was interrogated for genome-wide expression analysis.  RNA quality was 
assessed using the Agilent 2100 Bioanalyzer and quantified using the Thermo 
Scientific NanoDrop Spectrophotometer 2000.  Samples with RNA quality greater 
than 3.0 RNA Integrity Number (RIN) and absorbance ratios A260/A280 greater 
than 2.0 were used for further study.  One AD case sample did not meet this set 
of criteria and was not used for further RNA study.  The quality of RNA did not 
differ by LOAD cases and controls (mean RIN=6.0, p-value=0.8).  5 ug of RNA 
was used for cDNA synthesis using a T7-Oligo(dT) promoter primer.  An in vitro 
transcription (IVT) reaction produced biotin-labeled cRNA that was then 
fragmented. At the University of Michigan Affymetrix Core facility, cRNA was 
hybridized to the GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, 
900470) using the 16-hour hybridization protocol. Each sample was hybridized to 
its own chip.  The probe array was washed and stained according to the 
GeneChip Expression Wash, Stain and Scan User Manual (Affymetrix, 702731).  
The probe array was scanned using the Affymetrix Scanner 3000 instrument and 
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the image files were analyzed for probe intensities.  The GeneChip provided data 
on 20,722 unique genes using 54,675 probe sets.   
Affymetrix Data Processing.  All further data processing and statistical 
analyses were done in R Statistical Software (version 2.18).  Data was 
background corrected, log2 transformed, and quantile normalized with Robust 
Multichip Average (RMA) methods (Gautier et al. 2004).  Using the affyQCReport 
and simpleaffy packages, quality control between the chips was high.     
Gene specific differential expression and significance by AD case status 
was assessed using parallel linear models and empirical Bayesian variance 
methods at site-specific moderated t-tests (Smyth 2004).  The following parallel 
linear models were fit at each CpG site that adjusted for subject’s age and sex.   
Expression = β0
 + β1(AD Case Status) +β2(Age) + β3(Sex) 
Probesets with AD Case Status β values that are significant at false 
discovery <0.1 are listed in a table and are used for data visualization.  A 
heatmap with mean normalized expression values was used to cluster samples 
and probesets.  To further illustrate differences between gene expression profiles 
in LOAD cases and controls, principle component analysis was used.  Across all 
probes on the GeneChip, the first three principal components explain 67% of 
variance. 
For each probeset, the Entrez gene ID, corresponding AD Case Status β 
p-value, and T-test statistic for direction of association were uploaded to the 
LRpath gene set enrichment testing program (Sartor et al. 2009).  LRpath was 
used to test for enrichment in gene ontology terms, cytogenic bands, 
transcription factor binding sites, and microRNA binding sites.    
We also downloaded publicly available cell-type specific gene expression 
data from NCBI’s Gene Expression Omnibus (GEO).  Gene expression in 
embryonic stem cell derived neuronal precursor cells (GSE7178) and astrocytes 
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(GSE5080) were plotted in a heatmap alongside the top hits distinguishing LOAD 
cases and controls.    
Genome-wide DNA methylation.  One µg of DNA from the twelve case-control 
pairs in the Discovery Phase was bisulfite-treated according to manufacturer’s 
instructions with the EZ DNA Methylation Kit (Zymo, D5001).  The Illumina 
recommended extended bisulfite thermocycling protocol (98ºC 10 minutes, hold 
at 64ºC for 17 hours) was followed.  Bisulfite-treated DNA was prepped and 
applied to the Infinium HumanMethylation27 BeadArray (Illumina, WG-311-2201) 
by the University of Michigan DNA Sequencing Core facility using methods 
published by Illumina researchers (Bibikova et al. 2009).  Across 27,578 probe 
sets, the BeadChip primarily targets CpG sites in the promoter regions of 14,475 
genes and 110 miRNAs.  Batch effects can potentially bias experimental 
differences, so six cases and six control samples were randomly applied to each 
of the 12-sample BeadChips.  Fluorescent intensities were imaged using the 
Illumina BeadArray Reader and the associated BeadScan software was used for 
image processing and data extraction.  Data were background normalized and 
percent methylation estimates (beta values) were calculated for each probe set.  
Data were exported to R for further processing.   
Illumina Data Processing.  The Illumina GenomeStudio software scored CpG 
sites for individual samples as failing based on fluorescence.  CpG sites that 
failed on greater than 10% of samples (n=171 sites) were excluded from 
analyses.  Tests for differences in methylation by epidemiological characteristics 
were performed using the limma BioConductor R package.  The following parallel 
linear models were fit at each CpG site that adjusted for subject’s age and sex.   
% Methylation = β0
 + β1(AD Case Status) +β2(Age) + β3(Sex) 
Data integration and statistical methods.  We filtered the list of genes 
differentially expressed between LOAD cases and controls and selected only the 
probe sets that met an expression difference threshold of p<0.05 (n=4,063 probe 
sets).  We removed 750 probe sets that did not map to Entrez gene ID’s 
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(n=3,313). To reduce the data to a single expression value per unique gene ID, if 
greater than one probe set was differentially expressed for a given gene, we 
selected the probe with the highest expression value.  The set of unique 
Affymetrix gene ID’s that were associated with LOAD case status included 2,768 
probe sets.   
We filtered the Illumina methylation data to only include CpG sites within 
1500 bp of a transcription start site with a known Entrez gene ID (n=25,811).  In 
the case of multiple Illumina probes for a given gene ID, we selected the CpG 
site with the lowest p-value for the association between LOAD cases and 
controls (n=13,865). 
We then matched the Affymetrix expression data and the Illumina 
methylation data by Entrez gene IDs.  This yielded a total of 2,094 unique gene 
ID’s where Illumina and Affymetrix matched and where the Affymetrix probe set 
was statistically significantly associated with LOAD case status (Figure 4.4).  
The Pearson’s correlation between gene expression and DNA methylation was 
calculated for each gene.  We performed LRpath gene set enrichment analysis 





Figure 4.1. Boxplots of gene expression of the 9 top genes that differ by LOAD 
case or control status.  LOAD cases display reduced gene expression at all of 9 





Figure 4.2. Heatmap of all of the 176 sites on the Affymetrix gene expression 
array (FDR < 0.1) associated with LOAD case status.  This plot used maximum 
distance and Ward’s hierarchical clustering methods.  Data has been normalized 








Figure 4.3. Principal Component Analysis. (A) Principal component loading 
histogram. (B). Principal component analysis scree plot for the top 176 probesets 









Figure 4.5 (A) Scatterplot of the 133 genes that displayed discordant gene 
expression and DNA methylation between LOAD cases and controls.  The top of 
the figure represents genes less expressed in AD (n=50) and the bottom of the 
figure represents genes upregulated (n=84) in LOAD.  The left of the figure 
shows genes more highly methylated in LOAD and the right shows less 
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methylation in LOAD. (B) Boxplot of the differences in methylation between AD 



































Table 4.1. Affymetrix expression differences between LOAD cases and controls (n=25) after adjusting for age and sex. 












1 1558740_s_at 80824 DUSP16 dual specificity phosphatase 16 12p13.2 7.11 0.531 -0.913 -6.63 8.85E-07 0.0316 
2 227016_at 157697 ERICH1 glutamate-rich 1 8p23.3 5.37 0.529 -0.917 -6.26 2.09E-06 0.0316 
3 218859_s_at 51575 ESF1 ESF1, nucleolar pre-rRNA processing protein, 
homolog (S. cerevisiae) 
20p12.1 7.72 0.393 -1.349 -6.16 2.65E-06 0.0316 
4 200635_s_at 5792 PTPRF protein tyrosine phosphatase, receptor type, F 1p34 7.35 0.488 -1.034 -6.12 2.96E-06 0.0316 
5 213940_s_at 23048 FNBP1 formin binding protein 1 9q34 7.03 0.425 -1.233 -5.87 5.33E-06 0.0316 
6 213718_at 5936 RBM4 RNA binding motif protein 4 11q13 5.86 0.537 -0.897 -5.85 5.57E-06 0.0316 
7 224933_s_at 221037 JMJD1C jumonji domain containing 1C 10q21.3 7.19 0.504 -0.990 -5.83 5.96E-06 0.0316 
8 208835_s_at 51747 LUC7L3 LUC7-like 3 (S. cerevisiae) 17q21.33 10.14 0.399 -1.327 -5.78 6.59E-06 0.0316 
9 212027_at 58517 RBM25 RNA binding motif protein 25 14q24.3 7.73 0.264 -1.919 -5.74 7.27E-06 0.0316 
10 241425_at 9818 NUPL1 nucleoporin like 1 13q12.13 5.70 0.558 -0.842 -5.73 7.60E-06 0.0316 
11 213311_s_at 22980 TCF25 transcription factor 25 (basic helix-loop-helix) 16q24.3 8.47 0.374 -1.420 -5.71 7.89E-06 0.0316 
12 212007_at 23190 UBXN4 UBX domain protein 4 2q21.3 8.97 0.421 -1.247 -5.66 8.88E-06 0.0316 
13 214464_at 8476 CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) 1q42.11 8.32 0.303 -1.722 -5.64 9.27E-06 0.0316 
14 227703_s_at 94121 SYTL4 synaptotagmin-like 4 Xq21.33 6.31 2.538 1.344 5.64 9.32E-06 0.0316 
15 224736_at 55749 CCAR1 cell division cycle and apoptosis regulator 1 10q21.3 8.02 0.446 -1.165 -5.64 9.47E-06 0.0316 
16 228711_at 7587 ZNF37A zinc finger protein 37A 10p11.2 7.10 0.584 -0.775 -5.61 1.01E-05 0.0316 
17 201430_s_at 1809 DPYSL3 dihydropyrimidinase-like 3 5q32 5.01 1.937 0.954 5.61 1.01E-05 0.0316 
18 226054_at 23476 BRD4 bromodomain containing 4 19p13.1 7.45 0.538 -0.894 -5.59 1.05E-05 0.0316 
19 201026_at 9669 EIF5B eukaryotic translation initiation factor 5B 2q11.2 7.24 0.465 -1.104 -5.58 1.10E-05 0.0316 
20 230781_at 100505875 LOC100505875 uncharacterized LOC100505875 NA 4.56 2.494 1.318 5.52 1.26E-05 0.0322 
21 222457_s_at 51474 LIMA1 LIM domain and actin binding 1 12q13 5.52 0.432 -1.212 -5.51 1.28E-05 0.0322 
22 219779_at 79776 ZFHX4 zinc finger homeobox 4 8q21.11 6.64 0.627 -0.674 -5.50 1.33E-05 0.0322 
23 212520_s_at 6597 SMARCA4 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 4 
19p13.2 7.19 0.427 -1.229 -5.49 1.35E-05 0.0322 
24 203215_s_at 4646 MYO6 myosin VI 6q13 7.26 0.253 -1.984 -5.47 1.41E-05 0.0322 









Table 4.2. Among genes with lower gene expression in AD cases vs. controls, the following are the top 15 biological 
processes that are down-regulated based on LR-Path. 
Rank Name #Genes P-Value FDR SigGenes 
1 synaptic transmission 353 4.92E-12 2.92E-09 223, 5368, 627, 6529, 7425, 9379 
2 transmission of nerve impulse 411 6.52E-12 3.38E-09 223, 5368, 627, 6529, 7425, 9379 
3 cell-cell signaling 700 5.95E-07 6.03E-05 223, 4826, 5368, 627, 6529, 7425, 9379, 9547, 9636 
4 oxidative phosphorylation 94 3.10E-06 1.81E-04 155066, 4704 
5 regulation of synaptic plasticity 53 8.57E-06 4.23E-04 627, 7425 
6 regulation of transmission of nerve impulse 132 2.83E-05 1.10E-03 627, 6529, 7425 
7 cellular respiration 94 2.90E-05 1.10E-03 4704 
8 regulation of neurological system process 142 4.41E-05 1.57E-03 627, 6529, 7425 
9 neurotransmitter transport 96 5.54E-05 1.93E-03 6529, 9379 
10 regulation of neuronal synaptic plasticity 32 5.96E-05 2.06E-03 7425 
11 regulation of synaptic transmission 121 7.69E-05 0.003 627, 6529, 7425 
12 respiratory electron transport chain 59 8.08E-05 0.003 4704 
13 regulation of neurotransmitter levels 82 1.13E-04 0.003 223, 9379 
14 nucleotide-excision repair, DNA damage removal 21 1.16E-04 0.003 2073 










Table 4.3. Among genes with higher gene expression in AD cases vs. controls, the following are the top 15 biological 
processes that are up-regulated based on LR-Path. 
Rank Name #Genes P-Value FDR SigGenes 
1 translational elongation 101 4.07E-20 1.69E-16 11224, 1937, 2197, 25873, 6135, 6154, 6173, 6176, 6188, 6193, 6207, 6222, 6232 
2 defense response 661 1.16E-16 2.42E-13 
10219, 10410, 1050, 10581, 11326, 12, 23643, 241, 2532, 2919, 313, 3440, 3487, 
3588, 3600, 3823, 4057, 4615, 4688, 51191, 58191, 6039, 604, 60675, 6283, 7097, 
7098, 710, 7100, 712, 713, 7132, 714, 718, 719, 7305, 8519, 929, 9332, 9450 
3 immune response 660 3.86E-15 5.34E-12 
10346, 10410, 10581, 11326, 23643, 2669, 2919, 3108, 3109, 3122, 3588, 3600, 
4057, 4615, 4688, 4860, 51191, 54209, 563, 58191, 604, 6398, 7097, 7098, 710, 
7100, 712, 713, 714, 718, 719, 8519, 929, 9450 
4 response to wounding 598 1.07E-14 1.11E-11 
10219, 1050, 11326, 12, 1462, 2162, 23643, 241, 2697, 2919, 313, 3399, 3440, 
3487, 3587, 3588, 3600, 4615, 4814, 604, 60675, 6283, 7097, 7098, 710, 7100, 712, 
713, 7132, 714, 718, 719, 7423, 929, 9332, 9450 
5 innate immune response 201 8.28E-13 6.68E-10 
10410, 10581, 11326, 23643, 4615, 4688, 51191, 58191, 7097, 7098, 710, 7100, 
712, 713, 714, 718, 8519, 929, 9450 
6 inflammatory response 365 9.65E-13 6.68E-10 
10219, 1050, 11326, 12, 23643, 241, 2919, 313, 3440, 3487, 3588, 3600, 4615, 604, 
60675, 6283, 7097, 7098, 710, 7100, 712, 713, 7132, 714, 718, 719, 929, 9332, 9450 
7 response to biotic stimulus 442 8.34E-12 3.85E-09 
10049, 10346, 10410, 10581, 11080, 1373, 1937, 23643, 3315, 3440, 3587, 3600, 
3665, 3669, 4057, 51191, 6283, 7079, 7097, 7098, 7100, 7132, 8519, 871, 929 
8 response to other organism 354 5.69E-11 2.36E-08 
10346, 10410, 10581, 1373, 1937, 23643, 3315, 3440, 3587, 3600, 3665, 3669, 
4057, 51191, 6283, 7079, 7097, 7098, 7100, 7132, 8519, 929 
9 activation of immune response 110 7.45E-11 2.81E-08 11326, 1997, 7097, 7098, 710, 7100, 712, 713, 714, 718, 719 
10 regulation of immune response 245 8.89E-10 3.08E-07 11326, 1997, 3600, 604, 7097, 7098, 710, 7100, 712, 713, 714, 718, 719 
11 response to bacterium 213 1.42E-09 4.53E-07 1373, 23643, 3587, 4057, 6283, 7079, 7097, 7098, 7100, 7132, 929 
12 I-kappaB kinase/NF-kappaB cascade 171 2.35E-09 6.98E-07 23643, 2697, 3965, 4615, 6275, 6283, 6398, 7097, 7098, 7100, 7105, 7132 
13 
regulation of toll-like receptor signaling 
pathway 9 2.97E-09 8.21E-07 7097, 7098, 7100 
14 
positive regulation of toll-like receptor 
signaling pathway 7 7.11E-09 1.85E-06 7097, 7098, 7100 









Table 4.4. Gene expression and methylation correlation. 


















1 7112 TMPO 209754_s_at cg23264519 0.309 0.041 0.411 0.046 0.617 0.002 
2 55843 ARHGAP15 218870_at cg23627134 0.457 0.003 -3.241 0.016 -0.614 0.002 
3 5724 PTAFR 227184_at cg18468844 0.436 0.011 -3.088 0.031 -0.591 0.003 
4 159091 FAM122C 239047_at cg16510010 -0.259 0.003 4.715 0.016 -0.586 0.003 
5 124460 SNX20 228869_at cg27081230 0.261 0.016 -4.881 0.016 -0.567 0.005 
6 8569 MKNK1 1560720_at cg15445332 0.230 0.002 -0.362 0.029 -0.540 0.008 
7 5663 PSEN1 207782_s_at cg11490446 0.430 0.008 -1.044 0.034 -0.534 0.009 
8 871 SERPINH1 207714_s_at 6.250186 0.878 0.041 1.507 0.026 0.525 0.010 
9 5375 PMP2 206826_at cg21649520 -1.124 0.000 4.849 0.024 -0.521 0.011 
10 5690 PSMB2 231323_at 3.890297 0.402 0.027 0.606 0.007 0.509 0.013 
11 3684 ITGAM 205786_s_at cg00833777 0.509 0.030 7.910 0.004 0.503 0.015 
12 10602 CDC42EP3 209288_s_at cg05469695 0.446 0.040 -1.993 0.027 -0.491 0.017 
13 200150 PLD5 1563933_a_at cg12613383 0.657 0.002 -2.358 0.042 -0.488 0.018 
14 6497 SKI 213755_s_at cg06382459 -0.263 0.032 1.217 0.011 -0.484 0.019 
15 2857 GPR34 223620_at cg22835805 0.670 0.031 -5.528 0.006 -0.464 0.026 
16 27296 TP53TG5 207482_at cg14226064 -0.407 0.029 3.634 0.006 -0.461 0.027 
17 25937 WWTR1 202133_at cg12507125 0.725 0.010 -2.123 0.004 -0.454 0.030 
18 9968 MED12 203506_s_at cg21693321 0.242 0.037 5.736 0.029 0.449 0.032 
19 57828 CATSPERG 231261_at cg18996334 -0.189 0.042 0.234 0.043 -0.448 0.032 
20 64098 PARVG 233510_s_at cg19863740 0.385 0.004 -2.099 0.035 -0.445 0.033 
21 25903 OLFML2B 213125_at cg20172280 0.242 0.043 0.803 0.022 0.443 0.034 
22 79660 PPP1R3B 222662_at cg24727203 0.601 0.004 -7.281 0.011 -0.441 0.035 
23 138151 NACC2 212993_at cg12004206 0.421 0.022 0.358 0.044 0.441 0.035 









Table 4.5. Study population characteristics. 
 LOAD Cases Neuropathologically 
Normal Controls 
N 11 12 







Ethnicity Caucasian Caucasian 
Braak Stage mean 4.75 1.33 
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Supplemental Figure 4.1. Heatmap of all of the 176 sites on the Affymetrix gene 
expression array (FDR < 0.1) associated with LOAD case status.  Publicly available data 
from embryonic stem cell derived neuronal precursor cells (GSE7178) and astrocytes 
(GSE5080) have been included.  This plot used maximum distance and Ward’s 
hierarchical clustering methods and normalized to the mean expression value per 
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Supplemental Figure 2.  Scatterplots of expression vs. methylation for the 23 genes 
significantly associated with AD via expression (p<0.05) and methylation (p<0.05), and 









Supplemental Table 4.1. Gene expression probesets associated with AD case vs. controls at FDR <0.1 (n=176) 












1 1558740_s_at 80824 DUSP16 dual specificity phosphatase 16 12p13.2 7.11 0.531 -0.913 -6.63 8.85E-07 0.0316 
2 227016_at 157697 ERICH1 glutamate-rich 1 8p23.3 5.37 0.529 -0.917 -6.26 2.09E-06 0.0316 
3 218859_s_at 51575 ESF1 ESF1, nucleolar pre-rRNA processing protein, 
homolog (S. cerevisiae) 
20p12.1 7.72 0.393 -1.349 -6.16 2.65E-06 0.0316 
4 200635_s_at 5792 PTPRF protein tyrosine phosphatase, receptor type, F 1p34 7.35 0.488 -1.034 -6.12 2.96E-06 0.0316 
5 213940_s_at 23048 FNBP1 formin binding protein 1 9q34 7.03 0.425 -1.233 -5.87 5.33E-06 0.0316 
6 213718_at 5936 RBM4 RNA binding motif protein 4 11q13 5.86 0.537 -0.897 -5.85 5.57E-06 0.0316 
7 224933_s_at 221037 JMJD1C jumonji domain containing 1C 10q21.3 7.19 0.504 -0.990 -5.83 5.96E-06 0.0316 
8 208835_s_at 51747 LUC7L3 LUC7-like 3 (S. cerevisiae) 17q21.33 10.14 0.399 -1.327 -5.78 6.59E-06 0.0316 
9 212027_at 58517 RBM25 RNA binding motif protein 25 14q24.3 7.73 0.264 -1.919 -5.74 7.27E-06 0.0316 
10 241425_at 9818 NUPL1 nucleoporin like 1 13q12.13 5.70 0.558 -0.842 -5.73 7.60E-06 0.0316 
11 213311_s_at 22980 TCF25 transcription factor 25 (basic helix-loop-helix) 16q24.3 8.47 0.374 -1.420 -5.71 7.89E-06 0.0316 
12 212007_at 23190 UBXN4 UBX domain protein 4 2q21.3 8.97 0.421 -1.247 -5.66 8.88E-06 0.0316 
13 214464_at 8476 CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) 1q42.11 8.32 0.303 -1.722 -5.64 9.27E-06 0.0316 
14 227703_s_at 94121 SYTL4 synaptotagmin-like 4 Xq21.33 6.31 2.538 1.344 5.64 9.32E-06 0.0316 
15 224736_at 55749 CCAR1 cell division cycle and apoptosis regulator 1 10q21.3 8.02 0.446 -1.165 -5.64 9.47E-06 0.0316 
16 228711_at 7587 ZNF37A zinc finger protein 37A 10p11.2 7.10 0.584 -0.775 -5.61 1.01E-05 0.0316 
17 201430_s_at 1809 DPYSL3 dihydropyrimidinase-like 3 5q32 5.01 1.937 0.954 5.61 1.01E-05 0.0316 
18 226054_at 23476 BRD4 bromodomain containing 4 19p13.1 7.45 0.538 -0.894 -5.59 1.05E-05 0.0316 
19 201026_at 9669 EIF5B eukaryotic translation initiation factor 5B 2q11.2 7.24 0.465 -1.104 -5.58 1.10E-05 0.0316 
20 230781_at 100505875 LOC100505875 uncharacterized LOC100505875 NA 4.56 2.494 1.318 5.52 1.26E-05 0.0322 
21 222457_s_at 51474 LIMA1 LIM domain and actin binding 1 12q13 5.52 0.432 -1.212 -5.51 1.28E-05 0.0322 
22 219779_at 79776 ZFHX4 zinc finger homeobox 4 8q21.11 6.64 0.627 -0.674 -5.50 1.33E-05 0.0322 
23 212520_s_at 6597 SMARCA4 SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily a, 
member 4 
19p13.2 7.19 0.427 -1.229 -5.49 1.35E-05 0.0322 
24 203215_s_at 4646 MYO6 myosin VI 6q13 7.26 0.253 -1.984 -5.47 1.41E-05 0.0322 
25 203975_s_at 10036 CHAF1A chromatin assembly factor 1, subunit A (p150) 19p13.3 4.89 0.674 -0.569 -5.45 1.51E-05 0.0330 
26 232595_at NA NA NA NA 3.49 1.360 0.444 5.41 1.66E-05 0.0349 
27 222628_s_at 51455 REV1 REV1 homolog (S. cerevisiae) 2q11.1-q11.2 7.19 0.530 -0.916 -5.37 1.81E-05 0.0366 
28 200842_s_at 2058 EPRS glutamyl-prolyl-tRNA synthetase 1q41 7.79 0.367 -1.444 -5.36 1.88E-05 0.0366 
29 222792_s_at 29080 CCDC59 coiled-coil domain containing 59 12q21.31 6.50 0.566 -0.822 -5.34 1.98E-05 0.0366 
30 214375_at 8496 PPFIBP1 PTPRF interacting protein, binding protein 1 (liprin 
beta 1) 
12p12.1 6.27 0.440 -1.185 -5.33 2.03E-05 0.0366 
31 220727_at 54207 KCNK10 potassium channel, subfamily K, member 10 14q31.3 6.30 0.577 -0.794 -5.30 2.16E-05 0.0366 
32 206726_at 27306 HPGDS hematopoietic prostaglandin D synthase 4q22.3 3.32 1.353 0.436 5.29 2.23E-05 0.0366 
33 242233_at NA NA NA NA 5.52 0.603 -0.730 -5.28 2.25E-05 0.0366 







35 214911_s_at 6046 BRD2 bromodomain containing 2 6p21.3 8.26 0.467 -1.098 -5.25 2.47E-05 0.0386 
36 216563_at 23253 ANKRD12 ankyrin repeat domain 12 18p11.22 7.50 0.389 -1.363 -5.22 2.64E-05 0.0399 
37 211993_at 65125 WNK1 WNK lysine deficient protein kinase 1 12p13.3 6.85 0.344 -1.540 -5.20 2.76E-05 0.0399 
38 219387_at 55704 CCDC88A coiled-coil domain containing 88A 2p16.1 8.08 0.286 -1.807 -5.16 3.05E-05 0.0399 
39 226176_s_at 84132 USP42 ubiquitin specific peptidase 42 7p22.1 6.36 0.510 -0.971 -5.16 3.09E-05 0.0399 
40 223185_s_at 79365 BHLHE41 basic helix-loop-helix family, member e41 12p12.1 4.14 0.464 -1.108 -5.15 3.10E-05 0.0399 
41 209945_s_at 2932 GSK3B glycogen synthase kinase 3 beta 3q13.3 5.25 0.703 -0.509 -5.14 3.19E-05 0.0399 
42 229353_s_at 64710 NUCKS1 nuclear casein kinase and cyclin-dependent kinase 
substrate 1 
1q32.1 10.51 0.526 -0.926 -5.14 3.20E-05 0.0399 
43 225041_at 54737 MPHOSPH8 M-phase phosphoprotein 8 13q12.11 8.89 0.376 -1.410 -5.14 3.24E-05 0.0399 
44 225565_at 1385 CREB1 cAMP responsive element binding protein 1 2q34 5.33 0.552 -0.857 -5.13 3.27E-05 0.0399 
45 222122_s_at 57187 THOC2 THO complex 2 Xq25-q26.3 7.11 0.462 -1.114 -5.13 3.28E-05 0.0399 
46 213298_at 4782 NFIC nuclear factor I/C (CCAAT-binding transcription 
factor) 
19p13.3 5.44 0.447 -1.161 -5.10 3.55E-05 0.0422 
47 209230_s_at 26471 NUPR1 nuclear protein, transcriptional regulator, 1 16p11.2 7.06 2.413 1.271 5.08 3.74E-05 0.0432 
48 222540_s_at 51773 RSF1 remodeling and spacing factor 1 11q14.1 8.25 0.398 -1.328 -5.07 3.79E-05 0.0432 
49 222620_s_at 64215 DNAJC1 DnaJ (Hsp40) homolog, subfamily C, member 1 10p12.31 7.29 0.385 -1.378 -5.04 4.08E-05 0.0442 
50 1569594_a_at 9147 NEMF nuclear export mediator factor 14q22 7.97 0.429 -1.221 -5.04 4.08E-05 0.0442 
51 229586_at 80205 CHD9 chromodomain helicase DNA binding protein 9 16q12.2 7.65 0.476 -1.072 -5.04 4.13E-05 0.0442 
52 208963_x_at 3992 FADS1 fatty acid desaturase 1 11q12.2-
q13.1 
7.71 0.556 -0.847 -5.00 4.52E-05 0.0467 
53 226975_at 55599 RNPC3 RNA-binding region (RNP1, RRM) containing 3 1p21 6.65 0.393 -1.346 -5.00 4.53E-05 0.0467 
54 229163_at 55450 CAMK2N1 calcium/calmodulin-dependent protein kinase II 
inhibitor 1 
1p36.12 7.38 0.567 -0.820 -4.99 4.69E-05 0.0472 
55 1555495_a_at 10283 CWC27 CWC27 spliceosome-associated protein homolog 
(S. cerevisiae) 
5q12.3 8.27 0.566 -0.820 -4.97 4.85E-05 0.0472 
56 200702_s_at 57062 DDX24 DEAD (Asp-Glu-Ala-Asp) box polypeptide 24 14q32 7.59 0.358 -1.480 -4.97 4.88E-05 0.0472 
57 225946_at 11228 RASSF8 Ras association (RalGDS/AF-6) domain family (N-
terminal) member 8 
12p12.3 6.58 1.665 0.736 4.96 5.04E-05 0.0472 
58 209376_x_at 9169 SCAF11 SR-related CTD-associated factor 11 12q12 7.02 0.468 -1.095 -4.96 5.09E-05 0.0472 
59 208994_s_at 9360 PPIG peptidylprolyl isomerase G (cyclophilin G) 2q31.1 7.81 0.406 -1.299 -4.95 5.10E-05 0.0472 
60 213850_s_at 9169 SCAF11 SR-related CTD-associated factor 11 12q12 7.86 0.460 -1.122 -4.94 5.27E-05 0.0480 
61 201183_s_at 1108 CHD4 chromodomain helicase DNA binding protein 4 12p13 7.21 0.461 -1.118 -4.93 5.35E-05 0.0480 
62 232323_s_at 55761 TTC17 tetratricopeptide repeat domain 17 11p11.2 6.38 0.469 -1.092 -4.92 5.60E-05 0.0494 
63 209088_s_at 29855 UBN1 ubinuclein 1 16p13.3 6.99 0.418 -1.257 -4.91 5.75E-05 0.0497 
64 215049_x_at 9332 CD163 CD163 molecule 12p13.3 5.22 3.284 1.715 4.90 5.85E-05 0.0497 
65 222616_s_at 10600 USP16 ubiquitin specific peptidase 16 21q22.11 6.39 0.329 -1.606 -4.89 5.92E-05 0.0497 
66 213729_at 55660 PRPF40A PRP40 pre-mRNA processing factor 40 homolog A 
(S. cerevisiae) 
2q23.3 6.87 0.460 -1.120 -4.89 5.99E-05 0.0497 
67 231061_at NA NA NA NA 5.42 0.540 -0.888 -4.88 6.11E-05 0.0499 
68 217728_at 6277 S100A6 S100 calcium binding protein A6 1q21 8.34 1.537 0.620 4.87 6.26E-05 0.0500 
69 203729_at 2014 EMP3 epithelial membrane protein 3 19q13.3 5.56 1.977 0.983 4.86 6.47E-05 0.0500 
70 227298_at 401264 FLJ37798 uncharacterized LOC401264 6p12.3 6.06 0.750 -0.414 -4.86 6.48E-05 0.0500 







72 208685_x_at 6046 BRD2 bromodomain containing 2 6p21.3 8.27 0.487 -1.038 -4.84 6.73E-05 0.0511 
73 217832_at 10492 SYNCRIP synaptotagmin binding, cytoplasmic RNA interacting 
protein 
6q14-q15 7.35 1.764 0.819 4.82 7.16E-05 0.0536 
74 208772_at NA NA NA NA 8.03 0.579 -0.788 -4.80 7.56E-05 0.0557 
75 219437_s_at 29123 ANKRD11 ankyrin repeat domain 11 16q24.3 6.84 0.376 -1.411 -4.79 7.75E-05 0.0557 
76 238595_at NA NA NA NA 5.86 0.487 -1.037 -4.79 7.77E-05 0.0557 
77 238584_at 79781 IQCA1 IQ motif containing with AAA domain 1 2q37.3 4.26 0.467 -1.099 -4.78 7.85E-05 0.0557 
78 35436_at 2801 GOLGA2 golgin A2 9q34.11 6.16 0.495 -1.015 -4.76 8.20E-05 0.0569 
79 1558965_at 51317 PHF21A PHD finger protein 21A 11p11.2 3.12 1.419 0.505 4.76 8.24E-05 0.0569 
80 241458_at NA NA NA NA 4.63 1.432 0.518 4.76 8.38E-05 0.0569 
81 220946_s_at 29072 SETD2 SET domain containing 2 3p21.31 3.30 0.550 -0.862 -4.75 8.53E-05 0.0569 
82 214843_s_at 23032 USP33 ubiquitin specific peptidase 33 1p31.1 6.00 0.600 -0.738 -4.75 8.59E-05 0.0569 
83 236869_at NA NA NA NA 4.33 0.553 -0.854 -4.74 8.74E-05 0.0569 
84 207542_s_at 358 AQP1 aquaporin 1 (Colton blood group) 7p14 6.41 2.433 1.283 4.74 8.75E-05 0.0569 
85 201914_s_at 11231 SEC63 SEC63 homolog (S. cerevisiae) 6q21 6.13 0.384 -1.380 -4.73 8.93E-05 0.0575 
86 221210_s_at 80896 NPL N-acetylneuraminate pyruvate lyase 
(dihydrodipicolinate synthase) 
1q25 3.93 2.039 1.028 4.72 9.21E-05 0.0581 
87 203181_x_at 6733 SRPK2 SRSF protein kinase 2 7q22-q31.1 9.55 0.496 -1.011 -4.71 9.43E-05 0.0581 
88 233080_s_at 55660 PRPF40A PRP40 pre-mRNA processing factor 40 homolog A 
(S. cerevisiae) 
2q23.3 6.77 0.490 -1.029 -4.70 9.70E-05 0.0581 
89 209466_x_at 5764 PTN pleiotrophin 7q33 8.46 0.411 -1.282 -4.69 9.81E-05 0.0581 
90 208663_s_at 7267 TTC3 tetratricopeptide repeat domain 3 21q22.2 8.39 0.298 -1.745 -4.69 9.98E-05 0.0581 
91 211737_x_at 5764 PTN pleiotrophin 7q33 9.37 0.445 -1.168 -4.68 1.02E-04 0.0581 
92 214314_s_at 9669 EIF5B eukaryotic translation initiation factor 5B 2q11.2 6.17 0.551 -0.861 -4.68 1.02E-04 0.0581 
93 206929_s_at 4782 NFIC nuclear factor I/C (CCAAT-binding transcription 
factor) 
19p13.3 7.19 0.499 -1.002 -4.67 1.03E-04 0.0581 
94 209127_s_at 9733 SART3 squamous cell carcinoma antigen recognized by T 
cells 3 
12q24.1 6.13 0.417 -1.260 -4.67 1.03E-04 0.0581 
95 212382_at 6925 TCF4 transcription factor 4 18q21.1 7.25 0.387 -1.371 -4.67 1.04E-04 0.0581 
96 225590_at 57630 SH3RF1 SH3 domain containing ring finger 1 4q32.3 5.92 0.595 -0.749 -4.67 1.04E-04 0.0581 
97 226782_at 253512 SLC25A30 solute carrier family 25, member 30 13q14.13 5.11 1.364 0.448 4.67 1.05E-04 0.0581 
98 204964_s_at 8082 SSPN sarcospan (Kras oncogene-associated gene) 12p11.2 6.29 0.497 -1.008 -4.66 1.06E-04 0.0581 
99 208942_s_at 7095 SEC62 SEC62 homolog (S. cerevisiae) 3q26.2 9.81 0.596 -0.746 -4.65 1.08E-04 0.0581 
100 232677_at NA NA NA NA 4.55 0.603 -0.731 -4.65 1.09E-04 0.0581 
101 208993_s_at 9360 PPIG peptidylprolyl isomerase G (cyclophilin G) 2q31.1 8.28 0.463 -1.111 -4.64 1.10E-04 0.0581 
102 208610_s_at 23524 SRRM2 serine/arginine repetitive matrix 2 16p13.3 7.99 0.326 -1.619 -4.64 1.11E-04 0.0581 
103 216520_s_at 7178 TPT1 tumor protein, translationally-controlled 1 13q14 11.68 1.383 0.468 4.64 1.12E-04 0.0581 
104 201224_s_at 10250 SRRM1 serine/arginine repetitive matrix 1 1p36.11 8.23 0.543 -0.882 -4.64 1.12E-04 0.0581 
105 225730_s_at 25917 THUMPD3 THUMP domain containing 3 3p25.3 5.40 0.463 -1.111 -4.64 1.12E-04 0.0581 
106 242916_at 11064 CNTRL centriolin 9q33.2 4.22 0.575 -0.799 -4.64 1.13E-04 0.0581 
107 212570_at 23052 ENDOD1 endonuclease domain containing 1 11q21 5.80 0.496 -1.012 -4.63 1.14E-04 0.0581 
108 215338_s_at 4820 NKTR natural killer-tumor recognition sequence 3p23-p21 7.00 0.510 -0.970 -4.61 1.20E-04 0.0609 
109 211996_s_at NA NA NA NA 10.44 0.621 -0.686 -4.60 1.24E-04 0.0615 







111 1569302_at 85459 KIAA1731 KIAA1731 11q21 5.21 0.508 -0.976 -4.59 1.27E-04 0.0625 
112 208676_s_at 5036 PA2G4 proliferation-associated 2G4, 38kDa 12q13.2 7.93 0.718 -0.478 -4.59 1.28E-04 0.0625 
113 218659_at 55252 ASXL2 additional sex combs like 2 (Drosophila) 2p24.1 6.85 1.483 0.568 4.57 1.32E-04 0.0634 
114 211948_x_at 23215 PRRC2C proline-rich coiled-coil 2C 1q23.3 8.90 0.557 -0.843 -4.57 1.33E-04 0.0634 
115 225377_at 55684 C9orf86 chromosome 9 open reading frame 86 9q34.3 7.78 0.408 -1.293 -4.57 1.33E-04 0.0634 
116 1555913_at 54856 GON4L gon-4-like (C. elegans) 1q22 4.58 0.643 -0.636 -4.57 1.34E-04 0.0634 
117 221745_at 10238 DCAF7 DDB1 and CUL4 associated factor 7 17q23.3 5.94 0.641 -0.642 -4.56 1.36E-04 0.0635 
118 1556211_a_at NA NA NA NA 4.88 0.300 -1.737 -4.55 1.41E-04 0.0654 
119 214305_s_at 23451 SF3B1 splicing factor 3b, subunit 1, 155kDa 2q33.1 6.57 0.510 -0.971 -4.54 1.44E-04 0.0663 
120 209579_s_at 8930 MBD4 methyl-CpG binding domain protein 4 3q21.3 8.48 0.529 -0.918 -4.52 1.50E-04 0.0683 
121 228801_at 94101 ORMDL1 ORM1-like 1 (S. cerevisiae) 2q32 4.16 0.678 -0.561 -4.51 1.53E-04 0.0692 
122 239894_at 1E+08 LOC100128511 uncharacterized LOC100128511 10p12.31 3.94 0.614 -0.703 -4.51 1.55E-04 0.0694 
123 202845_s_at 10928 RALBP1 ralA binding protein 1 18p11.3 8.73 1.381 0.466 4.50 1.58E-04 0.0696 
124 201085_s_at 6651 SON SON DNA binding protein 21q22.1-
q22.2 
7.75 0.356 -1.492 -4.50 1.58E-04 0.0696 
125 206826_at 5375 PMP2 peripheral myelin protein 2 8q21.3-q22.1 10.04 0.459 -1.124 -4.47 1.70E-04 0.0739 
126 201024_x_at 9669 EIF5B eukaryotic translation initiation factor 5B 2q11.2 9.48 0.524 -0.934 -4.47 1.70E-04 0.0739 
127 203186_s_at 6275 S100A4 S100 calcium binding protein A4 1q21 5.35 1.685 0.753 4.46 1.74E-04 0.0742 
128 242835_s_at 728730 LOC728730 uncharacterized LOC728730 2p22.1 5.29 0.380 -1.395 -4.46 1.75E-04 0.0742 
129 239154_at NA NA NA NA 5.39 0.578 -0.790 -4.46 1.76E-04 0.0742 
130 232617_at 1520 CTSS cathepsin S 1q21 5.85 1.904 0.929 4.46 1.77E-04 0.0742 
131 203761_at 6503 SLA Src-like-adaptor 8q22.3-qter 6.22 1.909 0.933 4.45 1.78E-04 0.0742 
132 238893_at 338758 LOC338758 uncharacterized LOC338758 12q21.33 7.45 0.506 -0.983 -4.45 1.79E-04 0.0742 
133 204999_s_at 22809 ATF5 activating transcription factor 5 19q13.3 3.64 0.670 -0.577 -4.44 1.84E-04 0.0758 
134 241955_at 25831 HECTD1 HECT domain containing E3 ubiquitin protein ligase 
1 
14q12 5.29 0.413 -1.275 -4.43 1.89E-04 0.0770 
135 213509_x_at 8824 CES2 carboxylesterase 2 16q22.1 7.20 0.716 -0.482 -4.42 1.92E-04 0.0778 
136 218454_at 79887 PLBD1 phospholipase B domain containing 1 12p13.1 4.02 1.365 0.449 4.42 1.95E-04 0.0786 
137 209258_s_at 9126 SMC3 structural maintenance of chromosomes 3 10q25 5.46 0.386 -1.372 -4.41 2.00E-04 0.0794 
138 201730_s_at 7175 TPR translocated promoter region (to activated MET 
oncogene) 
1q25 6.69 0.426 -1.233 -4.41 2.01E-04 0.0794 
139 231729_s_at 828 CAPS calcyphosine 19p13.3 4.69 2.011 1.008 4.40 2.02E-04 0.0794 
140 1552326_a_at 220136 CCDC11 coiled-coil domain containing 11 18q21.1 4.19 1.442 0.528 4.39 2.11E-04 0.0822 
141 208095_s_at NA NA NA NA 6.95 0.353 -1.502 -4.38 2.12E-04 0.0822 
142 208879_x_at 24148 PRPF6 PRP6 pre-mRNA processing factor 6 homolog (S. 
cerevisiae) 
20q13.33 6.57 0.430 -1.218 -4.38 2.16E-04 0.0832 
143 212994_at 57187 THOC2 THO complex 2 Xq25-q26.3 6.17 0.506 -0.984 -4.37 2.22E-04 0.0850 
144 244154_at 80821 DDHD1 DDHD domain containing 1 14q21 4.89 0.722 -0.471 -4.36 2.25E-04 0.0853 
145 222020_s_at 50863 NTM neurotrimin 11q25 6.37 0.508 -0.977 -4.35 2.33E-04 0.0863 
146 204787_at 11326 VSIG4 V-set and immunoglobulin domain containing 4 Xq12-q13.3 5.92 2.774 1.472 4.34 2.35E-04 0.0863 
147 209715_at 23468 CBX5 chromobox homolog 5 12q13.13 7.32 0.564 -0.825 -4.34 2.36E-04 0.0863 
148 242974_at 961 CD47 CD47 molecule 3q13.1-q13.2 5.50 1.343 0.426 4.34 2.38E-04 0.0863 
149 214129_at 9659 PDE4DIP phosphodiesterase 4D interacting protein 1q12 6.28 1.945 0.960 4.34 2.38E-04 0.0863 







151 219507_at 51319 RSRC1 arginine/serine-rich coiled-coil 1 3q25.32 5.74 0.360 -1.473 -4.33 2.41E-04 0.0863 
152 223138_s_at 170506 DHX36 DEAH (Asp-Glu-Ala-His) box polypeptide 36 3p13-q23 5.53 0.471 -1.085 -4.33 2.41E-04 0.0863 
153 222737_s_at 29117 BRD7 bromodomain containing 7 16q12 7.03 0.513 -0.962 -4.33 2.42E-04 0.0863 
154 1554470_s_at 29068 ZBTB44 zinc finger and BTB domain containing 44 11q24.3 4.40 1.524 0.608 4.33 2.43E-04 0.0864 
155 226416_at 90459 ERI1 exoribonuclease 1 8p23.1 5.18 1.401 0.486 4.33 2.46E-04 0.0868 
156 206167_s_at 395 ARHGAP6 Rho GTPase activating protein 6 Xp22.3 5.74 1.485 0.570 4.32 2.48E-04 0.0870 
157 204061_at 5613 PRKX protein kinase, X-linked Xp22.3 5.49 2.377 1.249 4.32 2.51E-04 0.0870 
158 202844_s_at 10928 RALBP1 ralA binding protein 1 18p11.3 7.35 0.470 -1.090 -4.32 2.51E-04 0.0870 
159 203645_s_at 9332 CD163 CD163 molecule 12p13.3 4.50 2.827 1.499 4.30 2.59E-04 0.0892 
160 224631_at NA NA NA NA 6.65 0.447 -1.162 -4.30 2.64E-04 0.0901 
161 217869_at 51144 HSD17B12 hydroxysteroid (17-beta) dehydrogenase 12 11p11.2 9.37 0.726 -0.461 -4.29 2.70E-04 0.0918 
162 235409_at 23269 MGA MAX gene associated 15q14 5.91 0.491 -1.026 -4.28 2.78E-04 0.0937 
163 224856_at 2289 FKBP5 FK506 binding protein 5 6p21.31 6.81 1.951 0.964 4.27 2.81E-04 0.0940 
164 212120_at 23433 RHOQ ras homolog family member Q 2p21 8.27 1.367 0.451 4.27 2.86E-04 0.0940 
165 241769_at NA NA NA NA 5.38 0.541 -0.888 -4.27 2.86E-04 0.0940 
166 226189_at 3696 ITGB8 integrin, beta 8 7p21.1 9.05 1.469 0.555 4.26 2.87E-04 0.0940 
167 223797_at 114224 PRO2852 uncharacterized protein PRO2852 NA 6.19 1.467 0.553 4.26 2.87E-04 0.0940 
168 208710_s_at 8943 AP3D1 adaptor-related protein complex 3, delta 1 subunit 19p13.3 8.12 0.627 -0.674 -4.26 2.91E-04 0.0946 
169 214055_x_at 23215 PRRC2C proline-rich coiled-coil 2C 1q23.3 8.85 0.553 -0.855 -4.25 2.99E-04 0.0961 
170 242728_at NA NA NA NA 4.54 1.474 0.560 4.25 2.99E-04 0.0961 
171 224605_at 401152 C4orf3 chromosome 4 open reading frame 3 4q26 8.04 0.611 -0.711 -4.25 3.00E-04 0.0961 
172 201606_s_at 11137 PWP1 PWP1 homolog (S. cerevisiae) 12q23.3 6.49 0.486 -1.040 -4.24 3.02E-04 0.0961 
173 221043_at NA NA NA NA 3.57 0.621 -0.687 -4.23 3.12E-04 0.0987 
174 213328_at 4750 NEK1 NIMA (never in mitosis gene a)-related kinase 1 4q33 6.24 0.463 -1.111 -4.23 3.16E-04 0.0987 
175 227221_at 64393 ZMAT3 zinc finger, matrin-type 3 3q26.32 6.74 1.315 0.395 4.22 3.17E-04 0.0987 







Supplemental Table 4.2. Among genes with lower expression in Alzheimer’s, several biological processes were 
enriched. 
Rank Name #Genes P-Value FDR SigGenes 
1 synaptic transmission 353 4.92E-12 2.92E-09 223, 5368, 627, 6529, 7425, 9379 
2 transmission of nerve impulse 411 6.52E-12 3.38E-09 223, 5368, 627, 6529, 7425, 9379 
3 cell-cell signaling 700 5.95E-07 6.03E-05 223, 4826, 5368, 627, 6529, 7425, 9379, 9547, 9636 
4 oxidative phosphorylation 94 3.10E-06 1.81E-04 155066, 4704 
5 regulation of synaptic plasticity 53 8.57E-06 4.23E-04 627, 7425 
6 regulation of transmission of nerve impulse 132 2.83E-05 1.10E-03 627, 6529, 7425 
7 cellular respiration 94 2.90E-05 1.10E-03 4704 
8 regulation of neurological system process 142 4.41E-05 1.57E-03 627, 6529, 7425 
9 neurotransmitter transport 96 5.54E-05 1.93E-03 6529, 9379 
10 regulation of neuronal synaptic plasticity 32 5.96E-05 2.06E-03 7425 
11 regulation of synaptic transmission 121 7.69E-05 0.003 627, 6529, 7425 
12 respiratory electron transport chain 59 8.08E-05 0.003 4704 
13 regulation of neurotransmitter levels 82 1.13E-04 0.003 223, 9379 
14 nucleotide-excision repair, DNA damage removal 21 1.16E-04 0.003 2073 
15 ATP synthesis coupled electron transport 51 1.89E-04 0.005 4704 
16 mitochondrial ATP synthesis coupled electron transport 51 1.89E-04 0.005 4704 
17 generation of a signal involved in cell-cell signaling 178 1.92E-04 0.005 4826, 627, 7425, 9379 
18 signal release 178 1.92E-04 0.005 4826, 627, 7425, 9379 
19 oxygen transport 5 2.37E-04 0.006 3049 
20 mitochondrial electron transport, NADH to ubiquinone 37 4.13E-04 0.01 4704 
21 tRNA metabolic process 113 5.68E-04 0.013 26995, 54938, 80222 
22 cerebellar cortex formation 9 8.19E-04 0.017   
23 synaptic vesicle transport 31 1.12E-03 0.023   
24 cellular amino acid metabolic process 227 1.17E-03 0.023 10157, 2954, 54938, 80222 
25 ncRNA metabolic process 230 1.32E-03 0.026 26995, 5393, 54938, 6839, 80222 
26 cerebellar cortex morphogenesis 12 1.50E-03 0.028   
27 synaptic vesicle exocytosis 14 1.52E-03 0.029   
28 nucleobase, nucleoside and nucleotide metabolic process 551 1.55E-03 0.029 155066, 254272, 3704, 482, 56342, 79077, 8382 
29 aspartate family amino acid catabolic process 6 1.70E-03 0.03 10157 
30 negative regulation of synaptic transmission, GABAergic 7 1.91E-03 0.033 6529 
31 generation of precursor metabolites and energy 324 2.01E-03 0.033 155066, 4704, 7425 
32 cellular amino acid catabolic process 68 2.32E-03 0.037 10157, 2954 
33 neurotransmitter secretion 47 2.36E-03 0.038 9379 
34 DNA dealkylation 6 2.40E-03 0.038   
35 DNA dealkylation involved in DNA repair 6 2.40E-03 0.038   
36 regulation of megakaryocyte differentiation 14 0.003 0.039 8364, 8366 
37 fear response 18 0.003 0.039 627 
38 L-amino acid import 8 0.003 0.041 6529 
39 lysosome organization 24 0.003 0.043 53, 84067 
40 nucleoside phosphate metabolic process 529 0.004 0.049 155066, 254272, 3704, 482, 56342, 79077, 8382 
41 nucleotide metabolic process 529 0.004 0.049 155066, 254272, 3704, 482, 56342, 79077, 8382 
42 ATP hydrolysis coupled proton transport 9 0.004 0.051 155066 
43 energy coupled proton transport, against electrochemical gradient 9 0.004 0.051 155066 
44 inner cell mass cell proliferation 5 0.004 0.053 27339 
45 glutamate secretion 19 0.004 0.053 627 
46 subpallium development 11 0.004 0.053 220, 585 
47 ATP metabolic process 96 0.004 0.056 155066, 482 







49 striatum development 9 0.004 0.058 220, 585 
50 cellular amine metabolic process 306 0.005 0.061 10157, 223, 2954, 54938, 80222 
51 electron transport chain 109 0.005 0.061 4704 
52 ATP synthesis coupled proton transport 38 0.005 0.061 155066 
53 energy coupled proton transport, down electrochemical gradient 38 0.005 0.061 155066 
54 ATP biosynthetic process 86 0.005 0.061 155066, 482 
55 establishment of melanosome localization 10 0.005 0.064 585 
56 RNA processing 557 0.005 0.064 23070, 26995, 27339, 5393, 56342, 6100, 6839, 85437, 9360 
57 amine metabolic process 403 0.005 0.065 10157, 223, 2954, 54938, 80222 
58 aerobic respiration 34 0.005 0.065   
59 amine catabolic process 78 0.006 0.071 10157, 2954 
60 second-messenger-mediated signaling 261 0.006 0.072 56342, 8364, 8366 
61 RNA methylation 11 0.006 0.072 23070 
62 oxidation reduction 614 0.006 0.073 10157, 220, 223, 242, 4704, 728294, 7923 
63 nucleobase, nucleoside and nucleotide biosynthetic process 290 0.007 0.077 155066, 482, 56342, 8382 
64 
nucleobase, nucleoside, nucleotide and nucleic acid biosynthetic 
process 290 0.007 0.077 155066, 482, 56342, 8382 
65 cellular amino acid and derivative metabolic process 355 0.007 0.079 10157, 223, 2954, 54938, 80222 
66 regulation of adenylate cyclase activity 96 0.007 0.079 56342 
67 establishment of pigment granule localization 11 0.008 0.083 585 
68 amino acid activation 45 0.008 0.083 54938, 80222 
69 tRNA aminoacylation 45 0.008 0.083 54938, 80222 
70 tRNA aminoacylation for protein translation 45 0.008 0.083 54938, 80222 
71 dicarboxylic acid metabolic process 42 0.008 0.084   
72 flagellum assembly 7 0.008 0.084 585 
73 flagellum organization 7 0.008 0.084 585 
74 small molecule catabolic process 419 0.008 0.084 10157, 254272, 2954, 79077 
75 purine nucleotide biosynthetic process 246 0.008 0.084 155066, 482, 56342, 8382 
76 cognition 115 0.008 0.084 585, 627, 6529 
77 nucleoside triphosphate metabolic process 244 0.008 0.085 155066, 254272, 482, 79077, 8382 
78 GPI anchor biosynthetic process 33 0.009 0.087 79087, 80235 
79 purine nucleotide metabolic process 422 0.009 0.088 155066, 254272, 482, 56342, 8382 
80 RNA modification 49 0.009 0.088 23070, 26995 
81 melanosome localization 14 0.009 0.088 585 
82 regulation of cAMP biosynthetic process 111 0.009 0.089 56342 
83 vesicle docking involved in exocytosis 25 0.009 0.091   
84 regulation of cytokinesis 9 0.009 0.091 585 
85 cerebellar Purkinje cell differentiation 6 0.009 0.091   
86 cerebellar Purkinje cell layer formation 6 0.009 0.091   
87 cerebellar Purkinje cell layer morphogenesis 6 0.009 0.091   
88 GPI anchor metabolic process 34 0.01 0.093 79087, 80235 
89 regulation of lyase activity 99 0.01 0.095 56342 
90 cAMP biosynthetic process 113 0.01 0.096 56342 
91 regulation of cyclase activity 98 0.01 0.099 56342 







Supplemental Table 4.3. Among genes with higher expression in Alzheimer’s, several biological processes were 
enriched. 
Rank Name #Genes P-Value FDR SigGenes 
1 translational elongation 101 4.07E-20 1.69E-16 11224, 1937, 2197, 25873, 6135, 6154, 6173, 6176, 6188, 6193, 6207, 6222, 6232 
2 defense response 661 1.16E-16 2.42E-13 
10219, 10410, 1050, 10581, 11326, 12, 23643, 241, 2532, 2919, 313, 3440, 3487, 3588, 3600, 3823, 4057, 4615, 4688, 51191, 
58191, 6039, 604, 60675, 6283, 7097, 7098, 710, 7100, 712, 713, 7132, 714, 718, 719, 7305, 8519, 929, 9332, 9450 
3 immune response 660 3.86E-15 5.34E-12 
10346, 10410, 10581, 11326, 23643, 2669, 2919, 3108, 3109, 3122, 3588, 3600, 4057, 4615, 4688, 4860, 51191, 54209, 563, 
58191, 604, 6398, 7097, 7098, 710, 7100, 712, 713, 714, 718, 719, 8519, 929, 9450 
4 response to wounding 598 1.07E-14 1.11E-11 
10219, 1050, 11326, 12, 1462, 2162, 23643, 241, 2697, 2919, 313, 3399, 3440, 3487, 3587, 3588, 3600, 4615, 4814, 604, 
60675, 6283, 7097, 7098, 710, 7100, 712, 713, 7132, 714, 718, 719, 7423, 929, 9332, 9450 
5 innate immune response 201 8.28E-13 6.68E-10 10410, 10581, 11326, 23643, 4615, 4688, 51191, 58191, 7097, 7098, 710, 7100, 712, 713, 714, 718, 8519, 929, 9450 
6 inflammatory response 365 9.65E-13 6.68E-10 
10219, 1050, 11326, 12, 23643, 241, 2919, 313, 3440, 3487, 3588, 3600, 4615, 604, 60675, 6283, 7097, 7098, 710, 7100, 712, 
713, 7132, 714, 718, 719, 929, 9332, 9450 
7 response to biotic stimulus 442 8.34E-12 3.85E-09 
10049, 10346, 10410, 10581, 11080, 1373, 1937, 23643, 3315, 3440, 3587, 3600, 3665, 3669, 4057, 51191, 6283, 7079, 7097, 
7098, 7100, 7132, 8519, 871, 929 
8 response to other organism 354 5.69E-11 2.36E-08 
10346, 10410, 10581, 1373, 1937, 23643, 3315, 3440, 3587, 3600, 3665, 3669, 4057, 51191, 6283, 7079, 7097, 7098, 7100, 
7132, 8519, 929 
9 activation of immune response 110 7.45E-11 2.81E-08 11326, 1997, 7097, 7098, 710, 7100, 712, 713, 714, 718, 719 
10 regulation of immune response 245 8.89E-10 3.08E-07 11326, 1997, 3600, 604, 7097, 7098, 710, 7100, 712, 713, 714, 718, 719 
11 response to bacterium 213 1.42E-09 4.53E-07 1373, 23643, 3587, 4057, 6283, 7079, 7097, 7098, 7100, 7132, 929 
12 I-kappaB kinase/NF-kappaB cascade 171 2.35E-09 6.98E-07 23643, 2697, 3965, 4615, 6275, 6283, 6398, 7097, 7098, 7100, 7105, 7132 
13 regulation of toll-like receptor signaling pathway 9 2.97E-09 8.21E-07 7097, 7098, 7100 
14 positive regulation of toll-like receptor signaling pathway 7 7.11E-09 1.85E-06 7097, 7098, 7100 
15 humoral immune response 80 8.56E-09 2.09E-06 11326, 4057, 54209, 710, 712, 713, 714, 718, 9450 
16 positive regulation of immune response 155 9.07E-09 2.09E-06 11326, 1997, 3600, 7097, 7098, 710, 7100, 712, 713, 714, 718, 719 
17 positive regulation of intracellular protein kinase cascade 222 1.03E-08 2.24E-06 2697, 3059, 3965, 4615, 6275, 6283, 6398, 7098, 7105, 7132, 7423 
18 regulation of response to stimulus 533 1.94E-08 4.02E-06 10488, 11326, 1997, 23411, 285, 2874, 3600, 4615, 604, 6188, 7097, 7098, 710, 7100, 712, 713, 7132, 714, 718, 719, 7423 
19 positive regulation of immune system process 268 2.77E-08 5.36E-06 11326, 1997, 3600, 4860, 604, 7097, 7098, 710, 7100, 712, 713, 714, 718, 719, 7423 
20 defense response to bacterium 96 2.84E-08 5.36E-06 4057, 6283, 7097, 7098, 7100, 7132 
21 
positive regulation of I-kappaB kinase/NF-kappaB 
cascade 115 4.25E-08 7.67E-06 2697, 3965, 4615, 6275, 6283, 6398, 7098, 7105, 7132 
22 
humoral immune response mediated by circulating 
immunoglobulin 37 4.47E-08 7.73E-06 710, 712, 713, 714, 718 
23 positive regulation of response to stimulus 276 5.08E-08 8.43E-06 10488, 11326, 1997, 3600, 7097, 7098, 710, 7100, 712, 713, 7132, 714, 718, 719, 7423 
24 complement activation 37 7.95E-08 1.24E-05 11326, 710, 712, 713, 714, 718 
25 toll-like receptor signaling pathway 22 8.06E-08 1.24E-05 7097, 7098, 7100 
26 regulation of I-kappaB kinase/NF-kappaB cascade 127 8.46E-08 1.25E-05 2697, 3965, 4615, 6275, 6283, 6398, 7098, 7105, 7132 
27 regulation of cytokine production 199 9.39E-08 1.34E-05 11326, 1997, 4615, 604, 7097, 7098, 7100, 718, 719, 929 
28 innate immune response-activating signal transduction 25 1.02E-07 1.41E-05 7097, 7098, 7100 
29 pattern recognition receptor signaling pathway 24 1.11E-07 1.49E-05 7097, 7098, 7100 
30 activation of innate immune response 26 1.24E-07 1.61E-05 7097, 7098, 7100 
31 cytokine production 226 2.25E-07 2.83E-05 11326, 1997, 4615, 4860, 604, 7097, 7098, 7100, 718, 719, 929 
32 positive regulation of JNK cascade 23 2.34E-07 2.86E-05 7098 
33 positive regulation of signal transduction 275 3.05E-07 3.58E-05 2697, 3059, 3965, 4615, 4734, 6275, 6283, 6398, 7098, 7105, 7132, 7423 
34 positive regulation of tumor necrosis factor production 14 3.11E-07 3.58E-05 7097, 7098, 929 
35 positive regulation of signaling process 280 3.59E-07 3.97E-05 2697, 3059, 3965, 4615, 4734, 6275, 6283, 6398, 7098, 7105, 7132, 7423 
36 interleukin-6 production 44 3.63E-07 3.97E-05 4615, 7097, 7098 
37 complement activation, classical pathway 27 4.92E-07 5.24E-05 710, 712, 713, 714, 718 
38 positive regulation of cytokine production 104 5.08E-07 5.28E-05 4615, 7097, 7098, 7100, 718, 719, 929 
39 positive regulation of interleukin-6 production 23 7.62E-07 7.54E-05 4615, 7097, 7098 
40 regulation of interleukin-12 production 23 9.39E-07 9.07E-05 7097, 7098 








42 multi-organism process 772 1.17E-06 1.08E-04 
10346, 10410, 10488, 1050, 10581, 1373, 1937, 1981, 200186, 23411, 23643, 23764, 285, 3315, 3440, 358, 3587, 3600, 3665, 
3669, 4057, 4734, 51191, 5422, 5696, 6283, 6993, 7079, 7097, 7098, 7100, 7132, 8519, 929 
43 interleukin-12 production 24 1.31E-06 1.15E-04 7097, 7098 
44 positive regulation of signaling pathway 376 1.35E-06 1.15E-04 1950, 2697, 3059, 3965, 4615, 4734, 6275, 6283, 6398, 7097, 7098, 7100, 7105, 7132, 7423 
45 positive regulation of cell communication 408 1.64E-06 1.15E-04 1950, 2697, 3059, 3965, 4615, 4734, 6275, 6283, 6398, 7097, 7098, 7100, 7105, 7132, 7423 
46 response to molecule of bacterial origin 133 1.78E-06 1.15E-04 1373, 23643, 3587, 7079, 7097, 7100, 7132, 929 
47 regulation of response to stress 321 1.87E-06 1.15E-04 23411, 2874, 3600, 4615, 604, 6188, 7097, 7098, 710, 7100, 7132, 718, 7423 
48 
modulation by organism of defense response of other 
organism involved in symbiotic interaction 6 1.90E-06 1.15E-04 7097, 7098, 7100 
49 
modulation by organism of immune response of other 
organism involved in symbiotic interaction 6 1.90E-06 1.15E-04 7097, 7098, 7100 
50 
modulation by organism of innate immunity in other 
organism involved in symbiotic interaction 6 1.90E-06 1.15E-04 7097, 7098, 7100 
51 modulation by symbiont of host defense response 6 1.90E-06 1.15E-04 7097, 7098, 7100 
52 modulation by symbiont of host immune response 6 1.90E-06 1.15E-04 7097, 7098, 7100 
53 modulation by symbiont of host innate immunity 6 1.90E-06 1.15E-04 7097, 7098, 7100 
54 
pathogen-associated molecular pattern dependent 
induction by organism of innate immunity of other 
organism involved in symbiotic interaction 6 1.90E-06 1.15E-04 7097, 7098, 7100 
55 
pathogen-associated molecular pattern dependent 
induction by symbiont of host innate immunity 6 1.90E-06 1.15E-04 7097, 7098, 7100 
56 
pathogen-associated molecular pattern dependent 
modulation by organism of innate immunity in other 
organism involved in symbiotic interaction 6 1.90E-06 1.15E-04 7097, 7098, 7100 
57 
pathogen-associated molecular pattern dependent 
modulation by symbiont of host innate immunity 6 1.90E-06 1.15E-04 7097, 7098, 7100 
58 
positive regulation by organism of defense response of 
other organism involved in symbiotic interaction 6 1.90E-06 1.15E-04 7097, 7098, 7100 
59 
positive regulation by organism of immune response of 
other organism involved in symbiotic interaction 6 1.90E-06 1.15E-04 7097, 7098, 7100 
60 
positive regulation by organism of innate immunity in 
other organism involved in symbiotic interaction 6 1.90E-06 1.15E-04 7097, 7098, 7100 
61 positive regulation by symbiont of host defense response 6 1.90E-06 1.15E-04 7097, 7098, 7100 
62 positive regulation by symbiont of host immune response 6 1.90E-06 1.15E-04 7097, 7098, 7100 
63 positive regulation by symbiont of host innate immunity 6 1.90E-06 1.15E-04 7097, 7098, 7100 
64 response to host immune response 6 1.90E-06 1.15E-04 7097, 7098, 7100 
65 
response to immune response of other organism involved 
in symbiotic interaction 6 1.90E-06 1.15E-04 7097, 7098, 7100 
66 immune effector process 210 1.91E-06 1.15E-04 11326, 3600, 604, 7097, 7098, 710, 712, 713, 714, 718 
67 immunoglobulin mediated immune response 70 2.99E-06 1.77E-04 604, 710, 712, 713, 714, 718 
68 B cell mediated immunity 71 3.90E-06 2.25E-04 604, 710, 712, 713, 714, 718 
69 
activation of plasma proteins involved in acute 
inflammatory response 40 4.94E-06 2.81E-04 11326, 710, 712, 713, 714, 718 
70 regulation of interleukin-6 production 42 5.19E-06 2.91E-04 4615, 7097, 7098 
71 positive regulation of interleukin-8 production 10 5.38E-06 2.98E-04 7097, 7098, 7100 
72 regulation of transcription regulator activity 146 5.78E-06 3.16E-04 23411, 3399, 6188, 7097, 7098 
73 regulation of immune system process 424 5.94E-06 3.20E-04 11326, 1997, 3600, 4860, 604, 7097, 7098, 710, 7100, 712, 713, 714, 718, 719, 7423, 8399 
74 macrophage activation involved in immune response 10 6.04E-06 3.22E-04 7097, 7098, 7100 
75 regulation of transcription factor activity 145 6.66E-06 3.46E-04 23411, 3399, 6188, 7097, 7098 
76 
antigen processing and presentation of peptide or 
polysaccharide antigen via MHC class II 13 6.67E-06 3.46E-04 3108, 3109, 3122 
77 
modification by symbiont of host morphology or 
physiology 9 6.88E-06 3.53E-04 7097, 7098, 7100 
78 
modification of morphology or physiology of other 







79 regulation of innate immune response 61 7.69E-06 3.85E-04 7097, 7098, 710, 7100 
80 
regulation of vascular endothelial growth factor receptor 
signaling pathway 16 1.09E-05 5.30E-04 4734, 7423 
81 positive regulation of angiogenesis 43 1.15E-05 5.54E-04 285, 358, 7132, 718, 719, 7423 
82 symbiosis, encompassing mutualism through parasitism 64 1.17E-05 5.57E-04 358, 4734, 6993, 7097, 7098, 7100 
83 positive regulation of type I interferon production 15 1.18E-05 5.58E-04 7097, 7098 
84 microglial cell activation involved in immune response 7 1.25E-05 5.81E-04 7097, 7098, 7100 
85 positive regulation of interleukin-12 production 12 1.26E-05 5.81E-04 7097, 7098 
86 regulation of defense response 156 1.29E-05 5.90E-04 3600, 4615, 604, 7097, 7098, 710, 7100, 7132, 718 
87 cellular response to UV 6 1.31E-05 5.92E-04 358, 4734 
88 
adaptive immune response based on somatic 
recombination of immune receptors built from 
immunoglobulin superfamily domains 114 1.47E-05 6.58E-04 604, 710, 712, 713, 714, 718 
89 positive regulation of multicellular organismal process 279 1.53E-05 6.76E-04 1373, 358, 4615, 60675, 7097, 7098, 7100, 718, 719, 929, 9388 
90 cytokine production involved in immune response 22 1.60E-05 6.82E-04 604, 7097 
91 
response to defenses of other organism involved in 
symbiotic interaction 8 1.62E-05 6.82E-04 7097, 7098, 7100 
92 response to host 8 1.62E-05 6.82E-04 7097, 7098, 7100 
93 response to host defenses 8 1.62E-05 6.82E-04 7097, 7098, 7100 
94 adaptive immune response 116 1.63E-05 6.82E-04 604, 710, 712, 713, 714, 718 
95 antigen processing and presentation 50 1.69E-05 7.04E-04 3108, 3109, 3122, 563 
96 translation 394 2.07E-05 8.51E-04 11224, 1937, 1978, 1981, 2197, 25873, 283, 3315, 6135, 6154, 6173, 6176, 6188, 6193, 6207, 6222, 6232, 92399 
97 
vascular endothelial growth factor receptor signaling 
pathway 22 2.21E-05 8.99E-04 4734, 7423 
98 regulation of intracellular protein kinase cascade 328 2.33E-05 9.38E-04 2697, 2874, 3059, 3965, 4615, 6275, 6283, 6398, 7098, 7105, 7132, 7423 
99 regulation of type I interferon production 19 2.57E-05 1.03E-03 7097, 7098 
100 immune response-activating signal transduction 72 2.62E-05 1.04E-03 1997, 7097, 7098, 7100, 719 
101 acute inflammatory response 100 2.87E-05 1.10E-03 1050, 11326, 12, 710, 712, 713, 714, 718, 9332 
102 cellular response to light stimulus 7 2.87E-05 1.10E-03 358, 4734 
103 immune response-regulating signaling pathway 80 3.19E-05 1.20E-03 1997, 7097, 7098, 7100, 719 
104 detection of biotic stimulus 20 3.38E-05 1.27E-03 23643, 7097, 7098 
105 type I interferon production 21 3.84E-05 1.42E-03 7097, 7098 
106 
regulation of cytokine production involved in immune 
response 19 3.96E-05 1.46E-03 604, 7097 
107 interferon-beta production 17 4.07E-05 1.47E-03 7097, 7098 
108 regulation of interferon-beta production 17 4.07E-05 1.47E-03 7097, 7098 
109 positive regulation of interferon-beta production 13 4.10E-05 1.47E-03 7097, 7098 
110 I-kappaB phosphorylation 11 5.28E-05 1.86E-03 7097, 7098 
111 positive regulation of MAPKKK cascade 87 8.00E-05 0.003 7098, 7423 
112 anti-apoptosis 228 8.38E-05 0.003 1410, 23411, 25816, 26574, 3315, 4615, 57099, 60675, 7423, 81542, 8870, 9531 
113 regulation of humoral immune response 13 8.59E-05 0.003 710, 718 
114 negative regulation of cytokine production 42 8.86E-05 0.003 11326, 604, 7097 
115 intracellular protein kinase cascade 583 8.90E-05 0.003 1410, 1950, 23643, 2697, 2874, 3059, 3965, 4615, 60675, 6275, 6283, 6398, 7097, 7098, 7100, 7105, 7132, 7423, 9459 
116 signal transmission via phosphorylation event 583 8.90E-05 0.003 1410, 1950, 23643, 2697, 2874, 3059, 3965, 4615, 60675, 6275, 6283, 6398, 7097, 7098, 7100, 7105, 7132, 7423, 9459 
117 positive regulation of NF-kappaB import into nucleus 15 9.03E-05 0.003 7097, 7098 
118 regulation of immune effector process 103 9.09E-05 0.003 3600, 604, 7097, 710, 718 
119 negative regulation of transcription factor activity 61 9.53E-05 0.003 23411, 3399, 6188 
120 negative regulation of transcription regulator activity 61 9.53E-05 0.003 23411, 3399, 6188 
121 regulation of angiogenesis 87 9.73E-05 0.003 285, 358, 7132, 718, 719, 7423 
122 interferon-beta biosynthetic process 7 1.01E-04 0.003 7098 
123 positive regulation of interferon-beta biosynthetic process 7 1.01E-04 0.003 7098 
124 regulation of interferon-beta biosynthetic process 7 1.01E-04 0.003 7098 
125 regulation of lipid transport 40 1.05E-04 0.003 706, 8399, 9388 
126 lymphocyte mediated immunity 108 1.06E-04 0.003 604, 710, 712, 713, 714, 718 







128 type I interferon biosynthetic process 10 1.12E-04 0.003 7098 
129 tumor necrosis factor superfamily cytokine production 36 1.19E-04 0.003 7097, 7098, 929 
130 regulation of DNA binding 165 1.19E-04 0.003 23411, 3399, 6188, 7097, 7098 
131 blood vessel morphogenesis 276 1.30E-04 0.004 1950, 2697, 283, 285, 358, 60675, 7132, 718, 719, 7423 
132 positive regulation of protein transport 83 1.43E-04 0.004 1950, 283, 7097, 7098 
133 positive regulation of innate immune response 50 1.48E-04 0.004 7097, 7098, 7100 
134 negative regulation of immune effector process 18 1.57E-04 0.004 604, 710 
135 
regulation of production of molecular mediator of immune 
response 41 2.06E-04 0.006 604, 7097 
136 response to lipopolysaccharide 122 2.14E-04 0.006 1373, 23643, 3587, 7079, 7097, 7132, 929 
137 leukocyte mediated immunity 133 2.22E-04 0.006 604, 710, 712, 713, 714, 718 
138 myeloid leukocyte cytokine production 9 2.23E-04 0.006 604, 7097 
139 translational initiation 60 2.34E-04 0.006 1978, 1981, 3315, 6188, 6193 
140 negative regulation of DNA binding 69 2.44E-04 0.006 23411, 3399, 6188 
141 angiogenesis 234 2.45E-04 0.006 1950, 283, 285, 358, 60675, 7132, 718, 719, 7423 
142 regulation of tumor necrosis factor production 33 2.57E-04 0.007 7097, 7098, 929 
143 tumor necrosis factor production 33 2.57E-04 0.007 7097, 7098, 929 
144 response to mercury ion 9 2.60E-04 0.007 358, 5224 
145 positive regulation of intracellular transport 46 2.64E-04 0.007 1950, 4734, 7097, 7098 
146 prostaglandin metabolic process 25 2.73E-04 0.007 27306, 6916, 7132 
147 prostanoid metabolic process 25 2.73E-04 0.007 27306, 6916, 7132 
148 response to exogenous dsRNA 11 2.82E-04 0.007 7098 
149 wound healing 215 3.28E-04 0.008 2162, 2697, 3587, 3588, 4814, 710, 7423 
150 response to virus 153 3.49E-04 0.009 10346, 10410, 10581, 1937, 3315, 3440, 3600, 3665, 3669, 51191, 7098, 8519 
151 defense response to Gram-positive bacterium 29 3.51E-04 0.009 7097 
152 regulation of binding 209 3.55E-04 0.009 23411, 3399, 6188, 7097, 7098 
153 notochord development 7 3.92E-04 0.009 3399 
154 response to organic substance 886 4.14E-04 0.01 
10049, 10076, 1050, 11080, 1373, 1410, 1978, 2052, 23643, 2697, 283, 285, 3059, 3315, 3399, 358, 3587, 4615, 58191, 6402, 
7079, 7097, 7098, 7100, 713, 7132, 7913, 871, 900, 929 
155 positive regulation of phosphorylation 135 4.28E-04 0.01 1950, 283, 3059, 7423 
156 regulation of gene-specific transcription 220 4.29E-04 0.01 1050, 23411, 2874, 7097, 7098 
157 detection of molecule of bacterial origin 8 4.72E-04 0.011 23643, 7097 
158 
regulation of stress-activated protein kinase signaling 
cascade 90 4.74E-04 0.011 2874, 7098 
159 NF-kappaB import into nucleus 26 4.81E-04 0.011 7097, 7098 
160 regulation of NF-kappaB import into nucleus 26 4.81E-04 0.011 7097, 7098 
161 positive regulation of defense response 85 5.03E-04 0.012 7097, 7098, 7100, 7132, 718 
162 response to protein stimulus 115 5.26E-04 0.012 10049, 11080, 285, 3315, 3399, 7913, 871 
163 negative regulation of binding 84 5.48E-04 0.012 23411, 3399, 6188 
164 positive regulation of transmembrane transport 26 5.90E-04 0.013 7097, 7098 
165 regulation of localization 726 6.27E-04 0.014 
10076, 10488, 11037, 1410, 1950, 23411, 2697, 283, 285, 358, 4734, 58191, 5867, 604, 706, 7097, 7098, 718, 719, 7423, 8399, 
84876, 91624, 9388 
166 prostaglandin biosynthetic process 16 6.29E-04 0.014 27306, 6916 
167 prostanoid biosynthetic process 16 6.29E-04 0.014 27306, 6916 
168 protein maturation 116 6.30E-04 0.014 11326, 710, 712, 713, 714, 718, 871, 9049 
169 chemokine production 26 6.32E-04 0.014 7097, 7098 
170 regulation of cell fate commitment 9 6.61E-04 0.014 22943 
171 regulation of cell fate specification 9 6.61E-04 0.014 22943 
172 regulation of cellular response to stress 138 6.76E-04 0.015 23411, 2874, 6188, 7098 
173 interferon-alpha production 9 7.27E-04 0.015 7098 
174 regulation of interferon-alpha production 9 7.27E-04 0.015 7098 
175 positive regulation of chemokine production 16 7.36E-04 0.016 7097, 7098 
176 myeloid cell activation involved in immune response 27 7.80E-04 0.016 7097, 7098, 7100 
177 cellular response to molecule of bacterial origin 28 8.45E-04 0.018 7097, 929 







179 blood vessel development 324 9.91E-04 0.02 1950, 2697, 283, 285, 358, 60675, 7132, 718, 719, 7423 
180 regeneration 86 9.98E-04 0.021 10076, 1050, 1462, 2697, 285, 4814 
181 
positive regulation of transcription factor import into 
nucleus 20 1.05E-03 0.021 7097, 7098 
182 regulation of JNK cascade 81 1.06E-03 0.022 2874, 7098 
183 negative regulation of smooth muscle cell proliferation 13 1.08E-03 0.022 283, 3600 
184 positive regulation of transport 276 1.12E-03 0.023 10488, 1950, 283, 358, 4734, 7097, 7098, 718, 8399, 84876, 9388 
185 regulation of transport 514 1.17E-03 0.023 10488, 11037, 1410, 1950, 23411, 2697, 283, 358, 4734, 5867, 706, 7097, 7098, 718, 8399, 84876, 9388 
186 response to pH 13 1.17E-03 0.023 2697, 84329 
187 
gene-specific transcription from RNA polymerase II 
promoter 161 1.21E-03 0.024 1050, 23411, 2874, 7097, 7098 
188 
regulation of gene-specific transcription from RNA 
polymerase II promoter 161 1.21E-03 0.024 1050, 23411, 2874, 7097, 7098 
189 positive regulation of cytokine biosynthetic process 53 1.35E-03 0.026 7097, 7098 
190 icosanoid metabolic process 51 1.35E-03 0.026 241, 27306, 6916, 7132, 8399 
191 positive regulation of phosphate metabolic process 138 1.44E-03 0.028 1950, 283, 3059, 7423 
192 positive regulation of phosphorus metabolic process 138 1.44E-03 0.028 1950, 283, 3059, 7423 
193 negative regulation of immune system process 90 1.45E-03 0.028 11326, 1997, 604, 710 
194 regulation of interferon-gamma production 34 1.51E-03 0.028 7098 
195 microglial cell activation 10 1.54E-03 0.029 7097, 7098, 7100 
196 positive regulation of chemokine biosynthetic process 8 1.59E-03 0.029 7098 
197 positive regulation of protein import into nucleus 25 1.64E-03 0.03 7097, 7098 
198 response to unfolded protein 65 1.68E-03 0.03 10049, 11080, 3315, 871 
199 chemokine biosynthetic process 12 1.70E-03 0.03 7098 
200 chemokine metabolic process 12 1.70E-03 0.03 7098 
201 regulation of B cell apoptosis 8 1.70E-03 0.03 604 
202 negative regulation of cell death 402 1.71E-03 0.03 1410, 23411, 25816, 26574, 3315, 358, 4615, 57099, 604, 60675, 7423, 81542, 8870, 900, 9531 
203 cellular response to xenobiotic stimulus 27 1.71E-03 0.03 6283, 9049 
204 xenobiotic metabolic process 27 1.71E-03 0.03 6283, 9049 
205 interferon-gamma production 35 1.75E-03 0.031 7098 
206 response to xenobiotic stimulus 31 1.80E-03 0.032 6283, 9049 
207 cellular defense response 51 1.80E-03 0.032 10219, 23643, 3823, 4688, 7305 
208 response to fungus 22 1.82E-03 0.032 6283, 7097 
209 negative regulation of apoptosis 391 1.83E-03 0.032 1410, 23411, 25816, 26574, 3315, 358, 4615, 57099, 604, 60675, 7423, 81542, 8870, 900, 9531 
210 S phase of mitotic cell cycle 25 1.85E-03 0.032 5422, 5424, 604, 8099, 84967 
211 regulation of mononuclear cell proliferation 93 1.85E-03 0.032 11326, 3600, 4860, 604 
212 regulation of lymphocyte proliferation 92 1.88E-03 0.032 11326, 3600, 4860, 604 
213 positive regulation of nucleocytoplasmic transport 32 1.92E-03 0.033 4734, 7097, 7098 
214 negative regulation of programmed cell death 396 1.93E-03 0.033 1410, 23411, 25816, 26574, 3315, 358, 4615, 57099, 604, 60675, 7423, 81542, 8870, 900, 9531 
215 regulation of leukocyte proliferation 94 1.95E-03 0.033 11326, 3600, 4860, 604 
216 negative regulation of lipid transport 15 1.96E-03 0.033   
217 negative regulation of multi-organism process 18 1.96E-03 0.033 7097 
218 cell migration 455 1.97E-03 0.033 10076, 10488, 128954, 1462, 2191, 2697, 283, 285, 4478, 58191, 7097, 719, 7423, 91624 
219 regulation of digestive system process 14 1.99E-03 0.033 358 
220 regulation of G2/M transition of mitotic cell cycle 9 2.00E-03 0.033 900 
221 cellular response to abiotic stimulus 13 2.02E-03 0.033 358, 4734 
222 JNK cascade 109 2.03E-03 0.033 2874, 7098, 9459 
223 macrophage activation 27 2.05E-03 0.034 7097, 7098, 7100, 8399 
224 response to peptidoglycan 11 2.09E-03 0.034 7097 
225 unsaturated fatty acid metabolic process 54 2.16E-03 0.035 241, 27306, 6916, 7132, 8399 
226 detection of external stimulus 71 2.17E-03 0.035 56925, 7097, 7098 
227 lymphocyte proliferation 122 2.40E-03 0.038 11326, 3600, 4860, 604 
228 mononuclear cell proliferation 124 2.42E-03 0.038 11326, 3600, 4860, 604 
229 regulation of cholesterol transport 23 2.43E-03 0.038 706, 9388 







231 negative regulation of response to stimulus 122 2.47E-03 0.038 23411, 285, 2874, 604, 6188, 710 
232 vasculature development 334 2.47E-03 0.038 1950, 2697, 283, 285, 358, 60675, 7132, 718, 719, 7423 
233 interaction with host 39 0.003 0.039 4734, 6993, 7097, 7098, 7100 
234 cytokine biosynthetic process 89 0.003 0.04 7097, 7098 
235 cytokine metabolic process 90 0.003 0.04 7097, 7098 
236 response to glucocorticoid stimulus 97 0.003 0.04 10076, 1050, 1373, 358, 713 
237 cell activation involved in immune response 55 0.003 0.041 604, 7097, 7098, 7100 
238 leukocyte activation involved in immune response 55 0.003 0.041 604, 7097, 7098, 7100 
239 locomotion 599 0.003 0.041 10076, 10488, 128954, 1462, 2191, 2697, 283, 285, 2919, 4478, 4734, 5355, 58191, 6036, 60675, 7097, 719, 7423, 91624 
240 
positive regulation of production of molecular mediator of 
immune response 15 0.003 0.041 7097 
241 regulation of transcription in response to stress 6 0.003 0.041 4734 
242 
regulation of transcription from RNA polymerase II 
promoter 745 0.003 0.043 100125288, 1050, 1997, 23411, 26574, 2874, 29128, 3399, 3660, 3665, 4734, 57658, 5932, 604, 7097, 7098, 7132, 7913, 79366 
243 positive regulation of lipid transport 20 0.003 0.043 8399, 9388 
244 regulation of protein secretion 63 0.003 0.043 1950, 283 
245 response to external stimulus 645 0.003 0.043 
10488, 1050, 1373, 1509, 23411, 285, 2919, 358, 4615, 5355, 56925, 58191, 6036, 604, 60675, 7097, 7098, 710, 7132, 718, 
719, 7423, 9388 
246 leukocyte proliferation 126 0.003 0.043 11326, 3600, 4860, 604 
247 leukocyte activation 336 0.003 0.043 11326, 3600, 4860, 604, 7097, 7098, 7100, 81542, 8399 
248 ribosomal large subunit biogenesis 11 0.003 0.043 6135, 6154 
249 cellular response to lipoteichoic acid 6 0.003 0.043 7097, 929 
250 response to lipoteichoic acid 6 0.003 0.043 7097, 929 
251 positive regulation of intracellular protein transport 43 0.003 0.047 1950, 7097, 7098 
252 positive regulation of ERK1 and ERK2 cascade 34 0.003 0.047 7423 
253 lymphocyte chemotaxis 9 0.003 0.047 58191 
254 protein maturation by peptide bond cleavage 81 0.003 0.047 11326, 710, 712, 713, 714, 718 
255 response to corticosteroid stimulus 104 0.003 0.047 10076, 1050, 1373, 358, 713 
256 response to dsRNA 27 0.003 0.048 7098 
257 peptidyl-tyrosine modification 112 0.003 0.049 1950, 3059, 7423 
258 RNA catabolic process 74 0.004 0.049 1763, 3669, 6036, 6039, 87178 
259 tetrahydrobiopterin biosynthetic process 6 0.004 0.049 6697 
260 cellular response to inorganic substance 11 0.004 0.05 241, 358 
261 cellular response to metal ion 11 0.004 0.05 241, 358 
262 cellular response to stress 677 0.004 0.05 
1410, 1462, 1509, 1763, 23411, 26574, 27244, 2874, 29128, 358, 3978, 4438, 4734, 5422, 5424, 5932, 604, 6188, 7098, 79677, 
83932, 900, 9459 
263 positive regulation of transcription regulator activity 88 0.004 0.05 7097, 7098 
264 
positive regulation of NF-kappaB transcription factor 
activity 58 0.004 0.051 7097, 7098 
265 negative regulation of lymphocyte apoptosis 9 0.004 0.051 604 
266 response to heat 62 0.004 0.052 11080, 1410, 3315, 929 
267 regulation of epidermis development 21 0.004 0.053 23764 
268 regulation of protein transport 145 0.004 0.053 1950, 23411, 283, 7097, 7098 
269 positive regulation of cellular component movement 138 0.004 0.053 10488, 58191, 604, 7097, 719, 7423 
270 positive regulation of transcription factor activity 87 0.004 0.055 7097, 7098 
271 establishment of mitotic spindle orientation 7 0.004 0.057 6993 
272 establishment of spindle orientation 7 0.004 0.057 6993 
273 cell activation 381 0.005 0.059 11326, 3600, 4860, 604, 7097, 7098, 7100, 81542, 8399 
274 response to abiotic stimulus 393 0.005 0.06 11080, 1410, 2697, 2766, 285, 3315, 358, 4734, 5424, 56925, 7098, 84329, 929 
275 receptor-mediated endocytosis 73 0.005 0.061 10268, 4734, 58191 
276 regulation of inflammatory response 87 0.005 0.061 4615, 604, 7097, 7098, 710, 7132, 718 
277 pancreatic juice secretion 8 0.005 0.061 358 
278 mitotic cell cycle 480 0.005 0.061 10459, 1950, 1978, 246184, 26574, 5422, 5424, 54443, 54930, 55145, 5696, 604, 6993, 8099, 81930, 84967, 900, 90293 
279 cell cycle phase 509 0.005 0.061 10459, 1950, 1978, 246184, 4438, 5422, 5424, 54443, 54930, 604, 6993, 8099, 81930, 84967, 900, 90293 







281 protein processing 106 0.005 0.064 11326, 710, 712, 713, 714, 718 
282 regulation of gastrulation 9 0.005 0.067   
283 
positive regulation of cytokine production involved in 
immune response 11 0.005 0.067 7097 
284 regulation of lymphocyte apoptosis 15 0.006 0.067 604 
285 regulation of interleukin-8 production 21 0.006 0.067 7097, 7098, 7100 
286 regulation of response to external stimulus 187 0.006 0.069 10488, 285, 4615, 604, 7097, 7098, 710, 7132, 718, 719, 7423 
287 interferon-gamma biosynthetic process 14 0.006 0.069 7098 
288 peptidyl-tyrosine phosphorylation 110 0.006 0.069 1950, 3059, 7423 
289 complement activation, alternative pathway 14 0.006 0.069 11326, 718 
290 regulation of cell activation 189 0.006 0.07 11326, 3600, 4860, 604, 8399 
291 
positive regulation of interferon-gamma biosynthetic 
process 11 0.006 0.07 7098 
292 positive regulation of protein secretion 45 0.006 0.071 283 
293 regulation of multi-organism process 52 0.006 0.072 3600, 7097 
294 production of molecular mediator of immune response 64 0.006 0.072 604, 7097 
295 interphase of mitotic cell cycle 137 0.006 0.072 1978, 5422, 5424, 604, 8099, 84967, 900 
296 rRNA transcription 18 0.006 0.072 283 
297 positive regulation of humoral immune response 8 0.006 0.072 718 
298 transcription from RNA polymerase II promoter 900 0.006 0.073 
100125288, 1050, 1997, 23411, 23764, 26574, 2874, 29128, 29777, 3399, 3660, 3665, 4734, 57658, 5932, 604, 7097, 7098, 
7132, 7913, 79366 
299 interleukin-8 production 23 0.007 0.075 7097, 7098, 7100 
300 cell cycle process 662 0.007 0.076 10459, 1950, 1978, 246184, 27244, 4438, 5422, 5424, 54443, 54930, 5696, 604, 6993, 8099, 81930, 84967, 900, 90293 
301 regulation of establishment of protein localization 153 0.007 0.076 1950, 23411, 283, 7097, 7098 
302 mesenchyme development 81 0.007 0.077 1592, 6275 
303 regulation of leukocyte migration 40 0.007 0.077 7097, 719, 7423 
304 myeloid leukocyte activation 71 0.007 0.077 7097, 7098, 7100, 8399 
305 superoxide anion generation 14 0.007 0.079 26574, 4688 
306 regulation of chemokine production 24 0.007 0.081 7097, 7098 
307 regulation of leukocyte mediated immunity 59 0.007 0.082 604, 718 
308 tetrahydrobiopterin metabolic process 7 0.007 0.083 6697 
309 acute-phase response 44 0.008 0.083 1050, 12, 9332 
310 regulation of chemokine biosynthetic process 11 0.008 0.083 7098 
311 regulation of leukocyte activation 177 0.008 0.083 11326, 3600, 4860, 604, 8399 
312 regulation of B cell mediated immunity 24 0.008 0.083 604, 718 
313 regulation of immunoglobulin mediated immune response 24 0.008 0.083 604, 718 
314 protein secretion 94 0.008 0.084 1950, 283, 4860 
315 positive regulation of cell migration 129 0.008 0.084 10488, 58191, 7097, 719, 7423 
316 defense response to virus 41 0.008 0.084 3600, 7098 
317 tissue regeneration 30 0.008 0.084 2697, 4814 
318 regulation of body fluid levels 200 0.008 0.084 187, 2162, 358, 3587, 3588, 710 
319 positive regulation of leukocyte migration 31 0.008 0.084 7097, 719, 7423 
320 positive regulation of inflammatory response 43 0.008 0.084 7097, 7098, 7132, 718 
321 interspecies interaction between organisms 335 0.008 0.085 10346, 10488, 1050, 1981, 200186, 23411, 358, 3665, 4734, 5422, 5696, 6993, 7097, 7098, 7100, 7132 
322 cell motility 484 0.008 0.085 10076, 10488, 128954, 1462, 2191, 2697, 283, 285, 4478, 58191, 7097, 719, 7423, 91624 
323 localization of cell 484 0.008 0.085 10076, 10488, 128954, 1462, 2191, 2697, 283, 285, 4478, 58191, 7097, 719, 7423, 91624 
324 cellular response to lipopolysaccharide 25 0.008 0.085 929 
325 regulation of nucleocytoplasmic transport 84 0.008 0.085 1950, 23411, 4734, 7097, 7098 
326 positive regulation of mononuclear cell proliferation 65 0.008 0.086 3600, 4860, 604 
327 icosanoid biosynthetic process 36 0.008 0.086 241, 27306, 6916 
328 T cell proliferation 86 0.008 0.086 11326, 3600, 4860 
329 regulation of protein import into nucleus 67 0.008 0.086 1950, 23411, 7097, 7098 
330 positive regulation of lymphocyte proliferation 64 0.008 0.086 3600, 4860, 604 
331 reproductive process 791 0.009 0.087 100125288, 10149, 10488, 23411, 23764, 283, 285, 4438, 4734, 51314, 5224, 604, 60675, 6993, 7079, 7913 







somatic recombination of immune receptors built from 
immunoglobulin superfamily domains 
333 positive regulation of leukocyte proliferation 66 0.009 0.088 3600, 4860, 604 
334 reproduction 793 0.009 0.089 100125288, 10149, 10488, 23411, 23764, 283, 285, 4438, 4734, 51314, 5224, 604, 60675, 6993, 7079, 7913 
335 interphase 146 0.009 0.091 1978, 5422, 5424, 604, 8099, 84967, 900 
336 establishment of tissue polarity 12 0.009 0.091 57216 
337 positive regulation of immune effector process 46 0.009 0.091 7097, 718 
338 negative regulation of RNA metabolic process 412 0.009 0.091 100125288, 10049, 1050, 23411, 2874, 3399, 3660, 3665, 4734, 604, 6207, 84232 
339 transepithelial transport 10 0.01 0.093 358 
340 cellular response to hypoxia 6 0.01 0.093 358 
341 cellular response to oxygen levels 6 0.01 0.093 358 
342 renal water transport 5 0.01 0.093 358 
343 regulation of phospholipase A2 activity 6 0.01 0.094 283 
344 regulation of cell proliferation 834 0.01 0.095 
10076, 10488, 1050, 11326, 138151, 1950, 2014, 23411, 2697, 27244, 283, 2919, 3059, 358, 3600, 4860, 563, 604, 6282, 648, 
7423, 8519 
345 phospholipid catabolic process 21 0.01 0.095 9388 
346 response to oxygen levels 155 0.01 0.097 1410, 283, 285, 358, 51167, 54541, 7097, 9124 
347 positive regulation of gene-specific transcription 145 0.01 0.097 1050, 7097, 7098 




Supplemental Table 4.4. Among genes with lower expression in Alzheimer’s, 
several molecular functions were enriched. 
Rank Name #Genes P-Value FDR SigGenes 
1 neuropeptide hormone activity 21 5.46E-07 1.89E-04 2922, 5368, 7425 
2 cation transmembrane transporter activity 525 1.09E-05 0.001 155066, 482, 6529 
3 inorganic cation transmembrane transporter activity 203 5.44E-05 0.005 155066, 482, 6529 
4 porin activity 6 6.50E-05 0.005 10452 
5 calmodulin-dependent protein kinase activity 20 1.14E-04 0.008   
6 ion transmembrane transporter activity 683 1.34E-04 0.009 10452, 155066, 482, 6529 
7 MAP kinase tyrosine/serine/threonine phosphatase activity 12 1.43E-04 0.009 1846, 1848 
8 MAP kinase phosphatase activity 13 1.74E-04 0.009 1846, 1848 
9 monovalent inorganic cation transmembrane transporter activity 160 2.38E-04 0.012 155066, 482, 6529 
10 nucleoside-triphosphate diphosphatase activity 6 4.97E-04 0.021 3704, 79077 
11 hydrogen ion transmembrane transporter activity 83 0.001 0.023 155066 
12 NADH dehydrogenase (quinone) activity 38 0.001 0.044 4704 
13 NADH dehydrogenase (ubiquinone) activity 38 0.001 0.044 4704 
14 NADH dehydrogenase activity 38 0.001 0.044 4704 
15 transmembrane transporter activity 859 0.002 0.055 
10452, 11182, 155066, 21, 22, 482, 
6529 
16 cis-trans isomerase activity 36 0.002 0.068 2954, 9360 
17 substrate-specific transporter activity 916 0.004 0.099 
10452, 11182, 155066, 3049, 482, 
6529 
18 SNARE binding 29 0.004 0.113   
19 mannosyltransferase activity 15 0.005 0.12 10585, 79087, 80235 
20 phosphotyrosine binding 10 0.005 0.12 53 
21 oxygen transporter activity 8 0.005 0.123 3049 
22 ATPase activity 330 0.005 0.123 155066, 21, 22, 482, 57680 
23 RNA polymerase II carboxy-terminal domain kinase activity 13 0.006 0.127   
24 sodium:potassium-exchanging ATPase activity 10 0.007 0.138 482 
25 calcium channel regulator activity 13 0.007 0.138 9379 
26 ATPase activity, coupled 266 0.007 0.138 155066, 21, 22, 482, 57680 
27 channel regulator activity 53 0.007 0.14 57730, 9379 
28 gated channel activity 296 0.008 0.141 10452 
29 ATPase activity, coupled to transmembrane movement of ions 67 0.008 0.141 155066, 482 
30 ATPase activity, coupled to transmembrane movement of substances 100 0.009 0.146 155066, 21, 22, 482 
31 oxidoreductase activity, acting on the aldehyde or oxo group of donors 32 0.009 0.146 220, 223 
32 aldehyde dehydrogenase (NAD) activity 9 0.009 0.147 220, 223 
33 voltage-gated channel activity 185 0.011 0.157 10452 
34 voltage-gated ion channel activity 185 0.011 0.157 10452 
35 O-methyltransferase activity 12 0.011 0.157 23070 
36 oxidoreductase activity 648 0.011 0.157 
10157, 220, 223, 242, 2954, 4704, 
728294, 7923 
37 hydrolase activity, acting on acid anhydrides 742 0.012 0.157 
155066, 21, 22, 3704, 4636, 482, 
57680, 585, 79077, 79132 
38 
hydrolase activity, acting on acid anhydrides, in phosphorus-containing 
anhydrides 738 0.012 0.157 
155066, 21, 22, 3704, 4636, 482, 
57680, 585, 79077, 79132 
39 calmodulin binding 140 0.012 0.157   
40 
hydrolase activity, acting on acid anhydrides, catalyzing transmembrane 
movement of substances 102 0.012 0.159 155066, 21, 22, 482 
41 GABA receptor activity 22 0.013 0.159   
42 P-P-bond-hydrolysis-driven transmembrane transporter activity 109 0.013 0.159 155066, 21, 22, 482 
43 primary active transmembrane transporter activity 109 0.013 0.159 155066, 21, 22, 482 
44 pyrophosphatase activity 735 0.013 0.16 
155066, 21, 22, 3704, 4636, 482, 
57680, 585, 79077, 79132 
45 ATPase activity, coupled to movement of substances 101 0.013 0.161 155066, 21, 22, 482 
46 RNA methyltransferase activity 27 0.014 0.164 23070 
47 active transmembrane transporter activity 324 0.014 0.165 155066, 21, 22, 482, 6529 
48 aminoacyl-tRNA ligase activity 46 0.016 0.171 54938, 80222 
49 ligase activity, forming aminoacyl-tRNA and related compounds 46 0.016 0.171 54938, 80222 
50 ligase activity, forming carbon-oxygen bonds 46 0.016 0.171 54938, 80222 
51 ion channel activity 366 0.017 0.178 10452 
52 S-adenosylmethionine-dependent methyltransferase activity 90 0.018 0.182 23070, 6839 
53 nucleoside-triphosphatase activity 706 0.019 0.192 
155066, 21, 22, 4636, 482, 57680, 
585, 79132 
54 potassium-transporting ATPase activity 12 0.02 0.193 482 
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55 glutamate receptor activity 29 0.021 0.198   
56 syntaxin-1 binding 8 0.022 0.202   
57 cation:amino acid symporter activity 11 0.023 0.21 6529 
58 2 iron, 2 sulfur cluster binding 17 0.024 0.214   
59 cation channel activity 263 0.024 0.214   
60 substrate-specific channel activity 376 0.025 0.224 10452 
61 ARF GTPase activator activity 26 0.026 0.224   
62 syntaxin binding 23 0.031 0.258   
63 aldehyde dehydrogenase [NAD(P)+] activity 5 0.032 0.262 220 
64 calcium channel activity 78 0.032 0.263   
65 antibiotic transporter activity 7 0.033 0.265   
66 metal ion transmembrane transporter activity 125 0.034 0.272 482, 6529 
67 passive transmembrane transporter activity 393 0.036 0.273 10452 
68 peptidyl-prolyl cis-trans isomerase activity 34 0.036 0.273 9360 
69 
oxidoreductase activity, acting on the aldehyde or oxo group of donors, 
disulfide as acceptor 8 0.036 0.273   
70 
oxidoreductase activity, acting on NADH or NADPH, quinone or similar 
compound as acceptor 44 0.036 0.273 4704 
71 channel activity 392 0.039 0.285 10452 
72 
oxidoreductase activity, acting on sulfur group of donors, oxygen as 
acceptor 6 0.04 0.287   
73 hormone activity 96 0.04 0.287 2922, 5368, 7425 
74 tetracycline transporter activity 6 0.041 0.292   
75 E-box binding 7 0.041 0.292 7291 
76 sodium ion transmembrane transporter activity 75 0.042 0.295 482, 6529 
77 
oxidoreductase activity, acting on the aldehyde or oxo group of donors, 
NAD or NADP as acceptor 22 0.043 0.296 220, 223 
78 beta-tubulin binding 19 0.043 0.299 2010, 585 
79 fructose binding 6 0.048 0.324   
 
Supplemental Table 4.5. Among genes with higher expression in Alzheimer’s, 
several molecular functions were enriched. 
Rank Name #Genes 
P-
Value FDR SigGenes 
1 structural constituent of ribosome 149 
1.33E-
10 0 
11224, 2197, 25873, 6135, 6154, 6173, 6176, 
6188, 6193, 6207, 6222, 6232 
2 pancreatic ribonuclease activity 10 
7.58E-
08 0 283, 6036, 6039 
3 glycosaminoglycan binding 148 
2.16E-
06 0.0005 
1462, 26577, 283, 4057, 6402, 7097, 7423, 
79625, 929, 9388 
4 endoribonuclease activity, producing 3'-phosphomonoesters 13 
2.64E-
06 0.0005 283, 6036, 6039 
5 RAGE receptor binding 7 
4.03E-
06 0.0007 6275, 6283 
6 pattern binding 163 
9.22E-
06 0.0014 
1462, 26577, 283, 4057, 6402, 7097, 7423, 
79625, 929, 9388 
7 carbohydrate binding 339 
1.31E-
05 0.0015 
10219, 1462, 26577, 283, 3823, 3965, 4057, 
6402, 7097, 7423, 79625, 929, 9388, 9936 
8 peptidoglycan binding 9 
4.14E-
05 0.0043 7097, 929 
9 
endonuclease activity, active with either ribo- or deoxyribonucleic 
acids and producing 3'-phosphomonoesters 18 
5.51E-
05 0.0048 283, 6036, 6039 
10 coreceptor activity 19 0.0001 0.0089 10268, 23643 
11 cytokine binding 113 0.0002 0.0093 1436, 2532, 3587, 3588, 5355, 7132 
12 heparin binding 110 0.0002 0.0117 26577, 283, 4057, 6402, 7423, 79625, 9388 
13 transcription regulator activity 923 0.0003 0.0138 
100125288, 10049, 10346, 10488, 1050, 
10848, 138151, 165, 1997, 23411, 27005, 
2874, 29128, 29777, 3399, 3660, 3665, 
55145, 57658, 604, 7764, 7913, 79366, 
84232, 9049, 9124 
14 lipopolysaccharide binding 13 0.0004 0.0167 23643, 7097, 929 
15 rRNA binding 24 0.0004 0.0168 283, 6135, 6222 
16 cytokine receptor binding 179 0.0006 0.024 
10488, 2919, 3440, 3600, 4615, 58191, 7100, 
7423 
17 ribonuclease activity 58 0.0022 0.0683 283, 3669, 563, 6036, 6039, 87178 
18 vascular endothelial growth factor receptor binding 6 0.0022 0.0685 7423 
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19 structural molecule activity 570 0.0024 0.0707 
1101, 11224, 1410, 2197, 24146, 25873, 
4478, 4604, 6135, 6154, 6173, 6176, 6188, 
6193, 6207, 6222, 6232, 81493, 81578, 
84617, 9499 
20 cyclic nucleotide-dependent protein kinase activity 9 0.0032 0.0915 5613 
21 water transmembrane transporter activity 12 0.0033 0.0915 358 
22 phosphate binding 13 0.0039 0.1026 10797, 4860 
23 microtubule plus-end binding 10 0.0046 0.1153 81930 
24 cytokine receptor activity 56 0.0051 0.1203 3587, 3588 
25 metalloexopeptidase activity 37 0.0059 0.1283 10269, 10404, 165 
26 death receptor activity 13 0.0066 0.1377 7132 
27 monocarboxylic acid binding 57 0.007 0.1377 1592, 241, 563, 6646, 91452 
28 glycosphingolipid binding 6 0.0072 0.1379 6402 
29 monosaccharide binding 42 0.0076 0.1402 3965 
30 proline-rich region binding 9 0.008 0.1408 4734 
31 sphingolipid binding 8 0.0085 0.1464 6402 
32 metallocarboxypeptidase activity 24 0.0088 0.1464 10404, 165 
33 I-SMAD binding 10 0.009 0.1464   
34 actin binding 315 0.0094 0.1474 
170954, 283, 4478, 4542, 4604, 54443, 
81930, 822, 91624, 9499 
35 transcription repressor activity 336 0.0104 0.1569 
100125288, 10049, 10346, 10848, 138151, 
165, 1997, 23411, 2874, 3399, 604, 7764 
36 ubiquitin binding 35 0.0106 0.1569 3315, 4734, 81930 
37 anion binding 16 0.0109 0.1569 10797, 4860 
38 IgG binding 6 0.0114 0.1569   
39 voltage-gated chloride channel activity 15 0.0115 0.1569 1192, 1193 
40 low-density lipoprotein receptor activity 11 0.012 0.1584 58191 
41 protein complex binding 238 0.0123 0.1592 1050, 1373, 2857, 3059, 3384, 7045, 7132 
42 cAMP-dependent protein kinase activity 7 0.0133 0.1602 5613 
43 carboxypeptidase activity 36 0.0144 0.1662 10404, 165, 642 
44 GDP binding 26 0.0152 0.171 2669, 5867 
45 small conjugating protein binding 36 0.0153 0.171 3315, 4734, 81930 
46 interleukin-1 receptor binding 11 0.0159 0.171 7100 
47 metalloendopeptidase inhibitor activity 10 0.0165 0.171 56925, 7079 
48 metalloenzyme inhibitor activity 10 0.0165 0.171 56925, 7079 
49 metalloenzyme regulator activity 10 0.0165 0.171 56925, 7079 
50 intramolecular oxidoreductase activity 40 0.0165 0.171 10130, 27306, 6916 
51 sugar binding 173 0.0185 0.187 10219, 1462, 3823, 3965, 6402, 9936 
52 endoribonuclease activity 39 0.0187 0.1871 283, 6036, 6039 
53 exopeptidase activity 78 0.0205 0.1975 10269, 10404, 165, 2191, 642 
54 ATPase regulator activity 7 0.0205 0.1975 10049 
55 water channel activity 11 0.0208 0.1978 358 
56 cyclic nucleotide-gated ion channel activity 6 0.0238 0.2144 358 
57 intracellular cyclic nucleotide activated cation channel activity 6 0.0238 0.2144 358 
58 scavenger receptor activity 43 0.0255 0.2238 58191, 9332 
59 RNA polymerase II transcription factor activity 236 0.0261 0.2238 1050, 29128, 29777, 3660, 3665, 7913 
60 regulatory region DNA binding 148 0.0263 0.2238 1050, 57658, 7764 
61 transcription regulatory region DNA binding 148 0.0263 0.2238 1050, 57658, 7764 
62 interferon-alpha/beta receptor binding 8 0.0306 0.2581 3440 
63 collagen binding 38 0.0314 0.2613 871 
64 peptidase inhibitor activity 141 0.032 0.2619 12, 25816, 56925, 6590, 7079, 710, 718, 871 
65 endopeptidase inhibitor activity 133 0.0341 0.272 12, 25816, 56925, 6590, 7079, 710, 718, 871 
66 tumor necrosis factor receptor activity 11 0.0355 0.2733 7132 
67 alcohol transmembrane transporter activity 7 0.0365 0.2747 358 
68 polyol transmembrane transporter activity 7 0.0365 0.2747 358 
69 transcription cofactor activity 358 0.0367 0.2747 
10346, 10488, 10848, 165, 23411, 27005, 
2874, 29777, 3399, 57658, 9049, 9124 
70 RNA polymerase binding 6 0.0387 0.2849 4734 
71 phospholipase inhibitor activity 12 0.0389 0.2849   
72 growth factor binding 111 0.0394 0.2862 3487, 3587, 3588, 4052 
73 sequence-specific DNA binding 582 0.0423 0.295 
100125288, 10488, 1050, 1997, 23764, 
55145, 57658, 604, 7764 
74 titin binding 9 0.0464 0.3166 4604 
75 tumor necrosis factor binding 12 0.0466 0.3166 7132 
76 cytokine activity 188 0.0487 0.3268 2919, 3440, 3600, 58191, 6398 




Supplemental Table 4.6. Among genes with lower expression in Alzheimer’s, 
the binding motifs of several transcription factors were enriched. 
Rank Name #Genes P-Value FDR SigGenes 
1 NRSF_01 418 0 0.022 10307, 23130, 26505, 401190, 57574, 627 
2 NMYC_01 330 0.001 0.049 1846, 7291, 7425 
3 CREB_01 283 0.001 0.049 148304, 1846, 9360 
4 CREBP1CJUN_01 287 0.002 0.095 124044, 23070, 7425, 8364, 8366 
5 MEIS1BHOXA9_02 231 0.004 0.13 1408, 627, 79680, 9360 
6 AREB6_03 248 0.004 0.13 124044, 155066, 83694 
7 CREB_02 137 0.005 0.13 140597, 63917, 8364, 8366 
8 CREBP1_Q2 357 0.005 0.13 54984, 81576, 8364, 8366, 9360 
9 NFY_01 22 0.01 0.225   
10 AREB6_01 161 0.011 0.225 23130, 5368, 9379 
11 ROAZ_01 326 0.024 0.384 124808, 4330, 91851 
12 RFX1_02 420 0.028 0.384 124044, 145407, 1848, 29070 
13 TAXCREB_02 267 0.03 0.384 115548, 79132 
14 ATF_01 394 0.03 0.384 8364, 8366, 9360 
15 SREBP1_01 338 0.031 0.384 140597, 26995, 57795, 627 
16 MEIS1_01 101 0.042 0.484 10307 
17 LYF1_01 99 0.045 0.495 23130, 242 
 
Supplemental Table 4.7. Among genes with higher expression in Alzheimer’s, 
the binding motifs of several transcription factors were enriched. 
Rank Name #Genes P-Value FDR SigGenes 
1 NFKAPPAB_01 214 0.0020 0.0951 
11170, 1462, 24146, 27005, 2919, 3384, 56658, 56833, 57216, 
57658, 58191, 81493, 84876 
2 NKX22_01 219 0.0108 0.2252 285, 29128, 4734, 5422, 57633, 6646, 85450 
3 OCT_C 267 0.0146 0.2704 
10488, 1997, 25816, 4734, 55843, 56131, 58526, 6036, 712, 
9531 
4 PBX1_01 54 0.0300 0.3837 5166, 8334, 91947 
5 HOXA3_01 183 0.0318 0.3837 2197, 4038, 648, 84173, 85450 
6 CREL_01 274 0.0490 0.5000 1462, 23764, 2919, 55273, 56833, 57216, 57658, 58191, 84876 
 
Supplemental Table 4.8. Among genes with higher expression in Alzheimer’s, 
the binding sites of several microRNAs were enriched. 
Rank Name #Genes P-Value FDR SigGenes 
1 mir-506 893 0.023 0.831 
10269, 1050, 10848, 1462, 23593, 26511, 29128, 5355, 55227, 
57658, 58526, 604, 64089, 754, 79710 
2 mir-124 890 0.035 0.831 
10269, 1050, 10848, 1462, 23593, 26511, 29128, 5355, 55227, 
57658, 58526, 604, 64089, 754, 79710 
3 mir-433 163 0.045 0.831 256435, 284370, 91947 
 
Supplemental Table 4.9. Among genes with lower expression in Alzheimer’s, 
the binding sites of several microRNAs were enriched. 
Rank Name #Genes P-Value FDR SigGenes 
1 mir-129-5p 292 0.004 0.592 114034, 124808, 23251, 9379 
2 mir-185 118 0.014 0.831 81606 
3 mir-328 73 0.028 0.831 4330, 8364, 8366 
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Supplemental Table 4.10. Among genes with higher expression in Alzheimer’s, 
several cytogenic bands were enriched. 
Rank Name #Genes P-Value FDR SigGenes 
1 7p13-p12 7 8.12E-05 0.023 10268, 5224 
2 17p13 30 1.85E-04 0.036 2874, 58191, 6154 
3 4q25 26 2.08E-04 0.036 1950 
4 10p12.31 5 3.68E-04 0.046 219681 
5 1q25 21 4.45E-04 0.048 4688, 6646 
6 1q23.2 7 1.09E-03 0.086 54935, 56833 
7 1p36.3-p36.2 10 1.97E-03 0.122   
8 1p21.3 7 2.41E-03 0.129 51375 
9 17q11.2-q12 9 2.50E-03 0.129 26574 
10 5q31-q33 5 3.31E-03 0.143   
11 2p11.2 33 3.67E-03 0.152 822, 84173 
12 22q11.1 5 0.005 0.19 128954 
13 9q22 13 0.005 0.193 4814 
14 Xp21.1 13 0.005 0.193 8406 
15 1q21 78 0.006 0.193 6232, 6275, 6282, 6283 
16 1q23 16 0.008 0.227   
17 8q11 6 0.009 0.251   
18 12q 12 0.012 0.301   
19 9q33.2 15 0.012 0.301 92399 
20 3p26.2 6 0.014 0.329 57633 
21 1p31-p22 5 0.014 0.334 22802 
22 7p14 7 0.024 0.464 358 
23 6q24 8 0.025 0.478 23593 
24 14q21 7 0.026 0.48 57161 
25 5q14.3 8 0.028 0.49 1462 
26 12q24.11 24 0.033 0.541 338773, 84329 
27 3q24 12 0.034 0.546   
28 2p16.3 7 0.038 0.604 11037 
29 1p31.1 28 0.043 0.629 11080, 256435, 91624 
30 6p22.1 42 0.043 0.629 29777 
31 19q13.3 68 0.045 0.636 2014, 2828, 29998, 5424 
32 15q22.1 6 0.049 0.661 79811 
 
Supplemental Table 4.11. Among genes with lower expression in Alzheimer’s, 
several cytogenic bands were enriched. 
Rank Name #Genes P-Value FDR SigGenes 
1 16p13.3 169 1.81E-06 0.002 10573, 124093, 1877, 21, 3049 
2 10p11.2 6 7.64E-06 0.003 7587 
3 8p23 6 3.45E-04 0.046 54984 
4 12p12.3 25 9.67E-04 0.086 8364, 8366 
5 8p21.3 21 1.03E-03 0.086 10361 
6 15q25.1 11 1.81E-03 0.122 23251 
7 2q21.1 15 1.86E-03 0.122 653275 
8 7q31.3 11 2.61E-03 0.129 10157 
9 2p22.2 6 2.70E-03 0.129 10153 
10 7p14.3 8 2.83E-03 0.129 6100 
11 7p11.2 8 6.16E-03 0.203   
12 14q32.2 11 6.31E-03 0.203 57596 
13 8p23.3 5 6.66E-03 0.206 9172 
14 19q13.42 46 7.39E-03 0.221   
15 10q23.32 5 0.008 0.227   
16 9q34.11 42 0.011 0.286 26995 
17 20q11.2-q12 6 0.016 0.354 4826 
18 17p11.2 59 0.018 0.4 125170, 254272, 388341 
19 2p23.1 6 0.018 0.4 81606 
20 2q37.3 43 0.019 0.402 151176, 728294 
21 2p25.3 10 0.019 0.402   
22 14q32 16 0.021 0.416   
23 5p15.33 14 0.024 0.471 65980 
24 17q23 7 0.027 0.49 762 
25 10q24.31 9 0.029 0.509   
26 1p36.33 31 0.031 0.53 9636 
27 16q24.3 34 0.032 0.536 124044, 58189 
28 9q34 44 0.039 0.611 11182 
29 12q23.3 17 0.042 0.629 121053 
30 6p21.33 24 0.044 0.629 8364, 8366 
31 19p13.3 183 0.044 0.632 5657, 566, 84717 
32 14q11.2-q12 8 0.047 0.647   





Conclusions and Future Directions 
 
OVERALL SUMMARY 
 The goals of this dissertation are to understand (1) the regulation of 
homocysteine (Hcy), a one-carbon metabolite, by the heavy metal lead (Pb) and 
(2) the role of DNA methylation and gene expression in late onset Alzheimer’s 
disease (LOAD), a spontaneous neurodegenerative disease.  First, in the 
Normative Aging Study cohort, it is demonstrated that plasma total Hcy is 
regulated by Pb exposure and dietary availability of vitamin B6, vitamin B12, and 
folate.  LOAD is associated with changes in circulating Hcy, which is involved 
with methyl-group substrate availability for DNA methylation.  Second, modest, 
widespread differences in DNA methylation were observed in the frontal cortex of 
LOAD subjects vs. controls.  A follow-up study suggests that these DNA 
methylation marks may have functional gene expression implications.  Gene 
expression and DNA methylation values at an individual gene were validated in 
additional samples. This dissertation provides the foundation for further work on 
the environmental influences on Hcy and epigenetics in LOAD. 
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SUMMARY OF HOMOCYSTEINE (HCY) AND LEAD (PB) EXPOSURE 
Hcy is a thiol-containing intermediate in the one-carbon metabolism cycle.  
It is involved in folate metabolism and corresponding nucleotide synthesis, 
methionine metabolism and corresponding methylation of DNA, RNA, and 
proteins, and finally glutathione (antioxidant) synthesis (Selhub 1999).  
Elevations in homcysteine are associated with cardiovascular disease (CVD) 
(Wald et al. 2002) and neurodegeneration (Mattson and Shea 2003), including 
AD (Seshadri et al. 2002).  This dissertation chapter shows that recent lead 
exposure (measured in blood) is cross-sectionally associated with Hcy levels 
(8.14% increase in Hcy with 3ug/dl IQR increase in blood Pb).  This association 
was modified by vitamin B6, vitamin B12, and folate dietary factors as 
determined through stratified analysis.  Cumulative exposure to lead (measured 
in tibia) was also associated with homocysteine, but this relationship disappeared 
after blood lead was included in the model, suggesting that blood lead mediates 
the association between bone lead and homocysteine. 
Strengths and Weaknesses 
The current study is strengthened by the use of repeated measures of Hcy 
and blood Pb as well as repeated measures in Hcy with baseline bone Pb.  This 
allows us to look at longitudinal changes in Hcy with Pb exposure, not simply 
cross-sectional associations.  This study is the first to examine the Pb-Hcy 
relationship while examining plausible dietary interactions, namely folate and 
vitamins B6 and B12. 
 Previous research has looked at the cross-sectional association between 
lead exposure and homocysteine (Chia et al. 2007; Schafer et al. 2005).  Other 
studies have observed changes in homocysteine with diet over time (Clarke and 
Armitage 2000).  One paper has combined lead exposure and diet in the study of 
homocysteine (Yakub and Iqbal 2010).  This study is the first (that we are aware 
of) to include repeated measures of lead exposure, Hcy, and diet.  It is 
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strengthened by multiple measures of lead exposure (tibia, patella, and blood) 
and of dietary status (plasma levels and food frequency questionnaire levels). 
 This study had limited power to detect interactions, due in part to missing 
nutrient data.  In addition, results using food frequency questionnaires (FFQ) 
have been debated in the literature largely due to the poor correlation between 
FFQ and repeated dietary recall (Byers 2001; Kristal et al. 2005).  In our study 
the consistent associations observed with concurrent measures of plasma 
nutrients validate the use of FFQ.   
Scope and Implications of the Work   
 The results of this longitudinal study suggest a strong link between 
homocysteine and lead exposure.  This dissertation did not address the 
downstream consequences of the association.  Toxicology studies are needed to 
decipher the molecular mechanisms linking homocysteine and lead exposure.  
Potentially, Pb and Hcy may work through a common mechanism of binding and 
disrupting available sulfur-containing proteins (Krumdieck and Prince 2000; 
Needleman 2004), which may suggest synergistic or additive toxicity. 
 Based on the research in this dissertation, behavioral interventions to 
reduce blood Pb and improve dietary intake of vitamins B6 and B12 and folate 
will have a protective effect by lowering Hcy.  Multiple randomized control trials 
have attempted to reduce circulating Hcy levels in people who are already ill by 
using dietary interventions (Mei et al. 2010).  These studies have been 
successful in reducing circulating Hcy, but did not produce the hypothesized 
health benefits, specifically reductions in coronary heart disease, stroke, 
cardiovascular events, or all-cause mortality. Perhaps taking a public health 






SUMMARY OF DNA METHYLATION IN AD 
 The second part of the dissertation observed throughout the genome 
moderate changes in DNA methylation that are associated with LOAD in the 
frontal cortex (Bakulski et al. 2012).  This study was the largest genome-wide 
DNA methylation investigation of the LOAD brain to date.  Using 12 matched-pair 
LOAD case and control frontal cortex samples, we quantitatively determined 
DNA methylation at 27,578 CpG sites.  Across 948 CpG sites that were 
statistically different between LOAD cases and controls after adjusting for age 
and sex, the mean methylation difference was 2.9%.  A CpG site in the promoter 
for the gene Transmembrane Protein 59 (TMEM59) was 7.3% hypomethylated in 
LOAD cases.  This gene is involved in post-translational modification of Amyloid 
Precursor Protein (APP), and thus β-amyloid plaque formation.  We validated the 
DNA methylation findings using a second DNA methylation detection platform 
and 13 additional matched pairs.  DNA methylation was associated with 
TMEM59 mRNA gene expression, but not with the quantity of the full-length 
protein.  This study suggests that DNA methylation may be involved in LOAD, but 
future research is needed to determine the extent. 
Strengths and Weaknesses 
A major strength of this research was the use of well pathologically 
characterized human tissue from a brain region involved in LOAD.  The majority 
of epigenetic epidemiology studies test blood DNA methylation (Foley et al. 
2009).  The association between circulating lymphocytes and brain epigenetics is 
unknown (though our research group has a funded NIEHS p30 pilot grant to 
investigate this question).  Access to post-mortem human samples via the 
Michigan Alzheimer’s Disease Center provided valuable information on the in 
vivo inaccessible tissue. 
On the other hand, a potential weakness of this research is the use of 
tissue samples made up of complex mixtures of cell types.  Changes in 
composite DNA methylation may be due to changes in the percent cell-types 
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(Houseman et al. 2012).  The data presented in this paper could be interpreted 
as actual epigenetic changes with disease, as indicators of different cellular 
mixtures, or as markers of past environmental exposures.   
At the time, the Illumina Infinium HumanMethylation27K BeadArray was 
the most comprehensive and cost efficient method available.  This technology 
queries the quantitative DNA methylation levels of 27,578 CpG sites throughout 
the genome with approximately two tag CpG sites per gene.  Previous LOAD-
DNA methylation research was based on gene-specific DNA methylation founded 
in a priori assumptions about the disease.  The Illumina array was the most 
comprehensive DNA methylation array available and our study provided the most 
un-biased assessment of the DNA methylome of LOAD.  
Genomic technology is rapidly evolving.  In retrospect, with newer array 
and next-generation sequencing technologies available, the Illumina 27K 
BeadArray represents a fraction of the potential DNA methylation information that 
is available today.  Illumina’s latest 450K array has more than fifteen times the 
number CpG sites and these sites have a less biased genomic distribution.  The 
27K array CpG sites were 92.0% in promoters and 72.5% in CpG islands.  
Potentially important non-genic regulation sites were largely not included in the 
model used in the dissertation.  Studies suggest that CpG locations in gene 
deserts may be functionally important in the brain (Maunakea et al. 2010) and 
unfortunately they were unable to be captured in our study.   
Scope and Implications of the Work   
 This research suggests DNA methylation may be involved in LOAD, but it 
is far from definitive.  The methylation changes and sample size were modest, 
and results need to be confirmed in additional studies before mechanistic 
conclusions may be drawn.  Several research groups have ongoing projects to 
investigate Alzheimer’s disease and epigenetics.  The results of those studies 
combined with our research will provide a larger body of evidence on the topic.  
In addition, the effect sizes observed were moderate and future work will want to 
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consider separating complex cell mixtures to identify changes in neurons as a 
priority.  Further, the findings at TMEM59 were validated through gene 
expression, but the full-length protein levels did not differ+ between LOAD cases 
and controls.  The functional significance of these DNA methylation markers 
across the genome is presented in the next section of the dissertation. 
 
SUMMARY OF GENE EXPRESSION AND DNA METHYLATION IN AD 
 The final section of the dissertation builds on the second experimental 
section.  Using the same LOAD and neuropathologically confirmed controls as 
above, we observed correlations between DNA methylation differences and gene 
expression differences in the frontal cortex when comparing.  Integrating 
genome-wide analyses of DNA methylation and gene expression allowed us to 
detect additional potential sites at low false discovery rates with LOAD 
associated epigenetic change.  This research suggests that DNA methylation 
differences may have functional consequences, potentially relevant in disease.    
Strengths and Weaknesses 
 The samples and the technologies used overlap between this dissertation 
chapter and the previous, therefore the strengths and weaknesses of the 
samples and the Illumina technology still apply.  In addition, combining datasets 
from two companies (Illumina and Affymetrix) with multiple probesets per gene 
proved to be methodologically challenging.  We followed a previously published 
pipeline to integrate the data (Sartor et al. 2011).  This method proved to be 
successful in identifying genes for follow-up. 
Scope and Implications of the Work  
 This research extends previous dissertation study to continue building 
case for DNA methylation in LOAD.  Integrating gene expression and DNA 
methylation analyses yielded greater numbers of CpG sites for potential follow-up 
and mechanistic investigation.  This study is an example of how DNA methylation 
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research can be enhanced when done alongside gene expression research. As 
studies increase the sample number of LOAD and control brains tested, this 
method is recommended. 
 
FUTURE DIRECTIONS 
 This dissertation provides opportunities for rich potential areas of further 
research.  Late-onset Alzheimer’s disease is an enormous public health problem 
and the burden will continue to increase (International 2010).  LOAD is 
traditionally understudied in the laboratory relative to EOAD, due to the 
availability of EOAD analogous animal models.  Despite the public health 
potential, within the LOAD literature, environmental risk factors and potential 
mechanisms of environmental toxicants are further underrepresented.  Future 
research topics, directly related to this dissertation, include testing for a human 
epidemiologic link between Pb exposure and LOAD, examination of the roles of 
additional metals in neurodegeneration, cell-type specificity in the epigenetic 
molecular epidemiology, modifications to histones, and further work on dietary 
factors and methylation.  This is a broad field of research in which could 
potentially contribute to our understanding and prevention of an insidious 
disease.   
 
Exposure to lead has negative neurological consequences in early life 
(Fewtrell et al. 2004; Grosse et al. 2002).  It is also associated with cognitive 
decline in late life (Shih et al. 2007; Weisskopf et al. 2004; Wright et al. 2003), 
potentially through increased hippocampal gliosis (Weisskopf et al. 2007).  
Though a large body of research demonstrates Pb is associated with accelerated 
declines in cognition, the hypothesized causal association between lead 
exposure and LOAD, implied in this dissertation, has not been rigorously tested. 
Potential epidemiologic studies to test this link are challenged by the current 
clinical diagnoses of AD.  Clinical diagnoses of AD from 30 ADRC’s were 
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compared to post-mortem neuropathological diagnoses, with 71-87% sensitivity 
and 44-71% specificity (Beach et al. 2012).  The ranges of clinical diagnosis of 
disease misclassification would require a large study size for environmental 
epidemiology research.   
There are recent advances in neuroimaging (Matsuda and Imabayashi 
2012) and circulating biomarkers (Chintamaneni and Bhaskar 2012; Doecke et 
al. 2012) that improve AD diagnosis and are available for research purposes.  
For example, the UM ADC utilizes positron emission tomography (PET) imaging 
methods to visualize β-amyloid in the brain and diagnose cases more accurately 
(Burke et al. 2011).  Brain scan confirmed AD cases and controls could be 
measured for lead exposure at the UM Retrospective Lead Exposure Laboratory 
using the Cd109 K-shell X-ray Fluorescence instrument.  Alternatively, post-
mortem studies with neuropathologically confirmed LOAD and control samples 
may be able to reconstruct past metals exposure history using teeth. 
Researchers have identified a layer of molar tissue with relatively low turnover 
that dates from early development that can be quantified for metals using laser-
ablation ICP-MS (Hare et al. 2011).  With method validation, a case-control 
approach may be able to accurately reconstruct past exposure history.  Finally 
the Pb-LOAD argument could be tested with brain post-mortem lead mapping.  
Demonstrating that Pb is present at the site of pathology would strengthen the 
argument.  Post-mortem soft tissue metal content can be mapped in slices using 
rapid-scanning x-ray fluorescence methods (Popescu et al. 2009).  Grants that 
propose to study the Pb-induced epigenetic changes in LOAD will need to first 
demonstrate the Pb-LOAD relationship in humans. 
 
 Several metals beyond Pb have been implicated in AD with varying 
degrees of evidence, including aluminum (Frisardi et al. 2010; Shcherbatykh and 
Carpenter 2007), iron (Mandel et al. 2007), copper (Brown 2009; Shcherbatykh 
and Carpenter 2007), zinc (Shcherbatykh and Carpenter 2007), and mercury 
(Gerhardsson et al. 2008). Many metals work through shared mechanisms in the 
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body.  For example, lead, cadmium, mercury, and nickle bind protein sulfhydryl 
groups and deplete glutathione, resulting in oxidative stress (Stohs and Bagchi 
1995).  Future LOAD research could expand to include rigorous epidemiologic 
inquiry of metals in addition to Pb, using similar methods proposed above for Pb.  
Post-mortem exposure studies utilizing ICP-MS methods are capable of 
measuring up to twelve metals simultaneously.  The half-life of each of these 
metals varies in tissues such as bone and skin, thus post-mortem exposure 
assessment for metals besides Pb may not reflect exposure prior to disease 
onset.  KXRF in vivo technologies are being developed for additional metals 
including cadmium and arsenic (personal communication, Linda Huiling Nie, 
Purdue University).  In vivo metals epidemiology studies coupled with early stage 
disease diagnosis techniques may be an effective strategy to test metals 
exposure as a risk factor for LOAD. 
 Reports have proposed pesticides (Baldi et al. 2003; Santibanez et al. 
2007), solvents (Kukull et al. 1995), electromagnetic field (Sobel et al. 1996), and 
particulate matter in air pollution (Calderon-Garciduenas et al. 2004) may be risk 
factors for LOAD.  The links between these exposures and LOAD have not been 
yet been validated.  These types of environmental exposure studies have been 
underrepresented in the AD literature, likely due to the challenges of 
retrospective exposure assessment in older adults.  Retrospective exposure 
assessment for pesticides and solvents relies heavily on questionnaire data in 
the absence of effective biomarkers.  Future work may test the association 
between additional exposures and LOAD onset using long-running large cohorts 
where exposure information has been collected over time. 
 
In addition to the influence of toxicants on one-carbon metabolism and 
epigenetics, future research may look at the direct and indirect effects of diet on 
the system.  Results from the lead and homocysteine research paper 
demonstrate that dietary B6, B9, and B12 levels modify the association between 
blood Pb and homocysteine, an important methyl-donor for DNA methylation.  
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We have shown that DNA methylation change is associated with LOAD (Bakulski 
et al. 2012).  Future research could test whether AD-associated DNA methylation 
changes are prevented with B-vitamin supplemented diet.  The study of nutrient 
toxicant interactions is an emerging field in environmental health with potential for 
public health intervention. 
 
 To understand more precise mechanisms involved in LOAD pathogenesis, 
molecular epidemiology of epigenetics will need to refine the tissues and cell 
types studied.  AD epigenetic epidemiology compared blood from AD cases and 
controls as a tissue of epidemiologic convenience (Bollati et al. 2011; Maes et al. 
2007).  Blood DNA methylation has not yet been tested as a biomarker of brain 
epigenetics.  Whole brain region epigenetics is closer to the disease site, but it 
still represents a mixture of cell types that each likely have characteristic 
epigenetic profiles.  Recent studies suggest that changes in circulating 
lymphocyte epigenetics represent shifting cell type proportions (Houseman et al. 
2012).  The DNA methylation differences observed in this dissertation in the 
human brain with LOAD may represent the understood shifting cell type 
proportions with disease.  In future research, cell types will need to be separated 
from the tissue matrix.  This is logistically challenging in frozen archived tissues 
where the cell membrane is often no longer intact.  Ongoing work in the 
laboratory (particularly by 2nd year Ph.D. student, Zishaan Farooqui) seeks to 
separate nuclei of neurons from non-neurons.  This allows for the study of 
epigenetics in neurons, and associations with environmental exposures, but it 
does not allow for RNA or protein functional validation.  Further advancements 
may make the study of specific cell types more feasible.   
 
The focus of the current research has been DNA methylation.  However, 
recent research suggests that histones may be an important target for epigenetic 
modifications in the brain.  Histone modifications play a role in memory formation 
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(Levenson et al. 2004) and HDAC inhibitor treatment increases memory 
formation (Vecsey et al. 2007).  Indeed, HDAC inhibitors have been proposed for 
human AD clinical trials (Kazantsev and Thompson 2008) .  In the male rat brain, 
App mRNA expression is repressed by thyroid hormone (T3) sensitive histone 
modifications (Belakavadi et al. 2011).  T3 Treatment decreases H3K4 
methylation and H3 acetylation at the App promoter.  This silences App, reversed 
with histone deacetylase (HDAC) and histone lysine demethylase inhibitor 
treatment (Belakavadi et al. 2011). Histone modifications are also 
environmentally sensitive (Mathers et al. 2010).  Together, these observations 
suggest that future environmental molecular epidemiology research on AD 
should target histone modification.   
  
CONCLUDING REMARKS 
 In summary, this dissertation has provided important molecular 
epidemiology insights to chronic disease.  It has demonstrated moderate DNA 
methylation differences in the LOAD brain vs. controls that may have functional 
gene expression consequences.  In addition, homocysteine may be an important 
target for lead exposure toxicity and may link lead exposure to chronic disease 
including CVD and neurodegenerative disease.  This work has implications for 
prevention and potential homocysteine intervention through lowering blood lead 
levels.  This research has also spurred multiple additional research questions at 
the intersection of Alzheimer’s disease, one-carbon metabolism, epigenetics, and 
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